Anti-FGFR4 molecules and uses thereof

Abstract

Anti-FGFR4 molecules and uses thereof Provided herein are molecules or antibody-drug conjugates comprising an antigen binding domain that binds to FGFR4, and methods of treating conditions or diseases in a subject using the same.

Description

ANTI-FGFR4 MOLECULES AND USES THEREOFBACKGROUNDFGFR4 is a tyrosine kinase receptor involved in the regulation of several cellular phenotypes such as proliferation, differentiation, and survival. Imbalances in FGFR signaling have been shown to have oncogenic roles in many cancers. The function and kinase domain of FGFR4 differs from other FGF receptors, suggesting it may have a unique role when compared to other FGFRs.FGFR4 expression is upregulated in many cancer types, including many solid tumors (i.e., liver cancer, colorectal carcinoma, breast cancer, rhabdomyosarcoma). Elevated FGFR4 expression is also associated with shorter survival, increased tumor proliferation, increased invasion, or treatment resistance. Most of the pan-FGFR inhibitors, however, fall short in their ability to competitively bind FGFR4 due to its structural dissimilarity to FGFR1-3. In addition, clinical data suggests that targeting FGFR4 can cause liver toxicity. As such, there is a need to develop new anti-FGFR4 molecules.FGF19-FGFR4 signaling axis has been identified as an oncogenic driver of liver cancer (e.g., hepatocellular carcinoma). FGF19 / FGFR4 expression has been shown to be abnormally upregulated in liver cancer which correlates with poor prognosis, and gene set enrichment analysis reveals that the aggressiveness of the tumor is closely related to FGFR4 levels (Yamauchi M, Ono A, Ishikawa A, Kodama K, Uchikawa S, Hatooka H, et al. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2020;l l(5):e00179.).Increased FGFR4 levels were associated with the occurrence, advanced stage, and distal metastasis of colon adenocarcinoma (Shiu BH, Hsieh MH, Ting WC, Chou MC, Chang LC, Huang CC, et al. Impact of FGFR4 Gene Polymorphism on the Progression of Colorectal Cancer. Diagnostics (Basel). 2021;l l(6).). In addition, FGFR4 is implicated in the development of therapy resistance in colon cancer patients (Ahmed MA, Selzer E, Dorr W, Jomrich G, Harpain F, Silberhumer GR, et al. Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer. Oncotarget. 2016;7(43): 69976-90.).Hormone receptor-positive (HR+) and HER2- tumors represent 75% of all breast cancer, and are clinically and biologically heterogeneous. The current standard of care for metastatic HR+ / HER2- breast cancer is endocrine therapy plus CDK4 / 6 inhibitors (CDK4 / 6i). However, virtually alladvanced patients will eventually progress due to the development of CDK4 / 6i resistance mechanisms. As such, there is an urgent need to develop therapeutics against FGFR4 expressing cancers, including CDK4 / 6 resistant cancers.SUMMARYIn some embodiments, provided herein is a recombinant polynucleotide molecule comprising the polynucleotide sequences encoding the molecule described herein. In some embodiments, provided herein is a vector comprising the recombinant polynucleotide molecule described herein. In some embodiments, provided herein, is a cell comprising the recombinant polynucleotide molecule described herein or the vector described herein.In another aspect, provided herein is a pharmaceutical composition comprising the antigen binding molecule, the recombinant polynucleotide, the vector, the cell described herein and a pharmaceutically acceptable carrier, excipient, or diluent.In another aspect, provided herein, is a method of treating a condition or disease in subject in need thereof, comprising administering to the subject a therapeutically effective amount of the molecule of as described herein, the recombinant polynucleotide of as described herein, the vector of as described herein, the cell of as described herein, or the pharmaceutical composition as described herein, or a combination thereof, thereby treating the condition or disease in the subject.In a related aspect, provided herein, is the molecule of as described herein, the recombinant polynucleotide of as described herein, the vector of as described herein, the cell of as described herein, or the pharmaceutical composition as described herein, or a combination thereof, for use in a method of treating a condition or disease in subject in need thereof.In some embodiments, the condition or disease is cancer. In some embodiments, the cancer is a solid tumor cancer, a hematological cancer, a metastatic cancer, a soft tissue tumor, or a combination thereof.In some embodiments, the cancer is the solid tumor cancer, and wherein the solid tumor cancer is selected from the group consisting of squamous cell carcinoma, adenocarcinoma, adrenocortical carcinoma, head and neck cancer, esophageal cancer, gastric cancer, ovarian cancer, cervical cancer, uterine cancer, lung cancer, breast cancer, renal cancer, prostate cancer, sarcoma, skin cancer, melanoma, kidney cancer, duodenum cancer, small intestine cancer, large intestine cancer,colorectal cancer, liver cancer, pancreatic cancer, bladder cancer, rhabdomyosarcoma, cholangiocarcinoma, neuroendocrine tumors or testicular germ cell tumor.In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is a HER2- breast cancer.In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is a HER2+ breast cancer.In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is a HR+ / HER2- breast cancer. In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is a HR- / HER2+ breast cancer. In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is a Triple Negative Breast Cancer (TNBC). In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is a HER2-enriched breast cancer.In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is resistant or refractory to a CDK4 / 6 inhibitor. In some embodiments, the CDK4 / 6 inhibitor is selected from abemaciclib, palbociclib, and ribociclib.In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is resistant or refractory to an endocrine therapy. In some embodiments, the solid tumor cancer is breast cancer, and wherein the breast cancer is resistant or refractory to a CDK4 / 6 inhibitor and an endocrine therapy.In some embodiments, the solid tumor cancer is colorectal cancer.In some embodiments, the solid tumor cancer is liver cancer, preferably hepatocellular carcinoma.In some embodiments, the solid tumor cancer is gastric cancer.In some embodiments, the solid tumor cancer is esophageal cancer.In some embodiments, the cancer is the hematological cancer, and wherein the hematological cancer is leukemia or lymphoma.In some embodiments, the cancer is characterized by a cancer antigen present on the cancer. In some embodiments, the cancer antigen is a tumor antigen, a stromal antigen, or a hematological antigen. In some embodiments, the cancer antigen is FGFR4. In some embodiments, the cancer is a metastatic cancer.Also described herein, in some embodiments, is a method of treating a breast cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of a molecule comprising an antigen binding domain that binds to FGFR4 as described herein.In some embodiments, the molecule binds to a FGFR4 domain 1 (DI) comprising the amino acid sequence set forth in SEQ ID NO: 78 with higher affinity than to other FGFR4 domains selected from one or more of: a FGFR4 acid box (AB) comprising the amino acid sequence set for in SEQ ID NO: 82, a FGFR4 domain 2 (D2) comprising the amino acid sequence set forth in SEQ ID NO: 79, and a FGFR4 domain 3 (D3) comprising the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the treatment comprises a molecule comprising an antigen binding domain that binds to human FGFR4 and mouse FGFR4, wherein the molecule binds to human FGFR4 domain 1 (DI) comprising the amino acid sequence set forth in SEQ ID NO: 78. In preferred embodiments, the antigen binding domain binds to an epitope of human FGFR4 DI, wherein the epitope is defined by one or more of the following:(a) the epitope comprises His44, Tyr46, and Arg83 of SEQ ID NO: 78;(b) the epitope comprises at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least thirty, at least forty, or more consecutive amino acids of the sequence SEQ ID NO: 78;(c) the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 24-86 of SEQ ID NO: 78, preferably to amino acid residues 44-86 of SEQ ID NO: 78;(d) the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 44-65, preferably to amino acid residues 46-65 of SEQ ID NO: 78;(e) the epitope is within or overlapping amino acid residues 44-86 of SEQ ID NO: 78, preferably amino acid residues 44-65 of SEQ ID NO: 78, more preferably amino acid residues 44-62 of SEQ ID NO: 78; and(f) the epitope comprises one or more amino acid residues ranges selected from: 46- 52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78.Also described herein, in some embodiments, is a method of identifying a subject in need of treatment for breast cancer, the method comprising: determining whether the subject has cancer cells that express a higher level of FGFR4 as compared to a reference value, such as a controlsample in a healthy subject; and identifying the subject as a candidate for the treatment based on the determination that the subject has cancer cells that express a higher level of FGFR4 as compared to the reference value, such as the control sample; wherein the treatment comprises a molecule as described herein.In some embodiments, the treatment comprises a molecule comprising an antigen binding domain that binds to FGFR4, wherein: the molecule binds to a FGFR4 domain 1 (DI) comprising the amino acid sequence set forth in SEQ ID NO: 78 with higher affinity than to other FGFR4 domains selected from one or more of: a FGFR4 acid box (AB) comprising the amino acid sequence set forth in SEQ ID NO: 82, a FGFR4 domain 2 (D2) comprising the amino acid sequence set forth in SEQ ID NO: 79, a FGFR4 domain 3 (D3) comprising the amino acid sequence set forth in SEQ ID NO: 80, or a combination thereof.In some embodiments, the treatment comprises a molecule comprising an antigen binding domain that binds to human FGFR4 and mouse FGFR4, wherein the molecule binds to human FGFR4 domain 1 (DI) comprising the amino acid sequence set forth in SEQ ID NO: 78. In preferred embodiments, the antigen binding domain binds to an epitope of human FGFR4 DI, wherein the epitope is defined by one or more of the following:(a) the epitope comprises His44, Tyr46, and Arg83 of SEQ ID NO: 78;(b) the epitope comprises at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least thirty, at least forty, or more consecutive amino acids of the sequence SEQ ID NO: 78;(c) the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 24-86 of SEQ ID NO: 78, preferably to amino acid residues 44-86 of SEQ ID NO: 78;(d) the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 44-65, preferably to amino acid residues 46-65 of SEQ ID NO: 78;(e) the epitope is within or overlapping amino acid residues 44-86 of SEQ ID NO: 78, preferably amino acid residues 44-65 of SEQ ID NO: 78, more preferably amino acid residues 44-62 of SEQ ID NO: 78; and(f) the epitope comprises one or more amino acid residues ranges selected from: 46- 52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78.INCORPORATION BY REFERENCEAll publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGSThe novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:FIG. 1 shows FGFR4 extracellular domains (domain 1 (DI), acid box (AB), domain 2 (D2), and domain 3 (D3)) and intracellular tyrosine kinase domain.FIG. 2 shows FGFR4 mRNA expression in several cancer types (Koboldt et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012 Mar; Goldman, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol (2020). LAML-Acute Myeloid Leukemia; ACC-Adrenocortical carcinoma; BLCA-Bladder Urothelial Carcinoma; LGG-Brain Lower Grade Glioma; BRCA- Breast invasive carcinoma; CESC-Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL-Cholangiocarcinoma; COAD-Colon adenocarcinoma; ESCA- Esophageal carcinoma; GBM-Glioblastoma multiforme; KICH-Kidney Chromophobe; KIRC- Kidney renal clear cell carcinoma; KIRP-Kidney renal papillary cell carcinoma; LIHC-Liver hepatocellular carcinoma; LUAD-Lung adenocarcinoma; LUSC-Lung squamous cell carcinoma; DLBC-Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; MESO-Mesothelioma; OV- Ovarian serous cystadenocarcinoma; PAAD-Pancreatic adenocarcinoma; PCPG- Pheochromocytoma and Paraganglioma; PRAD-Prostate adenocarcinoma; READ-Rectum adenocarcinoma; SARC-Sarcoma; SKCM-Skin Cutaneous Melanoma; STAD-Stomach adenocarcinoma; TGCT-Testicular Germ Cell Tumors; THYM-Thymoma; THCA-Thyroidcarcinoma; UCS-Uterine Carcinosarcoma; UCEC-Uterine Corpus Endometrial Carcinoma; UVM- Uveal Melanoma.FIG. 3 shows binding of anti-FGFR4 antibodies Ab-67, Ab-18, Ab-32, Ab-91, and Ab-50 (at a concentration of 100 nM) to FGFR1-3 isoforms, FGFR4 and FGFR5 determined by ELISA. FIGs. 4A-D show binding of anti-FGFR4 antibodies Ab-67, Ab-18, Ab-32, Ab-91, and Ab-50 to high and mid, respectively, FGFR4 expressing breast cancer T47D Y367C (FIG. 4A), andZR-75- 1 (FIG. 4B), and mid FGFR4 expressing rhabdomyosarcoma cell line RH-4 (FIG. 4C), and an FGFR4-negative breast cancer cell line (MDA-MB-231) (FIG. 4D).FIG. 5 shows binding of anti-FGFR4 antibodies Ab-67, Ab-18, Ab-32, Ab-91, and Ab-50 to CHO cells stably expressing non-human primate FGFR4.FIGs. 6A-C show FGFR4 signaling pathway status and ligand binding after stimulation by anti- FGFR4 antibodies Ab-67, Ab-18, Ab-32, Ab-91, and Ab-50. FIG. 6A shows fold change of phosphorylated-ERK as compared to isotype control in cell-based assays. FIG. 6B shows percentage of FGF2 ligand binding to FGFR4 in presence of anti-FGFR4 antibodies. FIG. 6C shows the level of FGF19-induced activation of FGFR4 signaling in presence of anti-FGFR4 antibodies.FIG. 7 shows domain sequences comprising the extracellular domains 1, 2, and 3 of human FGFR4 (Umprot lD P22455). Figure discloses SEQ ID NO: 242.FIG. 8 shows binding of anti-FGFR4 antibodies Ab-67, Ab-18, Ab-32, Ab-91, and Ab-50 to recombinantly produced domain 1, domain 2, domain 3, or domain 2 + domain 3 of FGFR4.FIG. 9 shows heatmap and percentage of competition forFGFR4 binding between Ab-67, Ab- 18, Ab-32, Ab-91, Ab-50, Tool 1 and Tool 2.FIGs. 10A-C show internalization kinetics of anti-FGFR4 antibodies Ab-67, Ab-18, Ab-32, Ab- 91, and Ab-50 in FGFR4+ cell lines Huh-7 from liver cancer (FIG. 10A), ZR-75-1 from breast cancer (FIG. 10B) and MDA-MB-453 from breast cancer (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001) (FIG. 10C).FIGs. 11A-E showHDX-MS binding epitope determination of anti-FGFR4 antibodies Ab-67, Ab- 18, Ab-32, Ab-91, and Ab-50. FIG. 11A shows representative plots of deuterium (D) uptake between free- and antibody-bound FGFR4. FIG. 11B shows three-dimensional structure of FGFR4 ectodomain with the binding epitope. FIG. 11C shows epitope sequences encompassing residues 24-86 of domain 1. Residues 46-65 showed higher than 10% off deuterium update. In a preliminary approach, hotspot FGFR4 binding residues were defined to include His44, Tyr46,Arg51, Pro54, Trp61, Leu81, Arg83. Figure discloses SEQ ID NO: 78. FIG. 11D shows a plot with average AAG per FGFR4 residue, with primary hotspot residues (AAG >3 kcal / mol) highlighted with continuous arrows, and secondary hotspots (AAG >2 kcal / mol) highlighted with dashed arrows. Epitope region is highlighted according to experimental HDX-MS data (a wide epitope region comprising residues 44 to 86, and a narrower central epitope region comprising residues 44 to 65). FIG. HE shows a three-dimensional model of the interaction between Ab-67 and FGFR4, in agreement with HDX-MS results. Loop 1 is highlighted, which contains residues 39 and 43 that differ between mouse (m) and human (h) FGFR4. It is further shown how these amino acid changes affect the loop conformation.FIGs. 12A-B show PK profile of anti-FGFR4 antibodies Ab-67, Ab-18, Ab-32, Ab-91, Ab-50 and tool 1 mAb injected at 3 mg / kg intravenously in nude mice (FIG. 12A) and Ab-67, Ab-32 and tool 2 mAb injected at 3 mg / kg intravenously in non-human primates (FIG. 12B).FIG. 13 shows hepatic enzymes (ALT and AST) and bile acid levels in blood in response to anti- FGFR4 antibodies Ab-67, Ab-32 and tool 2 mAb at 3 mg / kg intravenously in non-human primates. FIG. 14 shows binding affinity (KD) of the different FcyRs and FcRn to ADC-67, ADC-18, ADC- 321, ADC-91, and ADC-50.FIGs. 15A-D show binding of ADC-67, ADC-18, ADC-321, ADC-91, and ADC-50 to FGFR4+ cell lines T47D Y347C (FIG. 15A), ZR-75-1 (FIG. 15B), RH4 (FIG. 15C) and a FGFR4-negative cell line MDA-MB-231 (FIG. 15D).FIG. 16 shows binding of ADC-67, ADC-18, ADC-321, ADC-91, and ADC-50 to CHO cells stably expressing non-human primate FGFR4.FIGs. 17A-K show cytotoxicity in vitro assay studying the effects of ADC-67, ADC-18, ADC- 321, ADC-91, and ADC-50, plus control tool ADC 2, isotype control ADC and MMAE, on a panel of cell lines with different FGFR4 levels and from breast, rhabdomyosarcoma, uterine and liver cancer: MDA-MB-453 (FIG. 17A), T47D Y367C (FIG. 17B), T47D-PR, being a CDK4 / 6 inhibitor (palbociclib) refractory HR+ HERZ- cell line (FIG. 17C), ZR-75-1 (FIG. 17D), BT474 (FIG. 17E), RH4 (FIG. 17F), Hec-IB (FIG. 17G), Huh7 (FIG. 17H), and FGFR4-negative MDA-MB-231 cells (FIG. 171), Fu97 (FIG. 17J), PaTu-8988-S (FIG. 17K).FIG. 18 shows PK profiles in nude mice of ADC-67, ADC- 18, ADC-321, ADC-91, ADC-50 and tool 1 ADC administered intravenously at 3 mg / kg.FIGs. 19A-E show in vivo antitumor response of ADC-67, ADC-18, ADC-321, ADC-91 and ADC-50 in cell-line derived xenografts with high FGFR4 expression in T47D Y367C (FIG. 19A)from breast cancer and mid FGFR4 expression in RH4 (FIG. 19B-C) from rhabdomyosarcoma. FIG. 19D shows in vivo antitumor response of ADC-321 in gastric cancer Fu97 cell line-derived xenograft. FIG. 19E shows in vivo antitumor response of ADC-321 and control isotype ADC-1 in esophageal cancer PDX model.FIG. 20 shows PK profile of ADC-322, ADC-325, ADC-326, and ADC-327 in nude mice administered intravenously at 3 mg / kg.FIGs. 21A-D show in vitro cytotoxicity assays studying the effects of Ab-32-derived ADCs on a panel of cell lines. FIGs. 21A-C show in vitro cytotoxicity assay studying the effects of ADC- 322, ADC-325, ADC-326, and ADC-327, isotype ADCs and exatecan on a panel of cell lines, from a CDK4 / 6 inhibitor (palbociclib) refractory HR+ HER2- cell line T47D-PR (FIG. 21A), breast cancer cell line T47D Y367C (FIG. 21B), and rhabdomyosarcoma cell line RH4 (FIG. 21C) FIG. 21D shows in vitro cytotoxicity assay studying the effect of ADC-328, control isotype ADC-5 and deruxtecan on the CDK4 / 6 inhibitor (palbociclib) refractory HR+ HER2- breast cancer cell line T47D-PR.FIGs. 22A-B show in vivo antitumor response of ADC-322, ADC-325, ADC-326, ADC-327 and ADC-328 in breast cancer models. FIG.22A shows in vivo antitumor response of ADC-322, ADC- 325, ADC-326, and ADC-327 in ZR-75-1 tumor-bearing mice. FIG. 22B shows in vivo antitumor response of ADC-328 in a xenograft derived from breast cancer cell line BT474.FIGs. 23A-B show in vivo antitumor response of ADC-327 and ADC-328 in colorectal cancer tumor models, including PDX from treated liver metastases (FIG. 23A) and PDX from lymph node metastasis (FIG. 23B).FIGs. 24A-B show in vivo antitumor response of ADC-327 and ADC-328 (FIG.24A), and ADC- 327 (Fc-silent) (FIG.24B) in hepatocellular carcinoma PDX tumor models.DETAILED DESCRIPTIONDEFINITIONCertain specific details of this description are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the present disclosure may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments.Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed disclosure.As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. The use of the words “a” or “an” when used in conjunction with the term “comprising” herein may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”It should also be noted that the term “or” is generally employed in its sense including “and / or” unless the content clearly dictates otherwise.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below.The term “about” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or in some instances ±10%, or in some instances ±5%, or in some instances ±1%, or in some instances ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. As used herein, “about” and “approximately” generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given range of values.The term “acquire” or “acquiring” as the terms are used herein, refer to obtaining possession of a physical entity (e.g., a sample, a polypeptide, a nucleic acid, or a sequence), or a value, e.g., a numerical value, by “directly acquiring” or “indirectly acquiring” the physical entity or value. “Directly acquiring” means performing a process (e.g., performing a synthetic or analytical method) to obtain the physical entity or value. “Indirectly acquiring” refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value). Directly acquiring a physical entity includes performing a process that includes a physical change in a physical substance, e.g., a starting material. Directly acquiring a value includes performing a process that includes a physical change in a sample oranother substance, e.g., performing an analytical process which includes a physical change in a substance, e.g., a sample.“Antibody molecule” as used herein refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain structure and / or sequence. An antibody molecule encompasses antibodies (e.g., full-length antibodies) and antibody fragments. In some embodiments, an antibody molecule comprises an antigen binding or functional fragment of a full length antibody, or a full length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes). In embodiments, an antibody molecule refers to an immunologically active, antigen-binding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody fragment, e.g., functional fragment, is a portion of an antibody, e.g., Fab, Fab', F(ab')2, F(ab)2, variable fragment (Fv), domain antibody (dAb), or single chain variable fragment (scFv). A functional antibody fragment binds to the same antigen as that recognized by the intact (e.g., full-length) antibody. The terms “antibody fragment” or “functional fragment” also include isolated fragments consisting of the variable regions, such as the “Fv” fragments consisting of the variable regions of the heavy and light chains or recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker (“scFv proteins”). In some embodiments, an antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues. Exemplary antibody molecules include full length antibodies and antibody fragments, e.g., dAb (domain antibody), single chain, Fab, Fab’, and F(ab’)2 fragments, and single chain variable fragments (scFvs). In some embodiments, the antibody molecule is an antibody mimetic. In some embodiments, the antibody molecule is, or comprises, an antibody-like framework or scaffold, such as, fibronectins, ankyrin repeats (e.g., designed ankyrin repeat proteins (DARPins)), avimers, affibody affinity ligands, anticalins, or affilin molecules.The term “human-like antibody molecule” as used herein refers to a humanized antibody molecule, human antibody molecule or an antibody molecule having at least 95% sequence identity with a non-murine germline framework region, e.g., FR1, FR2, FR3 and / or FR4. In some embodiments, the human-like antibody molecule comprises a framework region having at least 95% sequence identity to a human germline framework region, e.g., a FR1, FR2, FR3 and / or FR4 of a human germline framework region. In some embodiments, the human-like antibody molecule is arecombinant antibody. In some embodiments, the human-like antibody molecule is a humanized antibody molecule. In some embodiments, the human-like antibody molecule is human antibody molecule. In some embodiments, the human-like antibody molecule is a phage display or a yeast display antibody molecule. In some embodiments, the human-like antibody molecule is a chimeric antibody molecule. In some embodiments, the human-like antibody molecule is a CDR grafted antibody molecule.As used herein, an “immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations that are compatible with formation of the protein structure.In embodiments, an antibody molecule is monospecific, e.g., it comprises binding specificity for a single epitope. In some embodiments, an antibody molecule is multispecific, e.g., it comprises a plurality of immunoglobulin variable domain sequences, where a first immunoglobulin variable domain sequence has binding specificity for a first epitope and a second immunoglobulin variable domain sequence has binding specificity for a second epitope. In some embodiments, an antibody molecule is a bispecific antibody molecule. “Bispecific antibody molecule” as used herein refers to an antibody molecule that has specificity for more than one (e.g., two, three, four, or more) epitope and / or antigen.“Antigen” (Ag) as used herein refers to a molecule that can provoke an immune response, e.g., involving activation of certain immune cells and / or antibody generation. Any macromolecule, including almost all proteins or peptides, can be an antigen. Antigens can also be derived from genomic recombinant or DNA. For example, any DNA comprising a nucleotide sequence or a partial nucleotide sequence that encodes a protein capable of eliciting an immune response encodes an “antigen.” In embodiments, an antigen does not need to be encoded solely by a full length nucleotide sequence of a gene, nor does an antigen need to be encoded by a gene at all. In embodiments, an antigen can be synthesized or can be derived from a biological sample, e.g., a tissue sample, a tumor sample, a cell, or a fluid with other biological components. As used, herein a “tumor antigen” or interchangeably, a “cancer antigen” includes any molecule present on, or associated with, a cancer, e.g., a cancer cell or a tumor microenvironment that can provoke an immune response. As used, herein an “immune cell antigen” includes any molecule present on, or associated with, an immune cell that can provoke an immune response.The “antigen-binding site,” or “binding portion” of an antibody molecule refers to the part of an antibody molecule, e.g., an immunoglobulin (Ig) molecule, that participates in antigen binding. In embodiments, the antigen binding site is formed by amino acid residues of the variable (V) regions of the heavy (H) and light (L) chains. Three highly divergent stretches within the variable regions of the heavy and light chains, referred to as hypervariable regions, are disposed between more conserved flanking stretches called “framework regions,” (FRs). FRs are amino acid sequences that are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In embodiments, in an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface, which is complementary to the three- dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are referred to as “complementarity-determining regions,” or “CDRs.” The framework region and CDRs have been defined and described, e.g., in Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917. Each variable chain (e.g., variable heavy chain and variable light chain) is typically made up of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the amino acid order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.As used herein, an “immune cell” refers to any of various cells that function in the immune system, e.g., to protect against agents of infection and foreign matter. In embodiments, this term includes leukocytes, e.g., neutrophils, eosinophils, basophils, lymphocytes, and monocytes. Innate leukocytes include phagocytes (e.g., macrophages, neutrophils, and dendritic cells), mast cells, eosinophils, basophils, and natural killer cells. Innate leukocytes identify and eliminate pathogens, either by attacking larger pathogens through contact or by engulfing and then killing microorganisms, and are mediators in the activation of an adaptive immune response. The cells of the adaptive immune system are special types of leukocytes, called lymphocytes. B cells and T cells are important types of lymphocytes and are derived from hematopoietic stem cells in the bone marrow. B cells are involved in the humoral immune response, whereas T cells are involved in cell-mediated immune response. The term “immune cell” includes immune effector cells.The terms “polypeptide”, “peptide” and “protein” (if single chain) are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms alsoencompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. The polypeptide can be isolated from natural sources, can be produced by recombinant techniques from a eukaryotic or prokaryotic host, or can be a product of synthetic procedures.The terms “nucleic acid,” “nucleic acid sequence,” “nucleotide sequence,” or “polynucleotide sequence,” and “polynucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. The polynucleotide may be either single-stranded or double-stranded, and if single-stranded may be the coding strand or non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a non-natural arrangement.The term “isolated,” as used herein, refers to material that is removed from its original or native environment (e.g., the natural environment if it is naturally occurring). For example, a naturally- occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the co-existing materials in the natural system, is isolated. Such polynucleotides could be part of a vector and / or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of the environment in which it is found in nature. An isolated polynucleotide (ribonucleic acid (RNA), deoxyribonucleic acid (DNA)), or polypeptide is free of the genes / nucleic acids or sequences / amino acids that flank it in its naturally-occurring state.The compositions and methods of the present invention encompass polypeptides and nucleic acids having the sequences specified, or sequences substantially identical or similar thereto, e.g., sequences at least 80%, 85%, 90%, 95% identical or higher to the sequence specified. In the context of an amino acid sequence, the term “substantially identical” is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structuraldomain and / or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 80%, 85%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% 99%, 99.5%, 99.9%, or 100% sequence identity to a reference sequence, e.g., a sequence provided herein. In the context of nucleotide sequence, the term “substantially identical” is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% 99%, 99.5%, 99.9%, or 100% sequence identity to a reference sequence, e.g., a sequence provided herein.The term “variant” refers to a polypeptide that has a substantially identical amino acid sequence to a reference amino acid sequence, or is encoded by a substantially identical nucleotide sequence. In some embodiments, the variant is a functional variant.The term “functional variant” refers to a polypeptide that has a substantially identical amino acid sequence to a reference amino acid sequence, or is encoded by a substantially identical nucleotide sequence, and is capable of having one or more activities of the reference amino acid sequence.The term “functional fragment” refers to a polypeptide that has a partial amino acid sequence of a reference amino acid sequence, and is capable of having one or more activities of the reference amino acid sequence. In some embodiments, the functional fragment comprises at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% 99%, 99.5%, or 99.9% amino acid sequence of a reference amino acid sequence. In some embodiments, the functional fragment comprises an amino acid sequence that has at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 ammo acid deletion from the reference amino acid sequence. In some embodiments, the functional fragment comprises an amino acid sequence that has at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 350, 400, 450, or 500 ammo acids of the reference amino acid sequence.Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”).The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available at http: / / www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http: / / www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The nucleic acid and protein sequences described herein can be usedas a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.It is understood that the molecules of the present invention may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions. The term “amino acid” is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids. Exemplary amino acids include naturally-occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing. As used herein the term “amino acid” includes both the D- or L- optical isomers and peptidomimetics.A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).As used herein, the term “molecule” as used in, e.g., antibody molecule, cytokine molecule, receptor molecule, includes full-length, naturally-occurring molecules, as well as variants, e.g., functional variants (e.g., truncations, fragments, mutated (e.g., substantially similar sequences) or derivatized form thereof), so long as at least one function and / or activity of the unmodified (e.g., naturally-occurring) molecule remains.As used herein, the term “mutation” refers to an alteration in the nucleotide sequence of the genome of an organism, virus, or extrachromosomal DNA. In some embodiments, the mutation may be a large-scale mutation, such as amplifications (or gene duplications) or repetitions of a chromosomal segment, deletions of large chromosomal regions, chromosomal rearrangements (e.g., chromosomal translocations, chromosomal inversions, non-homologous chromosomal crossover, and interstitial deletions), and loss of heterozygosity. In some embodiments, the mutation may be a small-scale mutation, such as insertions, deletions, and substitution mutations. As used herein, the term “substitution mutation” refers to the transition that exchange a single nucleotide for another.As used herein, the term “blocking antibody” refers to an antibody that inhibits FGFR4-signaling. In some embodiments, the blocking antibody binds to one or more of the FGFR4 acid box (AB), FGFR4 domain 2 (D2), and FGFR4 domain 3 (D3). In some embodiments, the blocking antibody binds to FGFR4 domain 1 (DI). In some embodiments, the blocking antibody does not bind to FGFR4 domain 1 (DI), see FIG. 1. In some embodiments, the blocking antibody does interfere or inhibit ligand binding.As used herein, the term “non-blocking antibody” or “non-antagonistic antibody” refers to an antibody that does not inhibit FGFR4 signaling. In some embodiments, the non-blocking antibody preferentially binds to FGFR4 domain 1. In some embodiments, the non-blocking antibody binds to FGFR4 domain 1 with higher affinity than to other FGFR4 domains selected from one or more of the FGFR4 acid box (AB), FGFR4 domain 2 (D2), and FGFR4 domain 3 (D3). In some embodiments, the non-blocking antibody does not disrupt or inhibit FGFR4 signaling. In some embodiments, the non-blocking antibody does not interfere or inhibit FGFR4 ligand binding.As used herein, the term “expression” or “level of expression”, is understood to be the presence, detectable by standard techniques known in the state of the art, of a protein or a messenger RNA. As used herein, the term “higher expression”, alternatively referred to as “overexpression”, is understood to be the presence, detectable by standard techniques known in the state of the art, of a protein or a messenger RNA, above a reference value compared with a reference sample or in relation to the median of a reference population.As used herein, the term “reference sample” is understood as the sample from a healthy subject. In one embodiment, the cancer is breast cancer and the reference sample is the breast tissue sample of a healthy subject.As used herein, the term “reference value” is to be understood as a predefined value of a given molecular marker, which is derived from the levels of said molecular marker in a sample or group of samples. If the level of expression is determined at the protein level, then the “reference value” is a predefined value of protein quantity, whereas if the level of expression is determined at the mRNA level, then the “reference value” is a predefined value of mRNA quantity. The samples are taken from a subject or group of subjects wherein the presence, absence, stage, or course of the disease has been properly performed previously. This value is used as a threshold in order to discriminate subjects wherein the condition to be analyzed is present from those wherein such condition is absent.The subject or subjects from whom the “reference value” is derived may include subject / s wherein the condition is absent, subject / s wherein the condition is present, or both. The skilled person in the art, making use of the general knowledge, is able to choose the subject or group of subjects more adequate for obtaining the reference value for each of the methods of the present invention. Methods for obtaining the reference value from the group of subjects selected are well-known in the state of the art. In one embodiment, the reference value is determined in a sample or group of samples from healthy subject(s).In some embodiments, the level of expression of FGFR4 is determined prior to start the medical regimen. In some embodiments, FGFR4 can be used as a predictive biomarker to determine whether the subject will respond to the therapy, either because the subject is going to be administered for the first time with the CDK4 / 6 inhibitors or the subject is going to repeat the CDK4 / 6i medical regimen already provided in other phases of the disease. In a particular embodiment of the first aspect of the invention, the subject to which the analysis is performed, is going to be administered, for the first time, with the medical regimen comprising the one or more CDK4 / 6i(s). In an alternative embodiment, the subject has already been treated with one or more CDK4 / 6i(s) prior to determining the level of expression of FGFR4. In a further alternative embodiment of the first aspect of the invention, the level of expression of FGFR4 is determined during the CDK4 / 6i medical regimen, in order to monitor the onset of the CDK4 / 6i resistance (when an increase in FGFR4 expression is detected). Non-limiting examples of CDK4 / 6 inhibitors include abemaciclib, palbociclib, and ribociclib.In another embodiment of the first aspect of the invention, the medical regimen further comprises an endocrine therapy.In some embodiments, the term “endocrine therapy” is to be understood as any therapy designed to interrupt the signal generated by estrogen binding to estrogen receptor. Non-limiting examples include treatments which lower the estrogen level and treatments designed to block the estrogen receptor, such as administration of the drug tamoxifen. Non-limiting examples of endocrine therapy include tamoxifen, aromatase inhibitors, goserelin, leuprorelin, fulvestrant, anastrozole, raloxifene.In some embodiments, determining the level of expression of FGFR4 comprises determining the amount of FGFR4 mRNA.The level of expression of FGFR4 mRNA may be determined by quantitative real-time PCR (qPCR), reverse transcription-qPCR (RT-qPCR), a nucleic acid microarray, digital molecular barcoding technology (nCounter Nanostring), branched DNA (bDNA) signal amplification technology (Quantigene), mass spectrometry (Sequenom), or a combination of said methods.In some embodiments, the level of expression of FGFR4 is determined at protein level. In this embodiment, the protein marker includes, but is not limited to, native-sequence polypeptides, isoforms, chimeric polypeptides, all homologs, fragments, and precursors of the markers, including modified forms of the polypeptides and derivatives thereof.In some embodiments, the level of expression can be determined by immunochemistry.FGFR4The term “FGFR4” is a member of the fibroblast growth factor receptor superfamily. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. The genomic organization of FGFR4, compared to members 1-3, encompasses 18 exons rather than 19 or 20. Splice forms are also encompassed by “FGFR4”, in the context of the invention. In one embodiment, the FGFR4 is human FGFR4. Illustrative non-limitative examples of human FGFR4 are provided in GeneBank (Gene ID: 2264, updated on 9-Jul-2023) and UniProt (P22455, 2001-04-27 v2). In one embodiment, the FGFR4 is mice FGFR4. Illustrative non-limitative examples of mice FGFR4 are provided in NCBI (NCBI ID: NP_032037.2, updated on 27-Apr-2025) and UniProt (Q03142-1, 2006-03-21 v3). In oneembodiment, the FGFR4 is rat FGFR4. Illustrative non-limitative examples of rat FGFR4 are provided in NCBI (NCBI ID: NP_001103374.1, updated on 27-Apr-2025) and UmProt (Q498D6, 2005-09-13 vl). In one embodiment, the FGFR4 is cynomolgus monkey FGFR4, also referred herein as “non-human primate” or “nhp”. Illustrative non-limitative examples of cynomolgus monkey FGFR4 are provided in NCBI (NCBI ID: XP 014996982.2, updated on 26-Apr-2019) and UmProt (F7CEB0, 2019-12-11 v2).FGFR4 comprises an extracellular domain, a single hydrophobic membrane-spanning segment, and a cytoplasmic tyrosine kinase domain. In some embodiments, the extracellular domain comprises a FGFR4 domain 1 (DI), a FGFR4 acid box (AB), a FGFR4 domain 2 (D2), and a FGFR4 domain 3 (D3). The extracellular portion interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. In some embodiments, the FGFR4 comprises glycosylation sites. In some embodiments, the glycosylation sites comprise N112, N258, N290, and N311. In some embodiments, the FGFR4 comprises disulfide bridges between cysteines. In some embodiments, the disulfide bridge is C33- C56, C57-C101, C172-C224, or C271-C333.As used herein, the expression “binds to FGFR4” when referred to an anti-FGFR4 antibody, refers to an antibody or fragment thereof interacts (and binds) with its epitope, whether that epitope is linear or conformational, “does not bind to FGFR1, FGFR2, and FGFR3”, means that the anti- FGFR4 antibody does not significantly bind to any of these targets.Disclosed herein, in some embodiments, is an anti-FGFR4 antibody molecule or antigen binding variant thereof. In some embodiments, the anti-FGFR4 antibody selectively binds to domain 1. In some embodiments, domain 1 (DI) comprises an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 78. In some embodiments, domain 2 (D2) comprises an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 79. In some embodiments, domain 3 (D3) comprises an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at1 least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, acidic domain (AB) comprises an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 82.In some embodiments, the anti-FGFR4 antibody molecule is a non-murine antibody molecule, e.g., a human or humanized antibody molecule. In some embodiments, the anti-FGFR4 antibody molecule is a human antibody molecule. In some embodiments, the anti-FGFR4 antibody molecule is a humanized antibody molecule. In some embodiments, the anti-FGFR4 antibody molecule is isolated or recombinant.In some embodiments, the anti-FGFR4 antibody molecule binds to an epitope of FGFR4.In some embodiments, the anti-FGFR4 antibody described herein binds to an epitope of FGFR4. In some embodiments, the epitope is a FGFR4 domain 1 epitope. In preferred embodiments, the epitope is a conformational epitope within the FGFR4 domain 1.In some embodiments, the FGFR4 domain 1 epitope is common to human and mouse. Thus, the molecule (e.g., the anti-FGFR4 antibody molecule) binds to human FGFR4 and mouse FGFR4. In other words, the molecule cross-reacts with human and mouse FGFR4. In some embodiments, the FGFR4 domain 1 epitope is common to human, mouse and rat. In some embodiments, the FGFR4 domain 1 epitope is common to human, mouse, rat and cynomolgus monkey.In some embodiments, the epitope is defined by one or more of the following:(a) the epitope comprises His44, Tyr46, and Arg83 of SEQ ID NO: 78;(b) the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 24-86 of SEQ ID NO: 78, preferably to amino acid residues 44-86 of SEQ ID NO: 78;(c) the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 44-65, preferably to amino acid residues 46-65 of SEQ ID NO: 78; and(d) the epitope is within or overlapping amino acid residues 44-86 of SEQ ID NO: 78, preferably amino acid residues 44-65 of SEQ ID NO: 78, more preferably amino acid residues 44-62 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, or more consecutive amino acid residues of the sequence of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 25, at least 30, at least 35, at least 40, at least 45, or more consecutive amino acid residues of the sequence of SEQ ID NO: 78.In some embodiments, the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 24-86 of SEQ ID NO: 78, preferably to amino acid residues 44-86 or 46-86 of SEQ ID NO: 78.In some embodiments, the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 46-65 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 44-78 of SEQ ID NO: 78 or to amino acid residues 46- 78 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 44-65 of SEQ ID NO: 78 or to amino acid residues 46-65 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 44-68 of SEQ ID NO: 78 or to amino acid residues 46-68 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 44-67 of SEQ ID NO: 78 or to amino acid residues 46- 67 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 44-66 of SEQ ID NO: 78 or to amino acid residues 46- 66 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 44-52 of SEQ ID NO: 78 or to amino acid residues 46- 52 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 44-62 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 48-65 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 49-65 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 54-60 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 54-65 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%,at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 66-70 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 66-71 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 66-78 of SEQ ID NO: 78.In some embodiments, the epitope comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to amino acid residues 54-65 of SEQ ID NO: 78.In some embodiments, the epitope is within or overlaps amino acid residues 44-86 of SEQ ID NO: 78, preferably amino acid residues 44-65 of SEQ ID NO: 78, more preferably amino acid residues 44-62 of SEQ ID NO: 78. In preferred embodiments, the epitope is a conformational epitope within or overlapping amino acid residues 44-86 of SEQ ID NO: 78. In other preferred embodiments, the epitope is a conformational epitope within or overlapping amino acid residues 44-65 of SEQ ID NO: 78, more preferably is a conformational epitope within or overlapping amino acid residues 44-62 of SEQ ID NO: 78. In other preferred embodiments, the epitope is a conformational epitope overlapping amino acid residues 44-65 of SEQ ID NO: 78 and amino acid residues 81-86 of SEQ ID NO: 78.In some embodiments, the epitope comprises any one of amino acid residue ranges selected from: 46-52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78.In some embodiments, the epitope comprises amino acid residues 46-52, 46-65, 46-67, 46-68, 48- 65, 49-65, 54-65, 66-70, 66-71, or 66-78 of SEQ ID NO: 78.In some embodiments, the epitope comprises any one or more of His44, Tyr46, Arg51, Pro54, Trp61, Leu81, and Arg83 of SEQ ID NO: 78.In some embodiments, the epitope comprises His44, Tyr46, Arg51, Pro54, Trp61, Leu81, and Arg83 of SEQ ID NO: 78.In some embodiments, the epitope comprises His44, Tyr46 and Arg83 of SEQ ID NO: 78. In preferred embodiments, the epitope further comprises any one or more, preferably all, of Arg51, Pro54, Trp61 and Met86 of SEQ ID NO: 78, more preferably wherein the epitope still further comprises any one or more, preferably all of, Arg59 and Arg62 of SEQ ID NO: 78.In some embodiments, the epitope comprises His44, Tyr46, Arg51 and Arg83 of SEQ ID NO: 78. In some embodiments, the epitope comprises His44, Tyr46, Pro54 and Arg83 of SEQ ID NO: 78. In some embodiments, the epitope comprises His44, Tyr46, Trp61 and Arg83 of SEQ ID NO: 78. In some embodiments, the epitope comprises His44, Tyr46, Arg83 and Met86 of SEQ ID NO: 78. In some embodiments, the epitope comprises His44, Tyr46, Arg51, Pro54 and Arg83 of SEQ ID NO: 78.In some embodiments, the epitope comprises His44, Tyr46, Arg51, Pro54, Trp61 and Arg83 of SEQ ID NO: 78.In some embodiments, the epitope comprises His44, Tyr46, Arg51, Pro54, Trp61, Arg83 and Met86 of SEQ ID NO: 78.In some embodiments, the epitope comprises His44, Tyr46, Arg51, Pro54, Arg59, Trp61, Arg83 and Met86 of SEQ ID NO: 78.In some embodiments, the epitope comprises His44, Tyr46, Arg51, Pro54, Trp61, Arg62, Arg83 and Met86 of SEQ ID NO: 78.In some embodiments, the epitope comprises His44, Tyr46, Arg51, Pro54, Arg59, Trp61, Arg62, Arg83 and Met86 of SEQ ID NO: 78.In some embodiments, optionally in combination with any of the features or embodiments described herein, the epitope does not comprise Ala39 of SEQ ID NO: 78. In some embodiments, the epitope does not comprise Gly43 of SEQ ID NO: 78. In some embodiments, the epitope does not comprise to any of Ala39 or Gly43 of SEQ ID NO: 78. In some embodiments, the epitope does not comprise or overlap amino acid residues 37-43 of SEQ ID NO: 78.In some embodiments, the anti-FGFR4 antibody molecule defined herein, preferably, the anti- FGFR4 antibody molecule binding to the epitope comprising any one of amino acid residue ranges selected from: 46-52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78, induces lower liver toxicity as compared to a control anti-FGFR4 antibody molecule. In some embodiments, the anti-FGFR4 antibody molecule defined herein, preferably, the anti- FGFR4 antibody molecule binding to the epitope comprising any one of amino acid residue ranges selected from: 46-52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQID NO: 78 1 induces lower level of hepatic enzymes production as compared to a control anti- FGFR4 antibody molecule.In some embodiments, the anti-FGFR4 antibody molecule defined herein, preferably, the anti- FGFR4 antibody molecule binding to the epitope comprising any one of amino acid residue ranges selected from: 46-52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78, has increased cytotoxicity as compared to a control anti-FGFR4 antibody molecule.In some embodiments, the anti-FGFR4 antibody molecule defined herein, preferably, the anti- FGFR4 antibody molecule binding to the epitope comprising any one of amino acid residue ranges selected from: 46-52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78, has increased tumor toxicity as compared to a control anti-FGFR4 antibody molecule. In some embodiments, the anti-FGFR4 antibody molecule defined herein, preferably, the anti- FGFR4 antibody molecule binding to the epitope comprising any one of amino acid residue ranges selected from: 46-52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78, has improved internalization as compared to a control anti-FGFR4 antibody molecule. In some embodiments, the control anti-FGFR4 antibody molecule does not bind to an epitope comprising any one of amino acid residue ranges selected from: 46-52, 46-65, 46-67, 46-68, 48- 65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78.In some embodiments, the anti-FGFR4 antibody molecule or the derived ADC as described in any of the embodiments herein has increased cytotoxicity against cancer tumor cells or cell lines, such as any one or more of those described herein, increased tumor toxicity and / or reduction of tumor volume, improved cell internalization, improved pharmacokinetic properties (e.g., improved halflife), improved anti-tumoral properties, improved anti-metastatic effects, improved crossreactivity with preclinical animal models and / or lower level of immunogenicity (e.g., predicted immunogenicity, and / or higher degree of human content in the antibody variable domains) and / or lower level of toxicities, such as hepatic toxicity (e.g., a lower level of hepatic enzyme production and / or a lower level of bile acid production) as compared to a control anti-FGFR4 antibody molecule - all of which can contribute to improved therapeutic efficacy and ultimately, better patient survival (e.g., better Progression Free Survival (PFS) or Overall Survival (OS)). In some embodiments, the attachment of the linker to the anti-FGFR4 molecule described herein is configured to enable traceless release of the intact payload, a property that is desired for the cell- permeable drugs (e.g., exatecan) to diffuse from targeted cells into the surrounding microenvironment, thereby producing a bystander effect in neighboring tumor cells. In someembodiments, the anti-FGFR4 antibody molecule or the derived ADC as described in any of the embodiments herein has increased physicochemical stability (such as improved resistance to temperature or pH changes), better production yield (e.g., higher transient expression titer in eukaryotic cells, preferably in mammalian cells such as CHO or HEK cells), less propensity to aggregation or easier conjugation. In some embodiments, the control anti-FGFR4 antibody molecule is an anti-FGFR4 blocking antibody, such as one or more of the comparative antibodies used in the examples. In other embodiments, the control anti-FGFR4 antibody molecule is an anti- FGFR4 non-blocking antibody. In some embodiments, the control anti-FGFR4 antibody molecule is the murine anti-human FGFR4 antibody 3A11 which does not show cross-reactivity to mouse FGFR4 (TIAN MEIJIE ET AL: "Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma". CELL REPORTS MEDICINE, vol. 4, no. 10, page 101-212; see also US11078286 B2). In some embodiments, the control anti-FGFR4 antibody molecule binds to another epitope in domain 1.In some embodiments, the anti-FGFR4 antibody molecule as described herein is non-antagonistic or non-blocking. In some embodiments, the anti-FGFR4 antibody molecule as described herein results in a reduction of FGFR4 activity of less than 55%, preferably less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, more preferably less than 5% with respect to the FGFR4 ligand (FGF19, UNIPROT: 095750, 1999-05-01 vl). In some embodiments, FGFR4 activity is determined by a cell-based assay that monitors FGFR4 activation, as shown in Example 4, see FIG 6C.In some embodiments, the anti-FGFR4 antibody molecule or the derived ADC as described in any of the embodiments herein has a percentage of cell internalization which is of at least 70%, at least 75%, or preferably of at least 80%, after 4 hours in a FGFR4+ expressing cell line, such as in any of the FGFR4+ expressing cancer cell lines described herein. In preferred embodiments, the FGFR4+ cell line is a high expression FGFR4+ cancer cell line, such as the breast cancer cell line MDA-MB-453, see FIG. 10C.To assess the internalization of ADCs in cancer cells, the most widely employed methods include fluorescence-based techniques, such as confocal microscopy generally combined with lysosomal colocalization, which allows visualization of cellular uptake and trafficking (Lewis, G.D., Li, G., Guo, J. et al., Nat Commun 15, 466 (2024). https: / / doi.org / 10.1038 / s41467-023-44533-z). Flow cytometry can quantitatively measure internalization by incubating the cells with a fluorescently labeled secondary antibody that measures how much antibody remains surface-bound after anincubation period (Shi et al. Cancer Res (2023) 83 (22): 3783-3795; 10.1158 / 0008-5472.CAN- 23-1356). . Additionally, pH-sensitive fluorogenic probes which emit fluorescence exclusively upon endosomal acidification are often used to monitor internalization and intracellular trafficking (Costa, M.J., Kudaravalli, J., Ma, JT. et al., Set Rep 9, 2443 (2019). https: / / doi.org / 10.1038 / s41598-019-38745-x). Antibody internalization can be used as a surrogate marker of ADC internalization and can predict ADC potency (Shi et al. Cancer Res (2023) 83 (22): 3783-3795, Zwaagstra et al. Pios One (2019) Dec 31;14(12):e0226593. doi: 10.1371 / journal.pone.0226593). In preferred embodiments, cell internalization is measured by a flow cytometry assay or by live-cell imaging using pH-sensitive fluorogenic probes as described in the Examples, more preferably by a flow cytometry assay.In some embodiments, the anti-FGFR4 antibody molecule binding to the epitope comprising His44, Tyr46, Arg51, Pro54, Trp61, Leu81, and Arg83 of SEQ ID NO: 78 has increased cytotoxicity, increased tumor toxicity, improved internalization, and / or lower level of hepatic toxicity (e.g., a lower level of enzyme production and / or a lower level of bile acid production) as compared to a control anti-FGFR4 antibody molecule. In some embodiments, the control anti- FGFR4 antibody molecule does not bind to His44, Tyr46, Arg51, Pro54, Trp61, Leu81, and Arg83 of SEQ ID NO: 78.In some embodiments, the anti-FGFR4 antibody molecule binds to the FGFR4 domain 1 with a dissociation constant (KD) of 10 nM or less, 8 nM or less, or 5 nM or less.In some embodiments, the anti-FGFR4 antibody molecule comprises at least one antigen -binding region, e.g., a variable region or an antigen-binding fragment thereof, from an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences).In some embodiments, the anti-FGFR4 antibody molecule comprises at least one, two, three or four variable regions from an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) to any of the aforesaid sequences.In some embodiments, the anti-FGFR4 antibody molecule comprises at least one or two heavy chain variable regions from an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences.In some embodiments, the anti-FGFR4 antibody molecule comprises at least one or two heavy chain variable regions from an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) to any of the aforesaid sequences.In some embodiments, the anti-FGFR4 antibody molecule comprises a heavy chain constant region for an IgG4, e.g., a human IgG4. In still another embodiment, the anti-FGFR4 antibody molecule includes a heavy chain constant region for an IgGl, e.g., a human IgGl. In some embodiments, the heavy chain constant region comprises an amino sequence set forth in Table 2, or a sequence substantially (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) thereto.In some embodiments, the anti-FGFR4 antibody molecule comprises a kappa light chain constant region, e.g., a human kappa light chain constant region. In some embodiments, the light chain constant region comprises an amino sequence set forth in Table 2, or a sequence substantially (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) thereto.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, or three complementarity determining regions (CDRs) from a heavy chain variable region (VH) of an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences.In some embodiments, the anti-FGFR4 antibody molecule, includes at least one, two, or three CDRs (or collectively all of the CDRs) from a heavy chain variable region comprising an amino acid sequence shown in Table 2. In some embodiments, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, or three complementarity determining regions (CDRs) from a light chain variable region of an antibody described herein, e.g., an antibody chosen from an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, or three CDRs (or collectively all of the CDRs) from a light chain variable region comprising an amino acid sequence shown in Table 2. In some embodiments, one or more of the CDRs (or collectivelyall of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, three, four, five or six CDRs (or collectively all of the CDRs) from a heavy and light chain variable region comprising an amino acid sequence shown in Table 2. In some embodiments, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes all six CDRs from an antibody described herein, e.g., an antibody described in Table 2, or closely related CDRs, e.g., CDRs which are identical or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions). In some embodiments, the anti-FGFR4 antibody molecule may include any CDR described herein.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, or three CDRs according to Kabat et al. (e.g., at least one, two, or three CDRs according to the Kabat definition as set out in Table 2) from a heavy chain variable region of an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Kabat et al. shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, or three CDRs according to Kabat et al. (e.g., at least one, two, or three CDRs according to the Kabat definition as set out in Table 2) from a light chain variable region of an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Kabat et al. shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, three, four, five, or six CDRs according to Kabat et al. (e.g., at least one, two, three, four, five, or six CDRs according to the Kabat definition as set out in Table 2) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody described in Table 2; or a sequencesubstantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, three, four, five, or six CDRs according to Kabat et al. shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes all six CDRs according to Kabat et al. (e.g., all six CDRs according to the Kabat definition as set out in Table 2) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to all six CDRs according to Kabat et al. shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, or three hypervariable loops that have the same canonical structures as the corresponding hypervariable loop of an antibody described herein, e.g., an antibody described in Table 2, e.g., the same canonical structures as at least loop 1 and / or loop 2 of the heavy and / or light chain variable domains of an antibody described herein. See, e.g., Chothia et al., (1992) J. Mol. Biol. 227:799- 817; Tomlinson et al., (1992) J. Mol. Biol. 227:776-798 for descriptions of hypervariable loop canonical structures. These structures can be determined by inspection of the tables described in these references.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, or three CDRs according to Chothia et al. (e.g., at least one, two, or three CDRs according to the Chothia definition as set out in Table 2) from a heavy chain variable region of an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Chothia et al. shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, or three CDRs according to Chothia et al. (e.g., at least one, two, or three CDRs according to the Chothia definition as set out in Table 2) from a light chain variable region of an antibody described herein,e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Chothia et al. shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes at least one, two, three, four, five, or six CDRs according to Chothia et al. (e.g., at least one, two, three, four, five, or six CDRs according to the Chothia definition as set out in Table 2) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody described in Table 2; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, three, four, five, or six CDRs according to Chothia et al. shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes all six CDRs according to Chothia et al. (e.g., all six CDRs according to the Chothia definition as set out in Table 2) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to all six CDRs according to Chothia et al. shown in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes a combination of CDRs or hypervariable loops defined according to Kabat et al., Chothia et al., or as described in Table 2.In some embodiments, the anti-FGFR4 antibody molecule can contain any combination of CDRs or hypervariable loops according to the Kabat and Chothia definitions.In some embodiments, a combined CDR as set out in Table 2 is a CDR that comprises a Kabat CDR and a Chothia CDR.In some embodiments, the anti-FGFR4 antibody molecule includes a combination of CDRs or hypervariable loops identified as combined CDRs in Table 2. In some embodiments, the anti- FGFR4 antibody molecule can contain any combination of CDRs or hypervariable loops according the “combined” CDRs described in Table 2.In some embodiments, the anti-FGFR4 antibody molecule includes all six CDRs as defined in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% or 100%) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to all six CDRs shown in Table 2. In some embodiments, the six CDRs are those of the “Consensus” CDR sequences. In some embodiments, the six CDRs are those of the “Consensus Ab-32-Ab-44" CDR sequences. In some embodiments, the six CDRs are those of the “Consensus Ab32-Ab49" CDR sequences. In some embodiments, the six CDRs are those of the “Consensus Ab-67-Ab-79" CDR sequences. In some embodiments, the six CDRs are those of the “Consensus Ab-18-Ab-30" CDR sequences. In some embodiments, the six CDRs are those of the “Consensus Ab-91 -Ab- 103". In some embodiments, the six CDRs are those of the “Consensus Ab-50-Ab-62" CDR sequences. In preferred embodiments, the six CDRs are those of the “Consensus Ab-32 and Ab-67" CDR sequences. In preferred embodiments, the six CDRs are those of the “Consensus Ab-32, Ab-67, and Ab-18” CDR sequences. In preferred embodiments, the six CDRs are those of the “Consensus Ab-32, Ab-67, Ab-18, Ab-91 and Ab-50" CDR sequences.In some embodiments, e.g., an embodiment comprising a variable region, a CDR (e.g., a combined CDR, Chothia CDR or Kabat CDR), or other sequence referred to herein, e.g., in Table 2, the antibody molecule is a monospecific antibody molecule, a bispecific antibody molecule, a bivalent antibody molecule, a biparatopic antibody molecule, or an antibody molecule that comprises an antigen binding fragment of an antibody, e.g., a half antibody or antigen binding fragment of a half antibody.In some embodiments, the anti-FGFR4 antibody molecule comprises at least one or two light chain variable regions from an antibody described herein, e.g., an antibody described in Table 2 or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99%, or 100%) to any of the aforesaid sequences.In some embodiments, the anti-FGFR4 antibody molecule comprises a light chain variable region (VL) comprising: a light chain complementarity determining region 1 (LCDR1) amino acid sequence of SEQ ID NO: 61, a light chain complementarity determining region 2 (LCDR2) amino acid sequence of Sequence NO: A62, and a light chain complementarity determining region 3 (LCDR3) amino acid sequence of Sequence NO: A63.In some embodiments, the anti-FGFR4 antibody molecule comprises a heavy chain variable region (VH) comprising: a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence of Sequence NO: A58, a heavy chain complementarity determining region 2 (HCDR2) amino acid sequence of Sequence NO: A59, and a heavy chain complementarity determining region 3 (HCDR3) amino acid sequence of Sequence NO: A60.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising: a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 ammo acid sequence of QQANSFPLT (SEQ ID NO: 9).In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising: a HCDR1 ammo acid sequence of GGSFSGYYWS (SEQ ID NO: 1), GYYWS (SEQ ID NO: 4), or GGSFSGY (SEQ ID NO: 5); a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2) or DHSGS (SEQ ID NO: 6); a HCDR3 ammo acid sequence of NYDDDYWFFDL (SEQ ID NO: 3) or NYDEDYWFFDL (SEQ ID NO: 260); or any combination thereof.In some embodiments, the anti-FGFR4 antibody molecule comprises: a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 ammo acid sequence of QQANSFPLT (SEQ ID NO: 9); and a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 amino acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 amino acid sequence of NYDDDYWFFDL (SEQ ID NO: 3).In some embodiments, the anti-FGFR4 antibody molecule comprises: a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 ammo acid sequence of QQANSFPLT (SEQ ID NO: 9); and a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 amino acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 amino acid sequence of NYDEDYWFFDL (SEQ ID NO: 260).In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising: a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24).In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising: a HCDR1 ammo acid sequence of GFTFSSYAMH (SEQ ID NO: 12), SYAMH (SEQ ID NO: 15), orGFTFSSY (SEQ ID NO: 16); a HCDR2 amino acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), or SNDGND (SEQ ID NO: 17); a HCDR3 amino acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14); or any combination thereofIn some embodiments, the anti-FGFR4 antibody molecule comprises: a VL comprising a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14).In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising: a LCDR1 amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35).In some embodiments, the anti-FGFR4 antibody molecule comprises VH comprising: a HCDR1 ammo acid sequence of GFTFDDYAMH (SEQ ID NO: 26), DYAMH (SEQ ID NO: 29), or GFTFDDY (SEQ ID NO: 30); a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), or SGDGGN (SEQ ID NO: 31); a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28); or any combination thereof.In some embodiments, the anti-FGFR4 antibody molecule comprises: a VL comprising a LCDR1 amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28).In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising: a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 ammo acid sequence of QQYDNLPYT (SEQ ID NO: 46).In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising: a HCDR1 ammo acid sequence of GFTFSSYVMH (SEQ ID NO: 37), SYVMH (SEQ ID NO: 40), or GFTFSSY (SEQ ID NO: 41); a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG(SEQ ID NO: 38), or SYTGNN (SEQ ID NO: 42); a HCDR3 amino acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39); or any combination thereof.In some embodiments, the anti-FGFR4 antibody molecule comprises: a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 ammo acid sequence of QQYDNLPYT (SEQ ID NO: 46); and a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39).In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising: a LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 ammo acid sequence of QQYDNLPYT (SEQ ID NO: 46).In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising: a HCDR1 ammo acid sequence of GFTLSSYVMN (SEQ ID NO: 48), SYVMN (SEQ ID NO: 34), or GFTLSSY (SEQ ID NO: 51); a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), or SYTGNN (SEQ ID NO: 52); a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50); or any combination thereof.In some embodiments, the anti-FGFR4 antibody molecule comprises: a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50). In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 11. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 11 , wherein the CDRs are as defined for SEQ ID NO: 11.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 11.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 10. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 10, wherein the CDRs are as defined for SEQ ID NO: 10.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising the sequence of SEQ ID NO: 10.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 10.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 10.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 261. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 261, wherein the CDRs are as defined for SEQ ID NO: 261.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising the sequence of SEQ ID NO: 261.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence ofSEQ ID NO: 11 and a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 261. some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 261.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 25. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 25, wherein the CDRs are as defined for SEQ ID NO: 25.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 25.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 21. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 21, wherein the CDRs are as defined for SEQ ID NO: 21.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising the sequence of SEQ ID NO: 21.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99. sequence identity to the sequence of SEQ ID NO: 25 and a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least99.9% sequence identity to the sequence of SEQ ID NO: 21. Preferably, wherein the CDRs of SEQ ID NO: 25 and SEQ ID NO: 26, respectively, are unchanged.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 25 and a VH comprising the sequence of SEQ ID NO: 21 .In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 36. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 36, wherein the CDRs are as defined for SEQ ID NO: 36.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 36.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 32. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 32, wherein the CDRs are as defined for SEQ ID NO: 32.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising the sequence of SEQ ID NO: 32.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 36 and a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 32. Preferably, wherein the CDRs of SEQ ID NO: 36 and SEQ ID NO: 32, respectively, are unchanged.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 36 and a VH comprising the sequence of SEQ ID NO: 32.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 47. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 47, wherein the CDRs are as defined for SEQ ID NO: 47.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 47.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 43.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising the sequence of SEQ ID NO: 43.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having a at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 47 and a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 43. Preferably, wherein the CDRs of SEQ ID NO: 47 and SEQ ID NO: 43, respectively, are unchanged.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 47 and a VH comprising the sequence of SEQ ID NO: 43.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 57. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 57, wherein the CDRs are as defined for SEQ ID NO: 57.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 57.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 53. In preferred embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising a sequence having the mentioned sequence identity to the sequence of SEQ ID NO: 53, wherein the CDRs are as defined for SEQ ID NO: 53.In some embodiments, the anti-FGFR4 antibody molecule comprises a VH comprising the sequence of SEQ ID NO: 53.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 57 and a VH comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99. sequence identity to the sequence of SEQ ID NO: 53. Preferably, wherein the CDRs of SEQ ID NO: 57 and SEQ ID NO: 53, respectively, are unchanged.In some embodiments, the anti-FGFR4 antibody molecule comprises a VL comprising the sequence of SEQ ID NO: 57 and a VH comprising the sequence of SEQ ID NO: 53.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate binds to, preferably specifically binds to, FGFR4 domain 1.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate binds to FGFR4 domain 1 with higher affinity than other FGFR4 domains selected from one or more of: a FGFR4 acidic box (AB), a FGFR4 domain 2, and a FGFR4 domain 3. In some embodiments, the FGFR domain 1, the FGFR4 AB, the FGFR4 domain 2, or the FGFR4 domain3 comprises a sequence as set forth in Table 1. In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate comprises one or more sequences set forth in Table 2.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1 has improved internalization as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, has improved internalization as compared to the Tool 3 antibody or the Tool 3 ADC described herein. In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti- FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1 has improved pharmacokinetic (PK) properties as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, has improved pharmacokinetic (PK) properties as compared to the Tool 3 antibody or the Tool 3 ADC described herein.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1 has increased cytotoxicity as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, has increased cytotoxicity as compared to the Tool 3 antibody or the Tool 3 ADC described herein.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drugconjugate with higher affinity for FGFR4 domain 1 has increased tumor toxicity as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, has increased tumor toxicity as compared to the Tool 3 antibody or the Tool 3 ADC described herein.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1 induces lower liver toxicity as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, induces lower liver toxicity as compared to the Tool 3 antibody or the Tool 3 ADC described herein.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1 induces lower level of hepatic enzymes production as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof. In some embodiments, the hepatic enzymes include AST and ALT.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, induces lower level of hepatic enzymes production as compared to the Tool 3 antibody or the Tool 3 ADC described herein. In some embodiments, the hepatic enzymes include AST and ALT.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1 induces lower level of bile acid production as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, induces lower level of bile acid production as compared to the Tool 3 antibody or the Tool 3 ADC described herein.In some embodiments, anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1 induces increased tumor toxicity or tumor killing as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof. In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, induces increased tumor toxicity or tumor killing as compared to the Tool 3 antibody or the Tool 3 ADC described herein.In some embodiments, anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, induces increased expression in mammalian cells (e.g., increased transient expression) as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, induces increased expression in mammalian cells (e.g., increased transient expression) as compared to the Tool 3 antibody or the Tool 3 ADC described herein.In some embodiments, anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1, induces reduced immunogenicity (e.g., it has reduced predicted immunogenicity, and / or higher degree of human content in the antibody variable domains) as compared to an anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 AB, FGFR4 domain 2, FGFR4 domain 3, or a combination thereof.In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein, preferably the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate with higher affinity for FGFR4 domain 1 induces reduced immunogenicity (e.g., it has reduced predicted immunogenicity, and / or higher degree of human content in the antibody variable domains) as compared to the Tool 3 antibody or the Tool 3 ADC described herein.In some embodiments, internalization, pharmacokinetic (PK) properties, cytotoxicity, liver toxicity, tumor toxicity, or tumor killing, expression (e.g., transient expression) in mammalian cells or predicted immunogenicity and / or degree of human content in the antibody variable domains is determined by one or more in vitro or in vivo method as described in Examples 6-14. In some embodiments, FGFR4 expression is elevated in acute myeloid leukemia, adrenocortical carcinoma, bladder urothelial carcinoma, glioma, breast invasive carcinoma, cervical squamous cell carcinoma, endocervical adenocarcinoma, cholangiocarcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary-cell carcinoma, liver cancer (e.g., hepatocellular carcinoma), rhabdomyosarcoma, lung adenocarcinoma, lung squamous cell carcinoma, diffuse large B-cell lymphoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostate adenocarcinoma, colorectal cancer (including colon adenocarcinoma and rectum adenocarcinoma), sarcoma, skin cutaneous melanoma, stomach adenocarcinoma, testicular germ cell tumors, thymoma, thyroid carcinoma, uterine carcinosarcoma, uterine corpus endometrial carcinoma, neuroendocrine tumors or uveal melanoma.In some embodiments, FGFR4 expression is elevated in metastasis of acute myeloid leukemia, adrenocortical carcinoma, bladder urothelial carcinoma, glioma, breast invasive carcinoma, cervical squamous cell carcinoma, endocervical adenocarcinoma, cholangiocarcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary-cell carcinoma, liver cancer (e.g., hepatocellular carcinoma), rhabdomyosarcoma, lung adenocarcinoma, lung squamous cell carcinoma, diffuse large B-cell lymphoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostate adenocarcinoma, colorectal cancer (e.g., colon adenocarcinoma and rectum adenocarcinoma), sarcoma, skin cutaneous melanoma, stomach adenocarcinoma, testicular germ cell tumors, thymoma, thyroid carcinoma, uterine carcinosarcoma, uterine corpus endometrial carcinoma, neuroendocrine tumors or uveal melanoma.In some embodiments, elevated FGFR4 expression is associated with HER2+ breast cancer. In some embodiments, elevated FGFR4 expression is associated with HER2- breast cancer. In some embodiments, elevated FGFR4 expression is associated with HR+ breast cancer. In some embodiments, elevated FGFR4 expression is associated with HR- breast cancer. In some embodiments, elevated FGFR4 expression is associated with HER2-enriched breast cancer. In some embodiments, elevated FGFR4 expression is associated with Triple Negative breast cancer. In some embodiments, elevated FGFR4 expression is associated with HR+ / HER2+ breast cancer. In some embodiments, elevated FGFR4 expression is associated with HR- / HER2- breast cancer. In some embodiments, elevated FGFR4 expression is associated with HR- / HER2+ breast cancer. In some embodiments, elevated FGFR4 expression is associated with HR+ / HER2- breast cancer. In some embodiments, the anti-FGFR4 antibody, the anti-FGFR4 ADC or a composition comprising any thereof as disclosed herein is used to treating HR+ / HER2- breast cancer. In some embodiments, the HR+ / HER2- breast cancer is metastatic. In some embodiments, elevated FGFR4 expression is associated with endocrine-therapy resistant breast cancer. In some embodiments, elevated FGFR4 expression is associated with CDK4 / 6 inhibitors resistant breast cancer. In some embodiments, elevated FGFR4 expression is associated with endocrine-therapy resistant and CDK4 / 6 inhibitors resistant breast cancer. In some embodiments, elevated FGFR4 expression is associated with HER2-enriched breast cancer. Elevated FGFR4 expression correlates with worse progression-free survival (PFS) and overall survival (OS). Patients with or progressing to endocrine therapy resistance and / or CDK4 / 6 inhibitor resistance express higher levels of FGFR4. In some embodiments, the anti-FGFR4 antibody, the anti-FGFR4 ADC or a composition comprising any thereof as disclosed herein is used to treating HR+ / HER2- CDK4 / 6 inhibitor resistant breast cancer. In some embodiments, the anti-FGFR4 antibody, the anti-FGFR4 ADC or a composition comprising any thereof as disclosed herein is used to treating HR+ / HER2- endocrine-therapy resistant and CDK4 / 6 inhibitors resistant breast cancer.In some embodiments, elevated FGFR4 expression is associated with metastasis of HR+ / HER2- breast cancer, metastasis of HR+ / HER2+ breast cancer, metastasis of HER2-enriched breast cancer, metastasis of CDK4 / 6 inhibitor resistant breast cancer, or metastasis of TNBC.In some embodiments, elevated FGFR4 expression is associated with metastasis of colorectal cancer. In some embodiments, elevated FGFR4 expression is associated with metastasis of gastric cancer (e.g., gastroesophageal junction cancer). In some embodiments, elevated FGFR4 expression is associated with metastasis of esophageal cancer (e.g., gastroesophageal junctioncancer). In some embodiments, elevated FGFR4 expression is associated with metastasis of liver cancer (e.g., hepatocellular carcinoma).In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein does not inhibit FGFR4 signaling. In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein does not reduce FGFR4 ligand binding. In some embodiments, the anti-FGFR4 antibody molecule or anti-FGFR4 antibody drug conjugate described herein does not compete with FGFR4 ligand.Antibody MoleculesIn some embodiments, the antibody molecule binds to a cancer antigen, e.g., a tumor antigen or a stromal antigen. In some embodiments, the cancer antigen is, e.g., a mammalian, e.g., a human, cancer antigen. In other embodiments, the antibody molecule binds to an immune cell antigen, e.g., a mammalian, e.g., a human, immune cell antigen. For example, the antibody molecule binds specifically to an epitope, e.g., linear or conformational epitope, on the cancer antigen or the immune cell antigen.In some embodiments, an antibody molecule is a monospecific antibody molecule and binds a single epitope. E.g., a monospecific antibody molecule having a plurality of immunoglobulin variable domain sequences, each of which binds the same epitope.In some embodiments, an antibody molecule comprises a diabody, and a single-chain molecule, as well as an antigen-binding fragment of an antibody (e.g., Fab, F(ab’)2, and Fv). For example, an antibody molecule can include a heavy (H) chain variable domain sequence (abbreviated herein as VH), and a light (L) chain variable domain sequence (abbreviated herein as VL). In some embodiments, an antibody molecule comprises or consists of a heavy chain and a light chain (referred to herein as a half antibody. In another example, an antibody molecule includes two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequence, thereby forming two antigen binding sites, such as Fab, Fab’, F(ab’)2, Fc, Fd, Fd’, Fv, single chain antibodies (scFv for example), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which may be produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. These functional antibody fragments retain the ability to selectively bind with their respective antigen or receptor. Antibodies and antibody fragments can be from any class of antibodies including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and from any subclass (e.g., IgGl, IgG2, IgG3, and IgG4) of antibodies. The preparation of antibody molecules can be monoclonal or polyclonal. Anantibody molecule can also be a human, humanized, CDR-grafted, or in vitro generated antibody. The antibody can have a heavy chain constant region chosen from, e.g., IgGl, IgG2, IgG3, or IgG4. The antibody can also have a light chain chosen from, e.g., kappa or lambda. The term “immunoglobulin” (Ig) is used interchangeably with the term “antibody” herein.Examples of antigen-binding fragments of an antibody molecule include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab’)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a diabody (dAb) fragment, which consists of a VH domain; (vi) a camelid or camelized variable domain; (vii) a single chain Fv (scFv), see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883); (viii) a single domain antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.Antibody molecules include intact molecules as well as functional fragments thereof. Constant regions of the antibody molecules can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function).Antibody molecules can also be single domain antibodies. Single domain antibodies can include antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. Single domain antibodies may be any of the art, or any future single domain antibodies. Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, fish, shark, goat, rabbit, and bovine. According to another aspect of the invention, a single domain antibody is a naturally occurring single domain antibody known as heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed in WO 9404678, for example. For clarity reasons, this variable domain derived from a heavy chain antibody naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other speciesbesides Camelidae may produce heavy chain antibodies naturally devoid of light chain; such VHHs are within the scope of the invention.The VH and VL regions can be subdivided into regions of hypervariability, termed “complementarity determining regions” (CDR), interspersed with regions that are more conserved, termed “framework regions” (FR or FW).The extent of the framework region and CDRs has been precisely defined by a number of methods (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917; and the AbM definition used by Oxford Molecular’s AbM antibody modeling software. See, generally, e.g., Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer- Verlag, Heidelberg).The terms “complementarity determining region,” and “CDR,” as used herein refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, LCDR3). The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5thEd. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme). As used herein, the CDRs defined according the “Chothia” number scheme are also sometimes referred to as “hypervariable loops.”For example, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR ammo acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia, the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3).Each VH and VL typically includes three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.The antibody molecule can be a polyclonal or a monoclonal antibody.The terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. A monoclonal antibody can be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods).The antibody can be recombinantly produced, e.g., produced by phage display or by combinatorial methods, or by yeast display.Phage display and combinatorial methods for generating antibodies are known in the art (as described in, e.g., Ladner et al. U.S. Patent No. 5,223,409; Kang et al. International Publication No. WO 92 / 18619; Dower et al. International Publication No. WO 91 / 17271; Winter et al. International Publication WO 92 / 20791; Markland et al. International Publication No. WO 92 / 15679; Breitling et al. International Publication WO 93 / 01288; McCafferty et al. International Publication No. WO 92 / 01047; Garrard et al. International Publication No. WO 92 / 09690; Ladner et al. International Publication No. WO 90 / 02809; Fuchs et al. (1991) Bio / Technology 9: 1370- 1372; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275- 1281; Gnffths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J Mol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991) Bio / Technology 9: 1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982, the contents of all of which are incorporated by reference herein).The yeast display method for generating or identifying antibodies is known in the art, e.g., as described in Chao et al. (2006) Nature Protocols l(2):755-68, the entire contents of which is incorporated by reference herein.In some embodiments, the antibody is a fully human antibody (e.g., an antibody made in a mouse which has been genetically engineered to produce an antibody from a human immunoglobulin sequence), or a non-human antibody, e.g., a rodent (mouse or rat), goat, primate (e.g., monkey), camel antibody. Preferably, the non-human antibody is a rodent (mouse or rat antibody). Methods of producing rodent antibodies are known in the art.Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. InternationalApplication WO 91 / 00906, Kucherlapati et al. PCT publication WO 91 / 10741; Lonberg et al. International Application WO 92 / 03918; Kay et al. International Application 92 / 03917; Lonberg, N. et al. 1994 Nature 368:856-859; Green, L.L. et al. 1994 Nature Genet. 7: 13-21; Morrison, S.L. et al.claims 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman etal. 1993 Year Immunol 7:33-40; Tuaillon et al. 1993 PNAS 90:3720-3724; Bruggeman et al. 1991 Eur J Immunol 21 :1323-1326).An antibody molecule can be one in which the variable region, or a portion thereof, e.g., the CDRs, are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibody molecules generated in a non-human organism, e.g., a rat or mouse, and then modified, e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention.An “effectively human” protein is a protein that does substantially not evoke a neutralizing antibody response, e.g., the human anti -murine antibody (HAMA) response. HAMA can be problematic in a number of circumstances, e.g., if the antibody molecule is administered repeatedly, e.g., in treatment of a chronic or recurrent disease condition. A HAMA response can make repeated antibody administration potentially ineffective because of an increased antibody clearance from the serum (see, e.g., Saleh et al., Cancer Immunol. Immunother., 32:180-190 (1990)) and also because of potential allergic reactions (see, e.g., LoBuglio et al., Hybridoma, 5:5117-5123 (1986)).Chimeric antibodies can be produced by recombinant DNA techniques known in the art (see Robinson et al., International Patent Publication PCT / US86 / 02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86 / 01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better etal. (1988 Science 240: 1041-1043); Liu etal. (1987) PNAS 84:3439-3443; Liu et al., 1987, J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al., 1987, Cane. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al., 1988, J. Natl Cancer Inst. 80: 1553-1559).A humanized or CDR-grafted antibody will have at least one or two but generally all three recipient CDRs (of heavy and or light immunoglobulin chains) replaced with a donor CDR. The antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required forbinding to the antigen. Preferably, the donor will be a rodent antibody, e.g., a rat or mouse antibody, and the recipient will be a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDRs is called the “donor” and the immunoglobulin providing the framework is called the “acceptor.” In some embodiments, the donor immunoglobulin is a non-human (e.g., rodent). The acceptor framework is a naturally-occurring (e.g., a human) framework or a consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.As used herein, the term “consensus sequence” refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987; Banik, S.S.R., Deng, X., Davidson, E. et al. Nat Biotechnol 43, 170-174 (2025)). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A “consensus framework” refers to the framework region in the consensus immunoglobulin sequence.An antibody molecule can be humanized by methods known in the art (see e.g., Morrison, S. L., 1985, Science 229: 1202-1207, by Oi et al., 1986, BioTechniques 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of which are hereby incorporated by reference).Humanized or CDR-grafted antibody molecules can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced. See e.g., U.S. Patent 5,225,539; Jones et al. 1986 Nature 321:552-525; Verhoeyan et al. 1988 Science 239: 1534; Beidler et al. 1988 J. Immunol. 141:4053-4060; Winter US 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US 5,225,539), the contents of which is expressly incorporated by reference.Also within the scope of the invention are humanized antibody molecules in which specific amino acids have been substituted, deleted or added. Criteria for selecting amino acids from the donor are described in US 5,585,089, e.g., columns 12-16 of US 5,585,089, e.g., columns 12-16 of US 5,585,089, the contents of which are hereby incorporated by reference. Other techniques forhumanizing antibodies are described in Padlan et al. EP 519596 Al, published on December 23, 1992.The antibody molecule can be a single chain antibody. A single-chain antibody (scFV) may be engineered (see, for example, Colcher, D. et al. (1999) Ann N Y Acad Sci 880:263-80; and Reiter, Y. (1996) Clin Cancer Res 2:245-52). The single chain antibody can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target protein.In yet other embodiments, the antibody molecule has a heavy chain constant region chosen from, e.g., the heavy chain constant regions oflgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, andlgE; particularly, chosen from, e.g., the (e.g., human) heavy chain constant regions of lgGl, IgG2, IgG3, and IgG4. In another embodiment, the antibody molecule has a light chain constant region chosen from, e.g., the (e.g., human) light chain constant regions of kappa or lambda. The constant region can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, and / or complement function). In some embodiments the antibody has: effector function; and can fix complement. In other embodiments the antibody does not; recruit effector cells; or fix complement. In another embodiment, the antibody has reduced or no ability to bind an Fc receptor. For example, it is an isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.Methods for altering an antibody constant region are known in the art. Antibodies with altered function, e.g. altered affinity for an effector ligand, such as FcR on a cell, or the Cl component of complement can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 Al, U.S. Pat. No. 5,624,821 and U.S. Pat. No. 5,648,260, the contents of all of which are hereby incorporated by reference). Similar type of alterations could be described which if applied to the murine, or other species immunoglobulin would reduce or eliminate these functions.An antibody molecule can be derivatized or linked to another functional molecule (e.g., another peptide or protein). As used herein, a “derivatized” antibody molecule is one that has been modified. Methods of derivatization include but are not limited to the addition of a fluorescent moiety, a radionucleotide, a toxin, an enzyme or an affinity ligand such as biotin. Accordingly, the antibody molecules of the invention are intended to include derivatized and otherwise modifiedforms of the antibodies described herein, including immunoadhesion molecules. For example, an antibody molecule can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and / or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).One type of derivatized antibody molecule is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies). Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxy succinimide ester) or homobifunctional (e.g., disuccinimidyl suberate). Such linkers are available from Pierce Chemical Company, Rockford, Ill.In some embodiments, the anti-FGFR4 antibody comprises a VL comprising a LCDR1, LCDR2, and LCDR3 having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to any LCDR1, LCDR2, and LCDR3 disclosed in Table 2.In some embodiments, the anti-FGFR4 antibody comprises a VH comprising a HCDR1, HCDR2, and HCDR3 having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to any HCDR1, HCDR2, and HCDR3 disclosed in Table 2.In some embodiments, the anti-FGFR4 antibody comprises a VH having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to any VH disclosed in Table 2. Preferably, wherein the HCDR1, HCDR2, and HCDR3 have 100% identity to those of the corresponding VH disclosed in Table 2.In some embodiments, the anti-FGFR4 antibody comprises a VL having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity to any VL disclosed in Table 2. Preferably, wherein the LCDR1, LCDR2, and LCDR3 have 100% identity to those of the corresponding VL disclosed in Table 2.Antibody-like Frameworks or ScaffoldsA wide variety of antibody / immunoglobulin frameworks or scaffolds can be employed in the anti- FGFR4 antibody molecules as described herein or multifunctional formats thereof so long as the resulting polypeptide includes at least one binding region which specifically binds to the target antigen, e.g., a FGFR4, a FGFR4 domain 1, a tumor antigen, among others. Such frameworks or scaffolds include the 5 main idiotypes of human immunoglobulins, or fragments thereof, and include immunoglobulins of other animal species, preferably having humanized aspects. Novel frameworks, scaffolds and fragments continue to be discovered and developed by those skilled in the art.Domain antibodies (dAbs) can be used in the anti-FGFR4 antibody molecules as described herein or multifunctional formats thereof are small functional binding fragments of antibodies, corresponding to the variable regions of either the heavy or light chains of antibodies. Domain antibodies are well expressed in bacterial, yeast, and mammalian cell systems. Further details of domain antibodies and methods of production thereof are known in the art (see, for example, U.S. Pat. Nos. 6,291,158; 6,582,915; 6,593,081; 6,172,197; 6,696,245; European Patents 0368684 & 0616640; WO05 / 035572, W004 / 101790, W004 / 081026, W004 / 058821, W004 / 003019 and W003 / 002609. Nanobodies are derived from the heavy chains of an antibody.A nanobody typically comprises a single variable domain and two constant domains (CH2 and CH3) and retains antigen-binding capacity of the original antibody. Nanobodies can be prepared by methods known in the art (See e.g., U.S. Pat. No. 6,765,087, U.S. Pat. No. 6,838,254, WO 06 / 079372). Unibodies consist of one light chain and one heavy chain of an IgG4 antibody. Unibodies may be made by the removal of the hinge region of IgG4 antibodies. Further details of unibodies and methods of preparing them may be found in W02007 / 059782.In some embodiments, a scaffold domain, e.g., a folded domain, is based on an antibody, e.g., a “minibody” scaffold created by deleting three beta strands from a heavy chain variable domain of a monoclonal antibody (see, e.g., Tramontane et al., 1994, J Mol. Recognit. 7:9; and Martin et al., 1994, EMBO J. 13:5303-5309). The “minibody” can be used to present two hypervariable loops. In some embodiments, the scaffold domain is a V-like domain (see, e.g., Coia et al. WO 99 / 45110) or a domain derived from tendamistatin, which is a 74 residue, six-strand beta sheet sandwich held together by two disulfide bonds (see, e.g., McConnell and Hoess, 1995, J Mol. Biol. 250:460).Antibody-Based FusionsA variety of formats can be generated which contain additional binding entities attached to the N or C terminus of antibodies. These fusions with single chain or disulfide stabilized Fvs or Fabsresult in the generation of tetravalent molecules with bivalent binding specificity for each antigen. Combinations of scFvs and scFabs with IgGs enable the production of molecules which can recognize three or more different antigens.Antibody-Fab FusionAntibody-Fab fusions are bispecific antibodies comprising a traditional antibody to a first target and a Fab to a second target fused to the C terminus of the antibody heavy chain. Commonly the antibody and the Fab will have a common light chain. Antibody fusions can be produced by (1) engineering the DNA sequence of the target fusion, and (2) transfecting the target DNA into a suitable host cell to express the fusion protein. It seems like the antibody-scFv fusion may be linked by a (Gly)-Ser linker between the C-terminus of the CH3 domain and the N-terminus of the scFv, as described by Coloma, J. et al. (1997) Nature Biotech 15:159.Antibody-scFv FusionAntibody-scFv Fusions are bispecific antibodies comprising a traditional antibody and a scFv of unique specificity fused to the C terminus of the antibody heavy chain. The scFv can be fused to the C terminus through the Heavy Chain of the scFv either directly or through a linker peptide. Antibody fusions can be produced by (1) engineering the DNA sequence of the target fusion, and (2) transfecting the target DNA into a suitable host cell to express the fusion protein. It seems like the antibody-scFv fusion may be linked by a (Gly)-Ser linker between the C-terminus of the CH3 domain and the N-terminus of the scFv, as described by Coloma, J. et al. (1997) Nature Biotech 15:159.Duobody“Duobody” technology to produce bispecific antibodies with correct heavy chain pairing are known. The DuoBody technology involves three basic steps to generate stable bispecific human IgGl antibodies in a post-production exchange reaction. In a first step, two IgGls, each containing single matched mutations in the third constant (CH3) domain, are produced separately using standard mammalian recombinant cell lines. Subsequently, these IgGl antibodies are purified according to standard processes for recovery and purification. After production and purification (post-production), the two antibodies are recombined under tailored laboratory conditions resulting in a bispecific antibody product with a very high yield (typically >95%) (see e.g., Labrijn et al, PNAS 2013; 110(13): 5145-5150 and Labrijn et al. Nature Protocols 2014;9(10):2450-63, the contents of each of which are incorporated by reference herein).Variable Domain Immunoglobulin DVDA related format is the dual variable domain immunoglobulin (DVD), which are composed of VH and VL domains of a second specificity place upon the N termini of the V domains by shorter linker sequences.Other exemplary antibody formats include, e.g., those described in the following US20160114057A1, US20130243775A1, US20140051833, US20130022601,US20150017187A1, US20120201746A1, US20150133638A1, US20130266568A1, US20160145340A1, WO2015127158A1, US20150203591A1, US20140322221A1,US20130303396A1, US20110293613, US20130017200A1, US20160102135A1,WO2015197598A2, WO2015197582A1, US9359437, US20150018529, WO2016115274A1,WO2016087416A1, US20080069820A1, US9145588B, US7919257, and US20150232560 Al. Exemplary molecules utilizing a full antibody-Fab / scFab format include those described in the following, US9382323B2, US20140072581A1, US20140308285A1, US20130165638A1, US20130267686A1, US20140377269A1, US7741446B2, and WO1995009917A1. Exemplary molecules utilizing a domain exchange format include those described in the following, US20150315296A1, WO2016087650 Al, US20160075785 Al, WO2016016299A1, US20160130347A1, US20150166670, US8703132B2, US20100316645, US8227577B2,US20130078249.Fc region and variantsIn some embodiments, an anti-FGFR4 antibody molecule as described herein comprises an Fc region, e.g., as described herein. In some embodiments, the Fc region is a wildtype Fc region, e.g., a wildtype human Fc region. In some embodiments, the Fc region comprises a variant, e.g., an Fc region comprising an addition, substitution, or deletion of at least one amino acid residue in the Fc region which results in, e.g., reduced or ablated affinity for at least one Fc receptor.The Fc region of an antibody interacts with a number of receptors or ligands including Fc Receptors (e.g., FcyRI, FcyRIIA, FcyRIIIA), the complement protein Clq, and other molecules such as proteins A and G. These interactions are essential for a variety of effector functions and downstream signaling events including: antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement dependent cytotoxicity (CDC).In some embodiments, an anti-FGFR4 antibody comprising a variant Fc region has reduced, e.g., ablated, affinity for an Fc receptor, e.g., an Fc receptor described herein. In some embodiments, the reduced affinity is compared to an otherwise similar antibody with a wildtype Fc region.In some embodiments, an anti-FGFR4 antibody molecule comprising a variant Fc region has one or more of the following properties: (1) reduced effector function (e.g., reduced ADCC, ADCP and / or CDC); (2) reduced binding to one or more Fc receptors; and / or (3) reduced binding to Clq complement. In some embodiments, the reduction in any one, or all of properties (l)-(3) is compared to an otherwise similar antibody with a wildtype Fc region.In some embodiments, an anti-FGFR4 antibody molecule comprising a variant Fc region has reduced affinity to a human Fc receptor, e.g., FcyR I, FcyR II and / or FcyR III. In some embodiments, the anti-FGFR4 antibody a variant Fc region comprises a human IgGl region or a human IgG4 region.Exemplary Fc region variants are disclosed in Saunders O, (2019) Frontiers in Immunology; vol 10, article 1296, the entire contents of which is hereby incorporated by reference.In some embodiments, an anti-FGFR4 antibody molecule as described herein comprise an Asn297Ala (N297A) mutation. In some embodiments, an anti-FGFR4 antibody molecule as described herein comprise a Leu234Ala / Leu235Ala (LALA) mutation.In some embodiments, the immunoglobulin chain constant region (e.g., the Fc region) is altered, e.g., mutated, to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function.In other embodiments, an interface of a first and second immunoglobulin chain constant regions (e.g., a first and a second Fc region) is altered, e.g., mutated, to increase or decrease dimerization, e.g., relative to a non-engineered interface, e.g., a naturally-occurring interface. For example, dimerization of the immunoglobulin chain constant region (e.g., the Fc region) can be enhanced by providing an Fc interface of a first and a second Fc region with one or more of: a paired protuberance-cavity (“knob-in-a hole”), an electrostatic interaction, or a strand-exchange, such that a greater ratio of heteromultimer to homomultimer forms, e.g., relative to a non-engineered interface.Knob-in-Hole as described in US 5,731,116, US 7,476,724 and Ridgway, J. et al. (1996) Prot. Engineering 9(7): 617-621, broadly involves: (1) mutating the CH3 domain of one or both antibodies to promote heterodimerization; and (2) combining the mutated antibodies under conditions that promote heterodimerization. “Knobs” or “protuberances” are typically created byreplacing a small amino acid in a parental antibody with a larger amino acid (e.g., T366Y or T366W); “Holes” or “cavities” are created by replacing a larger residue in a parental antibody with a smaller amino acid (e.g., Y407T, T366S, L368A and / or Y407V).In some embodiments, the Fc region is a variant IgG Fc region. In some embodiments, Fc region exhibits reduced binding to human FcyRI when compared with a reference protein. In some embodiments, the Fc region comprises a Fc silent mutation. In some embodiments, the variant Fc region is as described in US12037380B2.In some embodiments, the variant Fc region comprises: (a) an amino acid substitution at position 234 or an amino acid substitution at position 235 or amino acid substitutions at both positions 234 and 235; and (b) an amino acid alteration to arginine I at position 236, wherein the amino acid numbering is according to the EU index as in Kabat, and wherein the binding of the protein to human FcyRI is significantly reduced compared with the binding of a LALAPG reference protein. In some embodiments, the variant Fc region comprises a one or more of amino acid substitutions selected from: L234A / L235A, L234A / L235A / G236R, L234A / L235S / G236R,L234A / L235T / G236R, L234D / L235H / G236R, L234D / L235K / G236R, L234D / L235Q / G236R, L234D / L235S / G236R, L234D / L235T / G236R, L234E / L235D / G236R, L234E / L235H / G236R, L234E / L235I / G236R, L234E / L235V / G236R, L234G / L235H / G236R, L234G / L235Q / G236R, L234G / L235S / G236R, L234H / L235I / G236R, L234H / L235S / G236R, L234K / L235Q / G236R, L234K / L235R / G236R, L234K / L235S / G236R, L234K / L235T / G236R, L234K / L235V / G236R, L234Q / L235A / G236R, L234Q / L235D / G236R, L234Q / L235H / G236R, L234Q / L235Q / G236R, L234Q / L235R / G236R, L234Q / L235S / G236R, L234Q / L235T / G236R, L234Q / L235V / G236R, L234R / L235D / G236R, L234R / L235E / G236R, L234R / L235H / G236R, L234R / L235I / G236R, L234R / L235K / G236R, L234R / L235Q / G236R, L234R / L235R / G236R, L234R / L235T / G236R, L234S / L235D / G236R, L234S / L235E / G236R, L234S / L235G / G236R, L234S / L235H / G236R, L234S / L235I / G236R, L234S / L235R / G236R, L234S / L235T / G236R, L234S / L235V / G236R, L234T7L235A / G236R, L234T / L235I / G236R, L234T7L235K / G236R, L234T7L235Q / G236R, L234T7L235R / G236R, L234T / L235S / G236R, L234T / L235T / G236R, L234A / L235A / P329G and L234T / L235V / G236R.In some embodiments, the variant Fc region comprises a variant IgG2 Fc. In some embodiments, the variant IgG2 Fc comprises one or more amino acid substitutions selected from: V234A / A235S / A236R, V234A / A235T / A236R, V234D / A235H / A236R, V234D / A235K / A236R, V234D / A235Q / A236R, V234D / A235S / A236R, V234D / A235T / A236R, V234E / A235D / A236R,V234E / A235H / A236R, V234E / A235I / A236R, V234E / A235V / A236R, V234G / A235H / A236R, V234G / A235Q / A236R, V234G / A235S / A236R, V234H / A235I / A236R, V234H / A235S / A236R, V234K / A235Q / A236R, V234K / A235R / A236R, V234K / A235S / A236R, V234K / A235T / A236R, V234K / A235V / A236R, V234Q / A235D / A236R, V234Q / A235H / A236R, V234Q / A235Q / A236R, V234Q / A235R / A236R, V234Q / A235S / A236R, V234Q / A235T / A236R, V234Q / A235V / A236R, V234R / A235D / A236R, V234R / A235E / A236R, V234R / A235H / A236R, V234R / A235I / A236R, V234R / A235K / A236R, V234R / A235L / A236R, V234R / A235Q / A236R, V234R / A235R / A236R, V234R / A235T / A236R, V234S / A235D / A236R, V234S / A235E / A236R, V234S / A235G / A236R, V234S / A235H / A236R, V234S / A235I / A236R, V234S / A235L / A236R, V234S / A235R / A236R, V234S / A235T / A236R, V234S / A235V / A236R, V234T / A235I / A236R, V234T / A235K / A236R, V234T / A235Q / A236R, V234T / A235R / A236R, V234T / A235S / A236R, V234T / A235T / A236R, and V234T / A235V / A236R.In some embodiments, the variant Fc region is a variant IgG4 Fc. In some embodiments, the variant IgG4 Fc comprises one or more amino acid substitutions F234A / L235A / G236R, F234A / L235S / G236R, F234A / L235T / G236R, F234D / L235H / G236R, F234D / L235K / G236R, F234D / L235Q / G236R, F234D / L235S / G236R, F234D / L235T / G236R, F234E / L235D / G236R, F234E / L235H / G236R, F234E / L235I / G236R, F234E / L235V / G236R, F234G / L235H / G236R, F234G / L235Q / G236R, F234G / L235S / G236R, F234H / L235I / G236R, F234H / L235S / G236R, F234K / L235Q / G236R, F234K / L235R / G236R, F234K / L235S / G236R, F234K / L235T / G236R, F234K / L235V / G236R, F234Q / L235A / G236R, F234Q / L235D / G236R, F234Q / L235H / G236R, F234Q / L235Q / G236R, F234Q / L235R / G236R, F234Q / L235S / G236R, F234Q / L235T / G236R, F234Q / L235V / G236R, F234R / L235D / G236R, F234R / L235E / G236R, F234R / L235H / G236R, F234R / L235I / G236R, F234R / L235K / G236R, F234R / L235Q / G236R, F234R / L235R / G236R, F234R / L235T / G236R, F234S / L235D / G236R, F234S / L235E / G236R, F234S / L235G / G236R, F234S / L235H / G236R, F234S / L235I / G236R, F234S / L235R / G236R, F234S / L235T / G236R, F234S / L235V / G236R, F234T / L235A / G236R, F234T / L235I / G236R, F234T / L235K / G236R, F234T / L235Q / G236R, F234T / L235R / G236R, F234T / L235S / G236R, F234T7L235T / G236R, andF234T7L235 V / G236R.In some embodiments, the amino acid numbering is according to the EU index as in Kabat.In some embodiments, the variant Fc region comprises one or more amino acid substitutions selected from L234G / L235S / G236R, L234S / L235T / G236R, L234S / L235V / G236R,L234T7L235Q / G236R, and L234T / L235T / G236R.Exemplary moleculesIn some embodiments, the anti-FGFR4 antibody molecule comprises a first heavy chain and a first light chain. In some embodiments, the anti-FGFR4 antibody molecule comprises a first heavy chain, a second heavy chain, and a first light chain. In some embodiments, the first heavy chain and the second heavy chain are non-contiguous. In some embodiments, the first heavy chain comprises a first portion of a dimerization domain linked to the VH; the first light chain comprises the VL; and the second heavy chain comprises a second portion of the dimerization domain. In some embodiments, the first portion of the dimerization domain and the second portion of the dimerization domain are dimerized.In some embodiments, the first heavy chain further comprises a heavy chain constant domain 1 (CHI) linked to the VH. In some embodiments, the CHI is linked to the C-terminus of the VH.In some embodiments, the first light chain further comprises a light chain constant domain (CL) linked to the VL. In some embodiments, the CL is linked to the C-terminus of the VL. In some embodiments, the first portion of the dimerization module is linked to C-terminus of the VH. In some embodiments, the first portion of the dimerization module is linked to C-terminus of the CHI.In some embodiments, the first portion of the dimerization module comprises a first immunoglobulin constant region (Fc region) and the second portion of the dimerization module comprises a second Fc region. In some embodiments, the first Fc region, the second Fc region, or a combination thereof is selected from the group consisting of an IgGl Fc region or a functional fragment thereof, an IgG2 Fc region or a functional fragment thereof, an IgG3 Fc region or a functional fragment thereof, an IgGAl Fc region or a functional fragment thereof, an IgGA2 Fc region or a functional fragment thereof, an IgG4 Fc region or a functional fragment thereof, an IgM Fc region or a functional fragment thereof, an IgD Fc region or a functional fragment thereof, and an IgE Fc region or a functional fragment thereof.In some embodiments, the first Fc region, the second Fc region, or a combination thereof comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 65 or SEQ ID NO: 66.In some embodiments, the first heavy chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 64, 69, 71, 73 and 75. In some embodiments, the first heavy chain comprises a sequence of any one of SEQ ID NOs: 64, 69, 71, 73 and 75.In some embodiments, the second heavy chain polypeptide comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 64, 69, 71, 73 and 75. In some embodiments, the second heavy chain comprises a sequence of any one of SEQ ID NOs: 64, 69, 71, 73 and 75.In some embodiments, the first light chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 67, 70, 72, 74, and 76. In some embodiments, the first light chain comprises a sequence of any one of SEQ ID NOs: 67, 70, 72, 74, and 76.In some embodiments, the molecule further comprises a second light chain.In some embodiments, the second light chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of SEQ ID NOs: 67, 70, 72, 74, and 76. In some embodiments, the second light chain comprises a sequence of any one of SEQ ID NOs: 67, 70, 72, 74, and 76.In some embodiments, the first heavy chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NO: 64, 85, 88, 92, 96, 69, 234, 111, 115, 119, 71, 134, 137, 140, 144, 73, 160, 164, 167, 170,75, 185, 190, 194, 199, 262, 264, 267 and 270. In some embodiments, the first heavy chain comprises a sequence of any one of SEQ ID NO: 64, 85, 88, 92, 96, 69, 234, 111, 115, 119, 71, 134, 137, 140, 144, 73, 160, 164, 167, 170,75, 185, 190, 194, 199, 262, 264, 267 and 270.In some embodiments, the second heavy chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NO: 64, 85, 88, 92, 96, 69, 234, 111, 115, 119, 71, 134, 137, 140, 144, 73, 160, 164, 167, 170,75, 185, 190, 194,199, 262, 264, 267 and 270.In some embodiments, the second heavy chain comprises a sequence of any one of SEQ ID NO: 64, 85, 88, 92, 96, 69, 234, 111, 115, 119, 71, 134, 137, 140, 144, 73, 160, 164, 167, 170,75, 185, 190, 194, 199, 262, 264, 267 and 270.In some embodiments, the first light chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 67, 70, 72, 74, 76, 99, 102, 122, 125, 128, 131, 147, 150, 153, 156, 173, 176, 179, 182, 202, 205, 208, 211, 233, 236 and 273.In some embodiments, the first light chain comprises a sequence of any one of SEQ ID NOs: 67, 70, 72, 74, 76, 99, 102, 122, 125, 128, 131, 147, 150, 153, 156, 173, 176, 179, 182, 202, 205, 208, 211, 233, 236 and 273.In some embodiments, the molecule further comprises a second light chain.In some embodiments, the second light chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 67, 70, 72, 74, 76, 99, 102, 122, 125, 128, 131, 147, 150, 153, 156, 173, 176, 179, 182, 202, 205, 208, 211, 233, 236 and 273.In some embodiments, the second light chain comprises a sequence of any one of SEQ ID NOs: 67, 70, 72, 74, 76, 99, 102, 122, 125, 128, 131, 147, 150, 153, 156, 173, 176, 179, 182, 202, 205, 208, 211, 233, 236 and 273.In some embodiments, the molecule comprises a first heavy chain, and optionally a second heavy chain, comprising a sequence having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of the heavy chain sequences (VH-CH) disclosed in Table 2; and a light chain, and optionally a second light chain, comprising a sequence having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of any one of the light chain sequences (VL-CL) disclosed in Table 2. In some embodiments, the molecule comprises a first heavy chain, and optionally asecond heavy chain, comprising the sequence of any one of the heavy chain sequences (VH-CH) disclosed in Table 2; and a first light chain, and optionally a second light chain, comprising the sequence of any one of the light chain sequences (VL-CL) disclosed in Table 2.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 64 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 64; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 64; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 64; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 85; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 85 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 85; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 85; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 85; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 85; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 88; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 88 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 88; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 88; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 88; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 88; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 92; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%,at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 92 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 92; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 92; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 92; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 92; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 96; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 96 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 96; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 96; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 96; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 96; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 99.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 64 and a first light chain comprising a sequence of SEQ ID NO: 99.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 64; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 99; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 99.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 64; a first light chain comprising a sequence of SEQ ID NO: 99; a second heavy chain comprising a sequence of SEQ ID NO: 64; and a second light chain comprising a sequence of SEQ ID NO: 99.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 102.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 64 and a first light chain comprising a sequence of SEQ ID NO: 102.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 64; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 102; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 102.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 64; a first light chain comprising a sequence of SEQ ID NO: 102; a second heavy chain comprising a sequence of SEQ ID NO: 64; and a second light chain comprising a sequence of SEQ ID NO: 102.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 233.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 64 and a first light chain comprising a sequence of SEQ ID NO: 233.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 64; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%,at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 233; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 233.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 64; a first light chain comprising a sequence of SEQ ID NO: 233; a second heavy chain comprising a sequence of SEQ ID NO: 64; and a second light chain comprising a sequence of SEQ ID NO: 233.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 236.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 64 and a first light chain comprising a sequence of SEQ ID NO: 236.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 64; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at1 least 99.9% sequence identity to the sequence of SEQ ID NO: 236; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 236.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 64; a first light chain comprising a sequence of SEQ ID NO: 236; a second heavy chain comprising a sequence of SEQ ID NO: 64; and a second light chain comprising a sequence of SEQ ID NO: 236.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 85; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 99.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 85 and a first light chain comprising a sequence of SEQ ID NO: 99.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 85; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 99; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 85; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 99.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 85; a first light chain comprising a sequence of SEQ ID NO: 99; a second heavy chain comprising a sequence of SEQ ID NO: 85; and a second light chain comprising a sequence of SEQ ID NO: 99.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 88; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 102.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 88 and a first light chain comprising a sequence of SEQ ID NO: 102.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 88; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 102; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 88; and a second light chain comprising a sequence havingat least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 102.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 88; a first light chain comprising a sequence of SEQ ID NO: 102; a second heavy chain comprising a sequence of SEQ ID NO: 88; and a second light chain comprising a sequence of SEQ ID NO: 102.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 92; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 233.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 92 and a first light chain comprising a sequence of SEQ ID NO: 233.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 92; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 233; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 92; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 233.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 92; a first light chain comprising a sequence of SEQ ID NO: 233; a second heavy chain comprising a sequence of SEQ ID NO: 92; and a second light chain comprising a sequence of SEQ ID NO: 233.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 96; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 236.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 96 and a first light chain comprising a sequence of SEQ ID NO: 236.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 96; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 236; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 96; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 236.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 96; a first light chain comprising a sequence of SEQ ID NO: 236; a second heavy chain comprising a sequence of SEQ ID NO: 96; and a second light chain comprising a sequence of SEQ ID NO: 236.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 264; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 264 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 264; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 264; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67. In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 264; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chaincomprising a sequence of SEQ ID NO: 264; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 267; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 267 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 267; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 267; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67. In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 267; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 267; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 270; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 270 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 267; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 270; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67. In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 270; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 270; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 273.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 64 and a first light chain comprising a sequence of SEQ ID NO: 273.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 64; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 273; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 64; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 273.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 64; a first light chain comprising a sequence of SEQ ID NO: 273; a second heavy chain comprising a sequence of SEQ ID NO: 64; and a second light chain comprising a sequence of SEQ ID NO: 273.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 262; and a first light chain comprising a sequence having at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence of SEQ ID NO: 262 and a first light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 262; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 262; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 262; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 262; and a second light chain comprising a sequence of SEQ ID NO: 67.In some embodiments, the molecule comprises: a first heavy chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 69 and a first light chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 70.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 69 and a first light chain comprising a sequence of SEQ ID NO: 70.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 69; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 70; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 69; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 70.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 69; a first light chain comprising a sequence of SEQ ID NO: 70; a second heavy chain comprising a sequence of SEQ ID NO: 69; and a second light chain comprising a sequence of SEQ ID NO: 70. In some embodiments, the molecule comprises: a first heavy chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 71 and a first light chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 72.In some embodiments, the molecule comprises a first heavy chain comprises a sequence of SEQ ID NO: 71 and a first light chain comprises a sequence of SEQ ID NO: 72.In some embodiments, the molecule comprises: a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 71; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 72; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 71; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 72.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 71; a first light chain comprising a sequence of SEQ ID NO: 72; a second heavy chain comprising a sequence of SEQ ID NO: 71; and a second light chain comprising a sequence of SEQ ID NO: 72.In some embodiments, the molecule comprises a first heavy chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 73 and a first light chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 74.In some embodiments, the molecule comprises a first heavy chain comprises a sequence of SEQ ID NO: 73 and a first light chain comprises a sequence of SEQ ID NO: 74.In some embodiments, the molecule comprises a first heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 73; a first light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 74; a second heavy chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 73; and a second light chain comprising a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 74.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 73; a first light chain comprising a sequence of SEQ ID NO: 74; a second heavy chain comprising a sequence of SEQ ID NO: 73; and a second light chain comprising a sequence of SEQ ID NO: 74.In some embodiments, the molecule comprises a first heavy chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 75 and a first light chain comprises a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 76. In some embodiments, the molecule comprises a first heavy chain comprises a sequence of SEQ ID NO: 75 and a first light chain comprises a sequence of SEQ ID NO: 76.In some embodiments, the molecule comprises a first heavy chain comprising a sequence having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 75; a first light chain comprising a sequence having at least 65%, at least 70%, at least 75%, at least 80%,at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%sequence identity to the sequence of SEQ ID NO: 76; a second heavy chain comprising a sequence having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 75; and a second light chain comprising a sequence having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% sequence identity to the sequence of SEQ ID NO: 76.In some embodiments, the molecule comprises a first heavy chain comprising a sequence of SEQ ID NO: 75; a first light chain comprising a sequence of SEQ ID NO: 76; a second heavy chain comprising a sequence of SEQ ID NO: 75; and a second light chain comprising a sequence of SEQ ID NO: 76.Antibody-drug conjugate (ADC)In some embodiments, the anti-FGFR4 antibody molecule described herein is conjugated to a cytotoxic drug. An antibody-drug conjugate (ADC) having a drug with cytotoxicity conjugated to an antibody, whose antigen is expressed on a surface of cancer cells and which also binds to an antigen capable of cellular internalization, and therefore can deliver the drug selectively to cancer cells and is thus expected to cause accumulation of the drug within cancer cells and to kill the cancer cell.LinkerIn some embodiments, the anti-FGFR4 antibody is conjugated to the cytotoxic drug or a small molecule cytotoxic payload with a linker. In some embodiments, the ADC comprises a cleavable linker. In some embodiments, the ADC comprises a linker architecture configured to enable traceless release of the intact payload, a property that is desired for cell membrane-permeable payloads such as exatecan to diffuse from targeted cells into the surrounding microenvironment. Linkers that enable a traceless release typically comprise a PABC spacer, an ethylenediaminecarbamate spacer or a hemiaminal spacer. In some embodiments, the ADC comprises a non- cleavable linker. In some embodiments, the linker is a covalent linker.In some embodiments, the linker comprises an antibody-attachment and a cytotoxic drugattachment.In some embodiments, the cytotoxic drug-attachment determines release rate, solubility, and potency of the ADC.In some embodiments, the antibody-attachment located at N-terminus of the linker, in some embodiments, the cytotoxic drug-attachment is located at C-terminus of the linker.In some embodiments, the cleavable linker is a chemically-cleavable linker. Non-limiting examples of chemically-cleavable linker include acid cleavable linker and reducible disulfide linker.In some embodiments, the acid cleavable linker aims at the acidity of the endosomes (pH 5.5-6.2) and lysosomes (pH4.5-5.0) while maintaining stability in circulation at pH 7.4. In some embodiments, the acid cleavable linker comprises an acid-sensitive N-acyl hydrazone linkage. In some embodiments, the acid-sensitive N-acyl hydrazone linkage hydrolyses to a ketone and a hydrazide-pay load. In some embodiments, the acid cleavable linker comprises a SN-38 payload. In some embodiments, the cleavable linker is cleaved by an exogenous stimulus.In some embodiments, the cleavable linker is an enzyme-cleavable linker. Non-limiting examples of enzyme-cleavable linker include dipeptide-containing linker, tri-peptide containing linker, tetrapeptide containing linker, glucuronide cleavable linker, glycosidase linker, and phosphatase- cleavable linker.In some embodiments, the dipeptide-containing linker can be cleaved by cathepsin B. A Phe-Arg sequence can serve as a substrate for cathepsin B and L. Two general trends were observed: (1) a hydrophilic residue at Pl is required and hydrolysis rates increase with basicity. Citrulline (Cit) is isoelectronic with Arg, and was preferred to Arg due to synthetic ease, despite the lower basicity. (2) The hydrophobic residues Phe, Vai and Ala at P2 enable cleavage by cathepsin B while imparting plasma stability. In some embodiments, an Ala residue is at Pl.In some embodiments, the peptide linker can be cleaved by legumain. A sequence containing asparagine (Asn) can serve as a substrate for legumain. Peptide linkers which are substrates for legumain include but are not limited to -NN-, -GNN- and -NNG-.In some embodiments, the dipeptide-containing linker includes a Valine-Citrulline (Val-Cit), a Valine- Alanine (Vai-Ala) linker, or a phenylalanine-lysine (Phe-Lys) linker.In some embodiments, the linker comprises a Ser-Val-Cit linker. In some embodiments, the linker comprises a Glu-Val-Cit linker, in some embodiments, the linker comprises a Vai- Ala linker.In some embodiments, the cleavable linker comprises a peptidyl linker cleavable by an intracellular protease.In some embodiments, the linker comprises any one of-GGF-,-DGGF- (SEQ ID NO: 243),-(D-) D-GGF- (SEQ ID NO: 244),-EGGF- (SEQ ID NO: 245),-GGFG- (SEQ ID NO: 246),-SGGF- (SEQ ID NO: 247),-KGGF- (SEQ ID NO: 248),-DGGFG-(SEQ ID NO: 249),-GGFGG- (SEQ ID NO: 250),-DDGGFG- (SEQ ID NO: 251),-KDGGFG- (SEQ ID NO: 252),-GGFGGGF- (SEQ ID NO: 253); wherein “(D-) D” represents D-aspartic acid,-AA- ,-AAA-,-L-Ala-D-Ala-L-Ala-,-GGG-,-VQ-,-NN-,-GNN- and-NNG-.Preferably, the linker comprises any one of-GGF-,-DGGF- (SEQ ID NO: 243),-(D-) D-GGF- (SEQ ID NO: 244),-EGGF- (SEQ ID NO: 245),-GGFG- (SEQ ID NO: 246),-SGGF- (SEQ ID NO: 247),-KGGF- (SEQ ID NO: 248),-DGGFG-(SEQ ID NO: 249),-GGFGG- (SEQ ID NO: 250),-DDGGFG- (SEQ ID NO: 251),-KDGGFG- (SEQ ID NO: 252), and-GGFGGGF- (SEQ ID NO: 253); wherein “(D-) D” represents D-aspartic acid.In some embodiments, the linker comprises a structure represented by -L1-L2-LP-NH — (CH2)n1-La- Lb-Lc-. In some embodiments, the Lcis -L1-L2-LP-NH — (CH2)n1-La-Lb-Lc-.In some embodiments, L1is -(Succinimid-3-yl-N) — (CH2)n2-C(=O) — , n2is an integer of 2 to 5, and L2 is a single bond.In some embodiments, n1represents an integer of 0 to 6. In some embodiments, n2 represents an integer of 0 to 5.In some embodiments, L1represents -(Succinimid-3-yl-N) — (CH2)n3-C(=O) — , wherein n3 represents an integer of 2 to 8.In some embodiments, L2represents — NH — (CH2CH2 — O)n4-CH2CH2 — C(=O) — or a single bond, wherein n4represents an integer of 1 to 6, LP represents a peptide residue consisting of 2 to 7 amino acids, Larepresents — O — or a single bond, and-(Succinimid-3-yl-N) — has a structure represented by the following formula:In some embodiments, the structure of the — NH — (CH2)n1-La-Lb-Lc- moiety in the linker is:— NH— CH2— C(=O)— ,— NH— (CH2)2— C(=O)— ,— NH— (CH2)3— C(=O)— ,— NH— CH2— O— CH2— C(=O)— , or— NH— (CH2)2— O— CH2— C(=O)— .In some embodiments, the structure of the — NH — (CH2)n1-La-Lb-Lc- moiety in the linker is:— NH— CH2— C(=O)— ,— NH— (CH2)2— C(=O)— , or— NH— (CH2)3— C(=O)— .In some embodiments, the cleavable linker is cleavable by a glycosidase, preferably by a glucuronidase. Beta-glucuronide based linkers are well known in the art and are described for instance in US8568728B2 or US11103593B2.In some embodiments, the linker comprises a maleimide or derivatives thereof. In some embodiments, the maleimide is selected from maleimidocaproyl, maleimidomethyl cyclohexane- 1 -carboxylate, maleimidopropyl or maleimidoacetyl. In some embodiments, the linker comprises a chemical handle that enables stable conjugation to the antibody cysteine residues, such as N-aryl maleimides, ethynylphosphonamidates, carbonylacrylic reagents, 6-(2- (Methylsulfonyl)pyrimidin-5-yl)hex-5-ynamide (MSPHY), and bis-alkylating disulfide rebridging agents.In some embodiments, the dipeptide-containing linker comprises a para-aminobenzyl carbamate (PABC) linkage (also referred herein as “PABC spacer”). In some embodiments, the PABC linkage can be used as a self-immolative spacer. The PABC can spontaneously undergo a 1,6- elimination upon proteolysis to release payload, CO2 and aza-quinone methide. In some embodiments, the linker comprises a hemiaminal spacer. In some embodiments, the linker comprises an ethylenediamine-carbamate spacer.In some embodiments, the linker comprises a solubilizing group. In some embodiments, the solubilizing group is hydrophilic moiety. In some embodiments, the solubilizing group is a polyethylene glycol. In some embodiments, the solubilizing group is an amino-polyethylene glycol. In some embodiments, the solubilizing group is a polypeptide with ionizable side chains. In some embodiments, the solubilizing group is polysarcosine. In some embodiments, the solubilizing group is a polysaccharide. In some embodiments, the solubilizing group is a polyalcohol. In some embodiments, the solubilizing group is sorbitol. In some embodiments, the number of ethylene glycol or sarcosine moieties can include between 2 and 500, between 5 and 100, or between 5 and 25. In some embodiments, the solubilizing group is attached to a peptide of the linker. In some embodiments, the solubilizing group is attached to the main chain of the peptide of the linker. In some embodiments, the solubilizing group is attached to a side chain of the peptide of the linker.In some embodiments, the solubilizing group comprises a polyethylene glycol (PEG) spacer. In some embodiments, the PEG spacer is PEG4, PEG5, PEG6, PEG7, PEG8, PEG9, PEG19, PEGU, or PEG12. In preferred embodiments, the PEG spacer is PEG8, PEG10 or PEG12, more preferably PEG8.In certain embodiments, the linker is a hydrophilic polyethylene glycol (PEG) linker comprising, e.g., up to 16 PEG units, and at least one ethylene glycol unit. The antibody drug conjugate of the present invention may be prepared by known methods.In some embodiments, the linker further comprises a chitosan. Chitosan is a co-polymer comprising two repeating units, glucosamine and N-acetylglucosamine. It is obtained from chitin, which is generally derived from crustacean exoskeletons. Chitosan is characterized by its molecular weight and degree of deacetylation. Chitosans of different molecular weights and degrees of deacetylation can be produced by varying the conditions of the chitin alkali treatment. The chitosan preferably has a weight average molecular weight of 300 to 1,500 Da. Weight average molecular weights can be determined using light scattering techniques. In some embodiments, the chitosan is a polymer ranging from 2-mer to 500-mer, preferably from 2-mer to 100-mer, from 2- mer to 50-mer, from 2-mer to 25 mer or from 2-mer to 15 mer. In some embodiments, the chitosan is a 5-mer.In some embodiments, the linker comprises a branching unit. In some embodiments, the branching unit allows for the attachment of additional payloads. In some embodiments, the linker is branched, which allows for the attachment of additional payloads.In some embodiments, the linker comprises:- a PABC spacer, an ethylenediamine-carbamate spacer or a hemiaminal spacer; preferably a PABC spacer;- a Gly;- a disulfide;- a carbonate;- a chitosan;- a polyethylene glycol (PEG);- Maleimidoacetyl, Maleimidocaproyl or Maleimidopropyl; or- any combination thereof.In preferred embodiments, the linker comprises:- PABC spacer, an ethylenediamine-carbamate spacer or a hemiaminal spacer; preferably a PABC spacer;- a Gly;- a chitosan;- a polyethylene glycol (PEG);- Maleimidoacetyl, Maleimidocaproyl or Maleimidopropyl; or- any combination thereof.In some embodiments, the linker comprises Maleimidocaproyl-Val-Cit-PABC. In some embodiments, the linker comprises Maleimidopropyl-Val-Ala-PABC, preferably Maleimidopropyl-PEG-Val-Ala-PABC, more preferably Maleimidopropyl-PEG(8)-Val-Ala- PABC. In some embodiments, the linker comprises Maleimidopropyl-Val-Cit-PABC, preferably Maleimidopropyl-Val-Cit-PABC-chitosan, more preferably Maleimidopropyl-Val-Cit-PABC- chitosan (5-mer). In some embodiments, the linker comprises Maleimidopropyl-Gly-PABC, preferably, Maleimidopropyl-Gly-PABC-D -glucuronic acid. In some embodiments, the linker comprises Maleimidocaproyl-Gly-Gly-Phe-Gly.PayloadIn some embodiments, the ADC comprises one or more therapeutic agents. In some embodiments, the therapeutic agent is selected from one or more of a cytotoxic agent, a chemotherapeutic drug, a tubulin inhibitor, a DNA damaging agent, an immunomodulating agent, an RNA targeting payload, an imaging agent, a therapeutic protein, a biopolymer, a PROTAC degrader or an oligonucleotide.In some embodiments, the therapeutic agent is selected from one or more of maytansinoid, an eribulin, a tubulysin, a cryptophycin, an auristatin, a topoisomerase inhibitor, a Pyrrolo[2,l-c][l,4] benzodiazepine (PBD), an EG5 inhibitor, an enediyne, a duocarmycin, a thailanstatin, a calicheamicin, an amatoxin, a toll-like receptor agonist, a STING agonist, a glucocorticoid receptor modulator, a Bcl-xL inhibitor, a NAMPT inhibitor, and a carmaphycin.In some embodiments, the therapeutic agent is selected from one or more of exatecan, SN-38, MMAE, MMAF, PF-06380101, camptothecin, doxorubicin, paclitaxel, methotrexate, adunorubucin, gemcitabine, calicheamicin, DM1, Dxd, IRDye700DX, SG3199, DM4, vedotin, deruxtecan, IRINOTECAN, PNU-159682, alpha-amanitin, clezutoclax, methotrexate, genistein, TLR7 / 8 agonist, IMMU-130, IMMU-140, AZD8205, SKB-264, Palbociclib, or a derivative thereof.Examples of suitable therapeutic agents for use in immunoconjugates include, but are not limited to, KRAS inhibitor, JAK kinase inhibitors, taxanes, maytansines, CC-1065 and the duocarmycins, the calicheamicins and other enediynes, and the auristatins. Other examples include the anti-folates, vinca alkaloids, and the anthracyclines. Plant toxins, other bioactive proteins, enzymes (i.e., ADEPT), radioisotopes, photosensitizers may also be used in immunoconjugates. In addition, conjugates can be made using secondary carriers as the cytotoxic agent, such as liposomes or polymers, Suitable cytotoxins include an agent that inhibits or prevents the function of cells and / or results in destruction of cells. Representative cytotoxins include antibiotics, inhibitors of tubulin polymerization, alkylating agents that bind to and disrupt DNA, and agents that disrupt protein synthesis or the function of essential cellular proteins such as protein kinases, phosphatases, topoisomerases, enzymes, and cyclins.Representative cytotoxins include, but are not limited to, doxorubicin, daunorubicin, idarubicin, aclarubicin, zorubicin, mitoxantrone, epirubicin, carubicin, nogalamycin, menogaril, pitarubicin, valrubicin, cytarabine, gemcitabine, trifluridine, ancitabine, enocitabine, azacitidine, doxifluhdine, pentostatin, broxuhdine, capecitabine, cladhbine, decitabine, floxuhdine, fludarabine, gougerotin, puromycin, tegafur, tiazofuhn, adhamycin, cisplatin, carboplatin, cyclophosphamide, dacarbazine, vinblastine, vincristine, mitoxantrone, bleomycin, mechlorethamine, prednisone, procarbazine, methotrexate, flurouracils, etoposide, taxol, taxol analogs, platins such as cis-platin and carboplatin, mitomycin, thiotepa, taxanes, vincristine, daunorubicin, epirubicin, actinomycin, authramycin, azaserines, bleomycins, tamoxifen, idarubicin, dolastatins / auristatins, hemiasterlins, esperamicins and maytansinoids.In some embodiments, the ADC is a radio-labeled ADC. In some embodiments, the radio-labeled ADC comprises a radioisotope. A radioisotope includes, but is not limited to,14C,3H, actinium- 225 (225 Ac), astatine-211 (211At), bismuth-213 (213Bi), indium-i l l (U lin), iodine-123 (1231), iodine-124 (1241), iodine-131 (1311), lead-212 (212Pb), lutetium-177 (177Lu), technetium-99m (99mTc), copper-64 (64Cu), gallium-68 (68Ga), yttrium-86 (86Y), yttrium-90 (90 Y), zirconium- 89 (89Zr), lutetium-177(177Lu), yttrium-90 (90Y), iodine-131 (1311), 211 (211At), actinium-225 (225 Ac), thorium-227 (227Th), and bismuth-213 (213Bi).In some embodiments, the ADC is prepared by a bio-conjugation process described herein. In some embodiments, the process improves homogeneity (e.g., Drug to Antibody Ratio (DAR) homogeneity) of the resulting ADC.In some embodiments, the anti-FGFR4 antibody molecule is conjugated to an agent or a therapeutic agent via a linker. In some embodiments, the anti-FGFR4 antibody molecule is conjugated to two or more agents or therapeutic agents via a linker. In some embodiments, the anti-FGFR4 antibody molecule is conjugated to four or more agents or therapeutic agents via alinker. In some embodiments, the anti-FGFR4 antibody molecule is conjugated to five or more agents or therapeutic agents via a linker. In some embodiments, the anti-FGFR4 antibody molecule is conjugated to six or more agents or therapeutic agents via a linker. In some embodiments, the anti-FGFR4 antibody molecule is conjugated to seven or more agents or therapeutic agents via a linker. In some embodiments, the anti-FGFR4 antibody molecule is conjugated to eight or more agents or therapeutic agents via a linker.The number of agents or therapeutic agents linked to each antibody is referred to as DAR. Typically, the DAR corresponds to the average DAR. Multiple methods have been described to determine the average DAR of an ADC. The simplest technique relies on a UV / VIS spectroscopic analysis of the ADC. This method requires that the UV / VIS spectra of the drug and of the antibody have different Amaxvalues. Using the measured absorbances of the ADC and the extinction coefficients of the antibody at its Amaxof ~280 nm and the drug at its Amax, the individual concentrations of antibody and drug can be determined by the solution of two simultaneous equations. From this, the molar ratio (moles of drug per mole of antibody) can be calculated. The application of orthogonal methods to verify the validity of the spectroscopic technique have also been described, including use of radiometric methods (conjugation with radiolabeled drugs) and chromatographic methods such as hydrophobic interaction chromatography (HIC) separation for quantification of individual drug loaded species for a conjugate prepared by linkage through the inter-chain disulfide residues. Comparisons between UV / VIS and UV-MALDI mass spectrometric methods are also described for a number of drug and chelator conjugates, and these include explanations for the differences that are sometimes observed, such as UV photolability of calicheamicin, linker lability and over-quantitation of the UV-DAR method due to high levels of non-covalently bound drug (Wakankar A et al. (2011) MAbs 3(2): 161 -72). In some embodiments, the average DAR is determined by Mass Spectrometry (MS) as described in the examples.In some embodiments, the antibody-attachment determines the drug-to-antibody ratio (DAR). In some embodiments, the DAR is at least 2, 3, 4, 5, 6, 7, or 8. In some embodiments, the DAR is at most 2, 3, 4, 5, 6, 7, or 8. In some embodiments, the DAR is less than 2, 3, 4, 5, 6, 7, or 8. In some embodiments, the DAR is greater than 2, 3, 4, 5, 6, 7, or 8. In some embodiments, the DAR is 1 - 10, preferably 2-8, more preferably 6-8, such as 4 or 8. In some embodiments, the DAR is 2, 3, 4, 5, 6, 7, or 8. In some embodiments, the DAR is 2, 4, 8, 16, 32 or more.In some embodiments, the average DAR is from 3.0 to 5.0, preferably from 3.5 to 4.5, such as 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4 and 4.5, preferably the average DAR is from 3.8 to 4.2, morepreferably the average DAR is about 4. In preferred embodiments, the agent is MMAE. In other preferred embodiments, the agent is a topoisomerase I inhibitor, preferably a camptothecin derivative, such as deruxtecan or exatecan.In some embodiments, the average DAR is from 7.0 to 9.0, preferably from 7.5 to 8.5, such as 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4 and 8.5, preferably the average DAR is from 7.8 to 8.2, more preferably the average DAR is about 8. In preferred embodiment, the agent is a topoisomerase I inhibitor, preferably a camptothecin derivative, such as deruxtecan or exatecan.In preferred embodiments, the linker-payload comprises or consists of: a) Maleimidopropyl-PEG-Val-Ala-PABC-exatecan, preferably wherein the payload is conjugated to the antigen binding domain with an average DAR of about 4 or of about 8; b) Maleimidopropyl-Val-Cit-PABC-Chitosan-exatecan, preferably wherein the payload is conjugated to the antigen binding domain with an average DAR of about 4 or of about 8; c) Maleimidopropyl-Gly-PABC-D-glucuronic acid-exatecan, preferably wherein the payload is conjugated to the antigen binding domain with an average DAR of about 4 or of about 8; ord) Maleimidocaproyl-Gly-Gly-Phe-Gly-deruxtecan, preferably wherein the payload is conjugated to the antigen binding domain with an average DAR of about 4 or of about 8, more preferably of about 8.In some embodiments, in the ADC prepared by the process described herein, the content of DAR0 or DAR8 is less than 10 % and the content of DAR6 is less than 12 %. Typically, the indicated percentage (%) refers to the percentage of monomers in the sample having the indicated DAR value. The monomer % can be determined based on size exclusion chromatography (SEC) data and peak integration as shown in the examples. In some embodiments, the content of DAR4 is more than 60 %, more than 61 %, more than 62 %, more than 63 %, more than 64 %, more than 65 %, more than 66 %, more than 67 %, more than 68 %, more than 69 %, more than 70 %, more than 71 %, more than 71.5 %, more than 72 %, more than 72.5 %, or more than 73 %. In preferred embodiments, the agent is MMAE or a topoisomerase I inhibitor, preferably a camptothecin derivative such as exatecan or deruxtecan.In some embodiments, in the ADC prepared by the process described herein, the content of DAR4 is of at least 60 %, at least 65 %, at least 70 %, at least 71 %, at least 72 %, at least 72.5 %, at least 73 %, at least 73.5 %, at least 74 %, at least 74.5 %, or at least 75 %. In preferred embodiments, the agent is MMAE or a topoisomerase I inhibitor, preferably a camptothecin derivative such as exatecan or deruxtecan.In some embodiments, the content of DAR8 is at least 80 %, at least 85 %, at least 87 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, at least 99.5 % or at least 99.7 %. In preferred embodiments, the agent is a topoisomerase I inhibitor, preferably a camptothecin derivative such as exatecan or deruxtecan.In some embodiments, the bio-incubation process comprises: (a) incubating a reductant (e.g., Tris(2-carboxyethyl)phosphine (TCEP)), and the antibody to be conjugated in the presence of an effective amount of transition metal ions (e.g., Zn2+, etc.) in a buffer system (e.g., Hepes, Histidine buffer, PBS, MES, etc.) to selectively reduce inter-chain disulfide bonds within the antibody;(b) introducing an excess amount of payload bearing reactive groups (e.g., maleimide linking drugs, etc.) to react with reduced thiol groups resulted from step (a); and adding an effective amount of oxidant (e.g., dehydroascorbic acid (DHAA)), together with a chelator (e.g., EDTA), to re-oxidize unreacted thiol groups, and then recovering the resultant antibody-drug conjugates.In some embodiments, the transition metal ions generate selectivity in disulfide reduction. In the presence of transition metal ions, the two interchain S-S bonds in Fab regions are preferentially reduced. And thus, four payload bearing reactive groups (i.e., four drug-linker complexes) are attached to one antibody to form DAR4. A high content of DAR4 in the resultant ADCs certainly improves the homogeneity of the ADCs.The reductant may be TCEP. The reductant may be added in an excess of 2 to 100 molar equivalents, relative to antibody. For example, the reductant may be added in an excess of 2.5 to 6.0 molar equivalents. The oxidant to be added in step I may be DHAA. The oxidant in the reaction solution may be added in an excess of 2 to 100 molar equivalents, relative to antibody, together with equimolar quantities of a chelator (e.g. EDTA).The transition metal ion which is suitable to be used in the bio-conjugation process of the present disclosure may include, but not limited to, Zn2+, Cd2+, Hg2+, and the like. Among others, Zn2+ is used due to its easily availability and low cost. For example, suitable transition metal salts may be added in step (a) as long as they are soluble in the reaction solution so that free transition metal ions can be released in the reaction solution. In this regard, ZnC12, Zn(NO3)2, ZnSO4, Zn(CH3COO)2, ZnI2, ZnBr2, Zinc formate, and zinc tetrafluoroborate may be mentioned as suitable zinc salts. Likewise, other transition metal salts which are soluble and can release free Cd2+, or Hg2+ ions in the reaction solution can be mentioned, which include, but not limited to, CdC12, Cd(NO3)2, CdSO4, Cd(CH3COO)2, CdI2, CdBr2, cadmium formate, and cadmiumtetrafluoroborate; HgC12, Hg(NO3)2, HgSO4, Hg(CH3COO)2, HgBr2, Mercury(II) formate, and Mercury(II) tetrafluoroborate; and the like.In some embodiments, the concentration of the transition metal ions in step (a) is between 2 and 50 molar equivalents, relative to antibody.In some embodiments, soluble cations such as Ca2+ or Mg2+ are added to the reduction step.In some embodiments, the transition metal ions will be removed in purification step by using EDTA or any suitable chelating reagent, which will be filtered out in subsequent itdialysis, ultrafiltration or gel filtration.Any suitable buffer system can be used for the reaction in step (a), including, but not limited to, Hepes, Histidine buffer, PBS, MES, phosphate and the like.In some embodiments, the pH for the reaction is between about 5.5 and about 8, for instance, about 5.5 to 7.5.In some embodiments, the optimum for the reaction is between about -10 and 37° C. For example, the reaction may occur at a temperature between about 0 and 20° C overnight. In some embodiments, the reaction occurs between 1-6 hours. In some embodiments, the reaction occurs between 6-12 hours.In some embodiments, the bio-conjugation process is as described as US11478553B2.In some embodiments, the anti-FGFR4 antibody is conjugated to a linker-payload. In some embodiments, the linker-payload is Maleimidocaproyl-Val-Cit-PABC-MMAE. In some embodiments, the linker-payload is Maleimidopropyl-PEG-Val-Ala-PABC-Exatecan, preferably Maleimidopropyl-PEG(8)-Val-Ala-PABC-Exatecan. In some embodiments, the linker-payload is Maleimidopropyl-Val-Cit-PABC-chitosan-Exatecan, preferably Maleimidopropyl-Val-Cit- PABC-chitosan (5 mer)-Exatecan. In some embodiments, the linker-payload is Maleimidopropyl- Gly-PABC-D-glucuronic acid-Exatecan. In some embodiments, the linker-payload is Maleimidocaproyl-Gly-Gly-Phe-Gly-Deruxtecan.Nucleic AcidsDescribed herein, in certain embodiments, is an isolated nucleic acid molecule comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, 99%, 99.5%, 99.9%, or 100% sequence identity to a nucleotide sequence encoding the antibody molecule as described herein. Nucleic acids encoding the aforementioned antibody molecules, e.g., anti-FGFR4 antibody molecules, are also disclosed.In certain embodiments, the invention features nucleic acids comprising nucleotide sequences that encode heavy and light chain variable regions and CDRs or hypervariable loops of the antibody molecules, as described herein. For example, the invention features a first and second nucleic acid encoding heavy and light chain variable regions, respectively, of an antibody molecule chosen from one or more of the antibody molecules as described herein. The nucleic acid can comprise a nucleotide sequence as set forth in the tables herein, or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, or which differs by no more than 3, 6, 15, 30, or 45 nucleotides from the sequences shown in the tables herein.In certain embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and / or having one or more substitutions, e.g., conserved substitutions). In other embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and / or having one or more substitutions, e.g., conserved substitutions). In yet another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and / or having one or more substitutions, e.g., conserved substitutions).In certain embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having the nucleotide sequence as set forth in the tables herein, a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and / or capable of hybridizing under the stringency conditions described herein). In another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having the nucleotide sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and / or capable of hybridizing under the stringencyconditions described herein). In yet another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having the nucleotide sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and / or capable of hybridizing under the stringency conditions described herein).In certain embodiments, the nucleic acid can comprise a nucleotide sequence encoding a cytokine molecule, an immune cell engager, or a stromal modifying moiety as described herein.In another aspect, the application features host cells and vectors containing the nucleic acids described herein. The nucleic acids may be present in a single vector or separate vectors present in the same host cell or separate host cell, as described in more detail hereinbelow.VectorsDescribed herein, in certain embodiments, is a vector comprising one or more of the nucleic acid molecules as described herein.Further provided herein are vectors comprising the nucleotide sequences encoding antibody molecules, e.g., anti-FGFR4 antibody molecules described herein. In some embodiments, the vectors comprise nucleic acid sequences encoding antibody molecules, e.g., anti-FGFR4 antibody molecules described herein. In some embodiments, the vectors comprise the nucleotide sequences described herein. The vectors include, but are not limited to, a virus, plasmid, cosmid, lambda phage or a yeast artificial chromosome (YAC).Numerous vector systems can be employed. For example, one class of vectors utilizes DNA elements which are derived from animal viruses such as, for example, bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (Rous Sarcoma Virus, MMTV or MOMLV) or SV40 virus. Another class of vectors utilizes RNA elements derived from RNA viruses such as Semliki Forest virus, Eastern Equine Encephalitis virus and Flaviviruses.Additionally, cells which have stably integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow for the selection of transfected host cells. The marker may provide, for example, prototropy to an auxotrophic host, biocide resistance (e.g., antibiotics), or resistance to heavy metals such as copper, or the like. The selectable marker gene can be either directly linked to the DNA sequences to be expressed, or introduced into the same cell by co-transformation. Additional elements may also be needed for optimal synthesis ofmRNA. These elements may include splice signals, as well as transcriptional promoters, enhancers, and termination signals.Once the expression vector or DNA sequence containing the constructs has been prepared for expression, the expression vectors may be transfected or introduced into an appropriate host cell. Various techniques may be employed to achieve this, such as, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, lipid based transfection or other conventional techniques. In the case of protoplast fusion, the cells are grown in media and screened for the appropriate activity.Methods and conditions for culturing the resulting transfected cells and for recovering the antibody molecule produced are known to those skilled in the art, and may be varied or optimized depending upon the specific expression vector and mammalian host cell employed, based upon the present description.CellsDescribed herein, in certain embodiments, is a cell comprising the nucleic acid as described herein or the vector as described herein.In another aspect, described herein are host cells and vectors containing the nucleic acids. The nucleic acids may be present in a single vector or separate vectors present in the same host cell or separate host cell. The host cell can be a eukaryotic cell, e.g., a mammalian cell, an insect cell, a yeast cell, or a prokaryotic cell, e.g., E. coli. For example, the mammalian cell can be a cultured cell or a cell line. Exemplary mammalian cells include lymphocytic cell lines (e.g., NSO), Chinese hamster ovary cells (CHO), COS cells, oocyte cells, and cells from a transgenic animal, e.g, mammary epithelial cell.In some embodiments, the host cells are eukaryotic cells. A number of powerful eukaryotic expression systems are available for expression of secreted proteins and membrane-bound receptors including those that contain unique post-translational modifications. The most common eukaryotic expression platforms currently include yeast (e.g., Pichia pastoris and Saccharomyces cerevisiae), baculovirus expression vector systems (Autographa californica multiple nuclear polyhedrosis virus and insect cell hosts Spodoptera frugiperda (e.g., Sf9 and Sf21 cells) or Trichoplusia ni), and mammalian cell systems (including a variety of transformed and / or genetically modified cell lines). More preferably, said cells are mammalian cells, including simian, human, dog and rodent cells. Examples of human cells are PER.C6 cells (WOOl / 38362), MRC-5 (ATCC CCL-171), WI-38 (ATCC CCL-75), HEK-293 cells (ATCC CRL-1573), HeLa cells(ATCC CCL2), and fetal rhesus lung cells (ATCC CL- 160). Examples of non-human primate cells are Vero cells (ATCC CCL81), COS-1 cells (ATCC CRL-1650) or COS-7 cells (ATCC CRL- 1651). Examples of dog cells are MDCK cells (ATCC CCL-34). Examples of rodent cells are hamster cells, such as BHK21-F, HKCC cells, or CHO cells. Any protein compatible expression system may be used to produce the disclosed single-chain polypeptides of the invention. Suitable expression systems include transgenic animals described in Gene Expression Systems, Academic Press, eds. Fernandez et al., 1999. In a preferred embodiment, the host cells are human cells or cell lines, preferably, HEK-293 cells. In some embodiments, the host cells, preferably mammalian cells, are selected to optimize expression yields of the anti-FGFR4 molecule described herein.In some embodiments, described herein are host cells comprising a nucleic acid encoding an antibody molecule as described herein.In some embodiments, described herein are the host cells genetically engineered to comprise nucleic acids encoding the antibody molecule.In some embodiments, the host cells are genetically engineered by using an expression cassette. The phrase “expression cassette,” refers to nucleotide sequences, which are capable of affecting expression of a gene in hosts compatible with such sequences. Such cassettes may include a promoter, an open reading frame with or without introns, and a termination signal. Additional factors necessary or helpful in effecting expression may also be used, such as, for example, an inducible promoter.In some embodiments, the cell has been genetically engineered to express a chimeric antigen receptor (CAR) which comprises the anti-FGFR4 antibody molecule described herein.Accordingly, in some embodiments, the invention relates to a chimeric antigen receptor (CAR) nucleic acid (also referred herein a chimeric receptor - nucleic acid) comprising a polynucleotide coding for the anti-FGFR4 antibody molecule described herein as targeting -moiety, optionally, a polynucleotide coding for a hinge or spacer region, a polynucleotide coding for a transmembrane domain; and a polynucleotide coding for an intracellular signaling domain. In preferred embodiments, the CAR nucleic acid further comprises a polynucleotide encoding a costimulatory signaling domain. In other preferred embodiments, the coding polynucleotide of the targeting moiety is operably linked to a hinge or spacer region coding polynucleotide which is operably linked to a transmembrane region coding polynucleotide which is operably linked to a polynucleotide coding for a costimulatory signaling domain which is operably linked to a intracellular signaling domain coding polynucleotide.In some embodiments, the invention relates to the chimeric receptor polypeptide coded by a chimeric receptor nucleic acid as described herein. It further relates to an expression vector comprising a chimeric receptor nucleic acid as described herein.In some further embodiments, the present invention provides a cell comprising the nucleic acid, a vector and / or the CAR polypeptide as described herein. In some embodiments, the cell is a Natural Killer (NK) cell. In other embodiments, the cell is a T-cell (referred to as CAR T-cell or CART). CD8+ cells and CD4+ cells can be obtained and further sorted into subsets by using standard methods well known in the art. In some embodiments, the cell is a CD8+ T lymphocyte cell selected from the group consisting of naive CD8+ T cells, stem cell memory CD8+ T cells, central memory CD8+ T cells, effector memory CD8+ T cells and bulk CD8+ T cells. In other embodiments, the cell is a CD4+ T lymphocyte cell selected from the group consisting of naive CD4+ T cells, stem cell memory CD4+ T cells, central memory CD4+ T cells, effector memory CD4+ T cells and bulk CD4+ T cells.Method of production

[0152] In some embodiments, the anti-FGFR4 antibody molecule described herein is produced by a method comprising transient transfection of mammalian cells.

[0153] A method for producing an antibody by transient transfection may comprise:1) providing a population of mammalian host cells , wherein the cells are capable of expressing recombinant proteins;2) transfecting the mammalian host cells using a transient transfection protocol with one or more nucleic acid constructs encoding at least a heavy chain and at least a light chain of the anti-FGFR4 antibody molecule described herein;3) culturing the transfected mammalian host cells under conditions that permit expression and secretion of the antibody molecule;4) harvesting the culture medium containing the expressed antibody molecule; and5) purifying the antibody molecule from the culture medium.In some embodiments, the anti-FGFR4 antibody molecule is produced by transient transfection of mammalian cells, such as in any of the mammalian host cells described herein, with a production yield of at least 300 mg / L, preferably of at least 350 mg / L, 400 mg / L, 450 mg / L, 500 mg / L, 550 mg / L or 600 mg / L. In preferred embodiments, these cells are CHO cells, e.g., CHO-K1 cells. In some embodiments, the anti-FGFR4 antibody molecule is produced by transient transfection of mammalian cells, such as in any of the mammalian host cells described herein, wherein theproduction yield is of at least 50%, preferably of at least 55%, 60%, 65%, 70% or preferably of at least 75% higher than a reference antibody, such as Tool 3 Ab described herein. In preferred embodiments, these cells are CHO cells, e.g., CHO-K1 cells. Methods for the transient expression and purification of endotoxin-free full-length IgG antibodies and antibody-derived constructs in mammalian cell lines are well known in the art. See for instance Vazquez-Lombardi R, et al. 208; Nat Protoc. 2018 Jan;13(l):99-117. doi: 10.1038 / nprot.2017.126.Typically, cells are cultured in a cell culture medium under appropriate temperature and atmosphere conditions (e.g., 37°C and 5% CO2 for mammalian cells).By “cell growth medium” or “cell culture medium” it is meant a nutritive solution for culturing or growing cells. The ingredients that compose such media may vary depending on the type of cell to be cultured. In addition to nutrient composition, osmolarity and pH are considered important parameters of culture media. The cell growth medium comprises a number of ingredients well known by the man skilled in the art, which typically for the culturing of eukaryotic cells includes amino acids, vitamins, organic and inorganic salts, sources of carbohydrates, lipids, trace elements (CuSO4, FeSO4, Fe(NO3)3, ZnSO4, etc), each ingredient being present in an amount which supports the cultivation of a cell in vitro (i.e, survival and growth of cells).Ingredients may also include different auxiliary substances, such as buffer substances (like sodium bicarbonate, Hepes, Tris, etc.), oxidation stabilizers, stabilizers to counteract mechanical stress, protease inhibitors, animal growth factors, plant hydrolyzates, anti-clumping agents, anti-foaming agents. If required, a non-ionic surfactant, such as polypropylene glycol can be added to the cell growth medium as an anti-foaming agent. These agents are generally used to protect cells from the negative effects of aeration since, without an addition of a surfactant, the ascending and bursting air bubbles can lead to damage of those cells that are located on the surface of these air bubbles (“sparging”).The cell growth medium is preferably an animal serum-free mediums” (SFM), which means that the cell growth medium is ready to use, that is to say that it does not required serum addition allowing cells survival and cell growth. The cell growth medium is preferably chemically defined, but it may also contain hydrolyzates of various origin, from plant for instance. Preferably, said cell growth medium is “non-animal origin” qualified, that is to say that it does not contain components of animal or human origin (FAO status: “free of animal origin”). Several media are commercially available and can be used. Media for the culturing of eukaryotic cells include, for example: Ham's F12 Medium (Sigma, St. Louis, MO), Dulbecco's Modified Eagles Medium (DMEM, Sigma), VPSFM (InVitrogen Ref 1 1681 -020, catalogue 2003), Opti Pro (InVitrogen Ref 12309-019, 20 catalogue 2003), Episerf (InVitrogen Ref 10732-022, catalogue 2003), Pro 293 S-CDM (Cambrex ref 12765Q, catalogue 2003), LC17 (Cambrex Ref BESP302Q), Pro CHO 5- CDM (Cambrex ref 12-766Q, catalogue 2003), HyQ SFM4CHO (Hyclone Ref SH30515- 02), HyQ SFM4CHO- Utility (Hyclone Ref SH30516.02), HyQ PF293 (Hyclone ref SH30356.02), HyQ PF Vero (Hyclone Ref SH30352.02), CDM4PERMAb (Hyclone Ref 25 SH30871), or Excell media (SAFC).Methods for polypeptide isolation and / or purification are well known in the art (see for instance, Isolation and Purification of Proteins, February 5, 2003 by CRC Press, ISBN 9780824707262). Procedures for purification of polypeptides initially depend on the site of expression of the protein. Some proteins are secreted into the cell culture media; others are intracellular proteins. In the second instance, the first step of a purification process involves lysis of the cell, which can be done by a variety of methods, including mechanical shear, osmotic shock, or enzymatic treatments. Optionally, cell debris is removed by differential centrifugation or by filtration.Once a clarified solution containing the polypeptide of interest has been obtained, its separation from the other proteins produced by the cell is usually attempted using a combination of different chromatography techniques. These techniques separate mixtures of proteins on the basis of their charge, degree of hydrophobicity, or size. Several different chromatography resins are available for each of these techniques, allowing accurate tailoring of the purification scheme to the particular protein involved. Affinity chromatography, which exploits a specific interaction between the protein to be purified and an immobilized capture agent, may also be an option for some polypeptides. Preferably, Protein A affinity chromatography is used for the purification of the anti- FGFR4 antibody molecules described herein. In preferred embodiments, the production and purification method is as described in Example 14.Pharmaceutical CompositionsDescribed herein, in certain embodiments, is a pharmaceutical composition comprising the molecules as described herein, the nucleic acid molecules as described herein, the vector as described herein, or the cell as described herein, and a pharmaceutically acceptable carrier, excipient, or diluent.Pharmaceutical compositions or formulations comprising the agent, e.g., the anti-FGFR4 molecules, of the described compositions and for use in any of the described methods can be prepared according to conventional techniques well known in the pharmaceutical industry anddescribed in the published literature. In some embodiments, a pharmaceutical composition or formulation for treating a subject comprises an effective amount of any molecules or the compositions as described herein, or a pharmaceutically acceptable salt, solvate, hydrate or ester thereof. The pharmaceutical formulation comprising the molecules as described herein may further comprise a pharmaceutically acceptable excipient, diluent or carrier.Treatment of SubjectsAny of the compositions provided herein may be administered to an individual. “Individual” may be used interchangeably with “subject” or “patient.” An individual may be a mammal, for example a human or animal such as a non-human primate, a rodent, a rabbit, a rat, a mouse, a horse, a donkey, a goat, a cat, a dog, a cow, a pig, or a sheep. In some embodiments, the individual is a human. In other embodiments, the individual may be another eukaryotic organism, such as a plant. In some embodiments, the compositions provided herein are administered to a cell ex vivo.In some embodiments, the compositions provided herein are administered to an individual as a method of treating a disease or disorder. In some embodiments, the individual has a genetic disease, such as any of the diseases described herein. In some embodiments, the individual is at risk of having a disease, such as any of the diseases described herein. In some embodiments, the individual is at increased risk of having a disease or disorder caused by insufficient amount of a protein or insufficient activity of a protein. If an individual is “at an increased risk” of having a disease or disorder caused insufficient amount of a protein or insufficient activity of a protein, the method involves preventative or prophylactic treatment. For example, an individual may be at an increased risk of having such a disease or disorder because of family history of the disease. Typically, individuals at an increased risk of having such a disease or disorder benefit from prophylactic treatment ( .g., by preventing or delaying the onset or progression of the disease or disorder).Suitable routes for administration of the antibody molecules or the compositions as described herein may vary depending on cell type to which delivery of the antibody molecules or the compositions is desired. The antibody molecules or the compositions as described herein may be administered to patients parenterally, for example, by intrathecal injection, intracer ebroventricular injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection.In some embodiments, the antibody molecules or the compositions as described herein are administered with one or more agents capable of promoting penetration of the subject the antibodymolecules or the compositions as described herein across the blood-brain barrier by any method known in the art. For example, delivery of agents by administration of an adenovirus vector to motor neurons in muscle tissue is described in U.S. Pat. No. 6,632,427, “Adenoviral-vector- mediated gene transfer into medullary motor neurons,” incorporated herein by reference. Delivery of vectors directly to the brain, e.g., the striatum, the thalamus, the hippocampus, or the substantia nigra, is described, e.g., in U.S. Pat. No. 6,756,523, “Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain,” incorporated herein by reference.In some embodiments, the antibody molecules or the compositions as described herein are linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. In some embodiments, the antibody molecules or the compositions as described herein are coupled to a substance, known in the art to promote penetration or transport across the blood-brain barrier, e.g., an antibody to the transferrin receptor. In some embodiments, the antibody molecules or the compositions as described herein are linked with a viral vector.In some embodiments, subjects treated using the methods and compositions are evaluated for improvement in condition using any methods known and described in the art.The terms “treat,” “treating”, and “treatment,” and the like are used herein to generally mean obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof and / or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease. The term “treatment” as used herein covers any treatment of a disease in a mammal, particularly, a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; or (c) relieving the disease, i.e., mitigating or ameliorating the disease and / or its symptoms or conditions. The term “prophylaxis” is used herein to refer to a measure or measures taken for the prevention or partial prevention of a disease or condition. In some embodiments, the terms “condition,” “disease,” or “disorder,” as used herein, are interchangeable.By “treating or preventing a disease or a disorder” is meant ameliorating any of the conditions or signs or symptoms associated with the disorder before or after it has occurred. As compared with an equivalent untreated control, such reduction or degree of prevention is at least 3%, 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique. A patientwho is being treated for a disease or a disorder, is one who a medical practitioner has diagnosed as having such a condition. Diagnosis may be by any suitable means. Diagnosis and monitoring may involve, for example, detecting the presence of pathological cells in a biological sample (e.g., tissue biopsy, blood test, or urine test), detecting the level of a surrogate marker of the disorder in a biological sample, or detecting symptoms associated with the disorder. A patient in whom the development of a disorder is being prevented may or may not have received such a diagnosis. One of ordinary skill in the art will understand that these patients may have been subjected to the same standard tests as described above or may have been identified, without examination, as one at high risk due to the presence of one or more risk factors (e.g., family history or genetic predisposition). In some embodiments, the anti-FGFR4 antibody or anti-FGFR4 ADC described herein is used to treat cancer. In some embodiments, a subject is successfully "treated" for cancer according to the methods of the present invention if the patient shows one or more of the following: a reduction in the number of or complete absence of cancer cells; a reduction in the tumor size; inhibition of or an absence of cancer cell infiltration into peripheral organs including, for example, the spread of cancer into soft tissue and bone; inhibition of or an absence of tumor metastasis; inhibition or an absence of tumor growth; relief of one or more symptoms associated with the specific cancer; reduced morbidity and mortality; improvement in quality of life; reduction in tumorigenicity, tumorigenic frequency, or tumorigenic capacity, of a tumor; reduction in the number or frequency of cancer stem cells in a tumor; differentiation of tumorigenic cells to a non-tumorigenic state; increased progression-free survival (PFS), disease-free survival (DFS), or overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), a decrease in progressive disease (PD), a reduced time to progression (TTP), or any combination thereof. In the context of metastatic cancer, treatment also refers to preventing the development of new metastatic tumors, reducing the size of metastatic tumors, or eliminating existing metastatic tumors.In some embodiments, the cancer is a solid tumor, a hematological cancer, a metastatic cancer, a soft tissue tumor, or a combination thereof.In some embodiments, the cancer is the solid tumor, and the solid tumor is selected from the group consisting of squamous cell carcinoma, adenocarcinoma, adrenocortical carcinoma, head and neck cancer, esophageal cancer (e.g., gastroesophageal junction cancer), gastric cancer (e.g., gastroesophageal junction cancer), ovarian cancer, cervical cancer, uterine cancer, lung cancer, breast cancer, renal cancer, prostate cancer, sarcoma, skin cancer, melanoma, kidney cancer, duodenum cancer, small intestine cancer, large intestine cancer, colorectal cancer (e.g., colonadenocarcinoma and rectum adenocarcinoma), liver cancer (e.g., hepatocellular carcinoma), pancreatic cancer, bladder cancer, rhabdomyosarcoma, cholangiocarcinoma, testicular germ cell tumors, neuroendocrine tumors or a combination thereof.In some embodiments, the cancer is a metastatic cancer. In some embodiments, the metastatic cancer is a metastasis of squamous cell carcinoma, adenocarcinoma, adrenocortical carcinoma, head and neck cancer, esophageal cancer (e.g., gastroesophageal junction cancer), gastric cancer (e.g., gastroesophageal junction cancer), ovarian cancer, cervical cancer, uterine cancer, lung cancer, breast cancer, renal cancer, prostate cancer, sarcoma, skin cancer, melanoma, kidney cancer, duodenum cancer, small intestine cancer, large intestine cancer, colorectal cancer (e.g., colon adenocarcinoma and rectum adenocarcinoma), liver cancer (e.g., hepatocellular carcinoma), pancreatic cancer, bladder cancer, rhabdomyosarcoma, cholangiocarcinoma, testicular germ cell tumors, neuroendocrine tumors or a combination thereof.In some embodiments, the breast cancer is selected from HR+ breast cancer, HR-breast cancer, HER2- breast cancer, HER2+ breast cancer, HR+ / HER2- breast cancer, HR+ / HER2+ breast cancer, HER2-enriched breast cancer, triple negative breast cancer.In some embodiments, the breast cancer is resistant or refractory to a CDK4 / 6 inhibitor. In some embodiments, the breast cancer is resistant or refractory to endocrine therapy. In some embodiments, the breast cancer is resistant to immunotherapy. In some embodiments, the breast cancer is resistant or refractory to a CDK4 / 6 inhibitor and endocrine therapy.In some embodiments, the subject has been previously treated with CDK4 / 6 inhibitor, endocrine therapy, or both as a first line therapy. In some embodiments, the subject has been previously treated with CDK4 / 6 inhibitor, endocrine therapy, or both as a second line therapy. In some embodiments, the subject has been previously treated with CDK4 / 6 inhibitor, endocrine therapy, or both as a third line therapy.In some embodiments, the subject has been previously treated with CDK4 / 6 inhibitor, endocrine therapy, or both and one or more additional anti-cancer therapy.In some embodiments, the cancer is the hematological cancer. In some embodiments, the hematological cancer is selected from the group consisting of Hodgkin’s lymphoma, NonHodgkin’s lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma, T-cell lymphoma, acute lymphocytic leukemia, and a combination thereof.In some embodiments, the Non-Hodgkin’s lymphoma is selected from the group consisting of B cell lymphoma, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia (B-CLL), mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, and a combination thereof.In some embodiments, the treatment reduces the size of tumors, primary or metastatic tumors, as measured by caliper, IVIS imaging or H&E staining. In some embodiments, the treatment inhibits the formation or development of metastatic tumors, as measured by caliper, IVIS imaging or H&E staining. In preferred embodiments, of any thereof, the size, formation or development of tumors is measured by caliper.In some embodiments, treatment results of tumor size reduction of at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 200%, at least 300%, at least 400% or at least 500% that of the untreated tumor or treated with a vehicle, for instance in any one of the xenograft-derived in vivo models described herein.In some embodiments, treatment results of tumor size reduction of at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 97.5%, or of 100% (regression) with respect to the untreated tumor at the treatment initiation time point (day 0), for instance in any one of the xenograft-derived in vivo models described herein.In some embodiments, treatment results in tumor regression in at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, or preferably in 100% of the treated individuals, for instance in any one of the xenograft-derived in vivo models described herein.In some embodiments, treatment results in a tumor size which remains stable within the measurement variability margin (typically ± 10-20% from the baseline value or the smallest recorded value) , for instance in any one of the xenograft-derived in vivo models described herein. In some embodiments, the treatment results in an increased overall survival rate of at least 50%, preferably at least 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62% or at least 63% vs vehicle, for instance in any one of the xenograft-derived in vivo models described herein. Preferably in a rhabdomyosarcoma xenograft mice model, such as the RH4 model described herein, further to a single dose intravenous administration of 5 mg / kg as shown in FIG. 18B.Anti-cancer therapiesIn some embodiments, the anti-FGFR4 antibody, anti-FGFR4 ADC, or any composition described herein is administered in combination with an anti-cancer therapy described herein. In some embodiments, the anti-FGFR4 antibody, anti-FGFR4 ADC, or any composition described herein is administered prior to the administration of an anti-cancer therapy described herein. In some embodiments, the anti-FGFR4 antibody, anti-FGFR4 ADC, or any composition described herein is administered after the administration of an anti-cancer therapy described herein. In some embodiments, the anti-FGFR4 antibody, anti-FGFR4 ADC, or any composition described herein is administered after the administration of the anti-FGFR4 ADC. Non-limiting examples of anticancer therapy includes low or small molecular weight chemotherapeutic agent, biologic, cancer therapeutic antibody, viral cancer therapeutic agent, nanopharmaceutical, RNAi, anti-sense RNA agents, a tyrosine kinase inhibitor, anti-angiogenic agent, vascular targeting agent, vascular disrupting agent, immune checkpoint inhibitor, and any suitable cancer therapeutic agents.In other embodiments, the antibody molecules (e.g., the anti-FGFR4 antibody or the anti-FGFR4 ADC) or any composition as described herein are administered in combination with a low or small molecular weight chemotherapeutic agent. In some embodiments, the antibody molecules as described herein are conjugated to a low or small molecular weight chemotherapeutic agent. Exemplary low or small molecular weight chemotherapeutic agents include, but not limited to, 13- cis-retinoic acid (isotretinoin, ACCUTANE®), 2-CdA (2-chlorodeoxyadenosine, cladribine, LEUSTATIN™), 5-azacitidine (azacitidine, VIDAZA®), 5 -fluorouracil (5-FU, fluorouracil, ADRUCIL®), 6-mercaptopurine (6-MP, mercaptopurine, PURINETHOL®), 6-TG (6- thioguanine, thioguanine, THIOGUANINE TABLOID®), abraxane (paclitaxel protein-bound), actinomycin-D (dactinomycin, COSMEGEN®), alitretinoin (PANREHN®), all-transretinoic acid (ATRA, tretinoin, VESANOID®), altretamine (hexamethylmelamine, HMM, HEXALEN®), amethopterin (methotrexate, methotrexate sodium, MTX, TREXALL™, RHEUMATREX®), amifostine (ETHYOL®), arabinosylcytosine (Ara-C, cytarabine, CYTOSAR-U®), arsenic trioxide (TRISENOX®), asparaginase (Erwinia L-asparaginase, L-asparaginase, ELSPAR®, KIDROLASE®), BCNU (carmustine, BiCNU®), bendamustine (TREANDA®), bexarotene (TARGRETIN®), bleomycin (BLENOXANE®), busulfan (BUSULFEX®, MYLERAN®), calcium leucovorin (Citrovorum Factor, folinic acid, leucovorin), camptothecin-11 (CPT-11, irinotecan, CAMPTOSAR®), capecitabine (XELODA®), carboplatin (PARAPLATIN®), carmustine wafer (prolifeprospan 20 with carmustine implant, GLIADEL® wafer), CCI-779 (temsirolimus, TORISEL®), CCNU (lomustine, CeeNU), CDDP (cisplatin, PLAHNOL®,PLATINOL-AQ®), chlorambucil (leukeran), cyclophosphamide (CYTOXAN®, NEOSAR®), dacarbazine (DIC, DTIC, imidazole carboxamide, DTIC-DOME®), daunomycin (daunorubicin, daunorubicin hydrochloride, rubidomycin hydrochloride, CERUBIDINE®), decitabine (DACOGEN®), dexrazoxane (ZINECARD®), DHAD (mitoxantrone, NOVANTRONE®), docetaxel (TAXOTERE®), doxorubicin (ADRIAMYCIN®, RUBEX®), epirubicin (ELLENCE™), estramustine (EMCYT®), etoposide (VP- 16, etoposide phosphate, TOPOS AR®, VEPESID®, ETOPOPHOS®), floxuridine (FUDR®), fludarabine (FLUDARA®), fluorouracil (cream) (CARAC™, EFUDEX®, FLUOROPLEX®), gemcitabine (GEMZAR®), capecitabine (Xeloda), hydroxyurea (HYDREA®, DROXIA™, MYLOCEL™), idarubicin (IDAMYCIN®), ifosfamide (IFEX®), ixabepilone (IXEMPRA™), LCR (leurocristine, vincristine, VCR, ONCOVIN®, VINCASAR PFS®), L-PAM (L-sarcolysin, melphalan, phenylalanine mustard, ALKERAN®), mechlor ethamine (mechlorethamine hydrochloride, mustine, nitrogen mustard, MUSTARGEN®), mesna (MESNEX™), mitomycin (mitomycin-C, MTC, MUTAMYCIN®), nelarabine (ARRANON®), oxaliplatin (ELOXATIN™), paclitaxel (TAXOL®, ONXAL™), pegaspargase (PEG-L-asparaginase, ONCOSPAR®), PEMETREXED (ALIMTA®), pentostatin (NIPENT®), procarbazine (MATULANE®), streptozocin (ZANOSAR®), temozolomide (TEMODAR®), teniposide (VM-26, VUMON®), TESPA (thiophosphoamide, thiotepa, TSP A, THIOPLEX®), topotecan (HYCAMTIN®), vinblastine (vinblastine sulfate, vincaleukoblastine, VLB, ALKABAN-AQ®, VELBAN®), vinorelbine (vinorelbine tartrate, NAVELBINE®), and vorinostat (ZOLINZA®).In another embodiment, the antibody molecules (e.g., the anti-FGFR4 antibody or the anti-FGFR4 ADC) or any composition as described herein are administered in conjunction with a biologic. Biologies useful in the treatment of cancers are known in the art and a binding molecule as described herein may be administered, for example, in conjunction with such known biologies. For example, the FDA has approved the following biologies for the treatment of breast cancer: HERCEPTIN® (trastuzumab, Genentech Inc., South San Francisco, Calif; a humanized monoclonal antibody that has anti-tumor activity in HER2-positive breast cancer); FASLODEX® (fulvestrant, AstraZeneca Pharmaceuticals, LP, Wilmington, Del.; an estrogen-receptor antagonist used to treat breast cancer); ARIMIDEX® (anastrozole, AstraZeneca Pharmaceuticals, LP; a nonsteroidal aromatase inhibitor which blocks aromatase, an enzyme needed to make estrogen); Aromasin® (exemestane, Pfizer Inc., New York, N.Y.; an irreversible, steroidal aromatase inactivator used in the treatment of breast cancer); Fam-trastuzumab deruxtecan (Enhertu),I l lSacituzumab govitecan (Trodelv); FEMARA® (letrozole, Novartis Pharmaceuticals, East Hanover, N. J.; a nonsteroidal aromatase inhibitor approved by the FDA to treat breast cancer); and NOLVADEX® (tamoxifen, Astrazeneca Pharmaceuticals, LP; a nonsteroidal antiestrogen approved by the FDA to treat breast cancer). Other biologies with which the binding molecules as described herein may be combined include: AVASTIN® (bevacizumab, Genentech Inc.; the first FDA-approved therapy designed to inhibit angiogenesis); and ZEVALIN® (ibritumomab tiuxetan, Biogen Idee, Cambridge, Mass. ; a radiolabeled monoclonal antibody currently approved for the treatment of B-cell lymphomas).In addition, the FDA has approved the following biologies for the treatment of colorectal cancer: AVASTIN®; ERBITUX® (cetuximab, ImClone Systems Inc., New York, N.Y., and Bristol- Myers Squibb, New York, N.Y.; is a monoclonal antibody directed against the epidermal growth factor receptor (EGFR)); GLEEVEC® (imatinib mesylate; a protein kinase inhibitor); and ERGAMISOL® (levamisole hydrochloride, Janssen Pharmaceutica Products, LP, Titusville, N.J.; an immunomodulator approved by the FDA in 1990 as an adjuvant treatment in combination with 5 -fluorouracil after surgical resection in patients with Dukes’ Stage C colon cancer).For the treatment of lung cancer, exemplary biologies include TARCEVA® (erlotinib HCL, OSI Pharmaceuticals Inc., Melville, N.Y.; a small molecule designed to target the human epidermal growth factor receptor 1 (HER1) pathway).For the treatment of multiple myeloma, exemplary biologies include VELCADE® (bortezomib, Millennium Pharmaceuticals, Cambridge Mass.; a proteasome inhibitor). Additional biologies include THALIDOMID® (thalidomide, Clegene Corporation, Warren, N.J.; an immunomodulatory agent and appears to have multiple actions, including the ability to inhibit the growth and survival of myeloma cells and anti-angiogenesis).Additional exemplary cancer therapeutic antibodies include, but are not limited to, 3F8, abagovomab, adecatumumab, afutuzumab, alacizumab pegol, alemtuzumab (CAMPATH®, MABCAMPATH®), altumomab pentetate (HYBRI-CEAKER®), anatumomab mafenatox, anrukinzumab (IMA-638), apolizumab, arcitumomab (CEA-SCAN®), bavituximab, bectumomab (LYMPHOSCAN®), behmumab (BENLYSTA®, LYMPHOSTAT-B®), besilesomab (SCINHMUN®), bevacizumab (AVASTIN®), bivatuzumab mertansine, blinatumomab, brentuximab vedotin, cantuzumab mertansine, capromab pendetide (PROSTASCINT®), catumaxomab (REMOVAB®), CC49, cetuximab (C225, ERBITUX®), citatuzumab bogatox, eixutumumab, clivatuzumab tetraxetan, conatumumab, dacetuzumab, denosumab (PROLIA®),detumomab, ecromeximab, edrecolomab (P ANOREX®), elotuzumab, epitumomab cituxetan, epratuzumab, ertumaxomab (REXOMUN®), etaracizumab, farletuzumab, figitumumab, fresolimumab, galiximab, gemtuzumab ozogamicin (MYLOTARG®), girentuximab, glembatumumab vedotin, ibritumomab (ibritumomab tiuxetan, ZEVALIN®), igovomab (INDIMACIS-125®), intetumumab, inotuzumab ozogamicin, ipilimumab, iratumumab, labetuzumab (CEA-CIDE®), lexatumumab, lintuzumab, lucatumumab, lumiliximab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, nacolomab tafenatox, naptumomab estafenatox, necitumumab, nimotuzumab (THERACIM®, THERALOC®), nofetumomab merpentan (VERLUMA®), ofatumumab (ARZERRA®), olaratumab, oportuzumab monatox, oregovomab (OVAREX®), panitumumab (VECTIBIX®), pemtumomab (THERAGYN®), pertuzumab (OMNITARG®), pintumomab, pritumumab, ramucirumab, ranibizumab (LUCENHS®), rilotumumab, rituximab (MABTHERA®, RITUXAN®), robatumumab, satumomab pendetide, sibrotuzumab, siltuximab, sontuzumab, tacatuzumab tetraxetan (AFP-CIDE®), taplitumomab paptox, tenatumomab, TGN1412, ticilimumab (tremelimumab), tigatuzumab, TNX-650, tositumomab (BEXXAR®), trastuzumab (HERCEPTIN®), tremelimumab, tucotuzumab celmoleukin, veltuzumab, volociximab, votumumab (HUMASPECT®), zalutumumab (HUMAX-EGFR®), and zanolimumab (HUMAX- CD4®).In some embodiments, the antibody molecules (e.g., the anti-FGFR4 antibody or the anti-FGFR4 ADC) or any composition as described herein are administered in combination with a viral cancer therapeutic agent. Exemplary viral cancer therapeutic agents include, but not limited to, vaccinia virus (vvDD-CDSR), carcinoembryonic antigen-expressing measles virus, recombinant vaccinia virus (TK-deletion plus GM-CSF), Seneca Valley virus-001, Newcastle virus, coxsackie virus A21, GL-ONC1, EBNA1 C-terminal / LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine, carcinoembryonic antigen-expressing measles virus, G207 oncolytic virus, modified vaccinia virus Ankara vaccine expressing p53, OncoVEX GM-CSF modified herpes-simplex 1 virus, fowlpox virus vaccine vector, recombinant vaccinia prostate-specific antigen vaccine, human papillomavirus 16 / 18 LI virus-like particle / AS04 vaccine, MVA- EBNA1 / LMP2 Inj. Vaccine, quadrivalent HPV vaccine, quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (GARDASIL®), recombinant fowlpox- CEA(6D) / TRICOM vaccine; recombinant vaccinia-CEA(6D)-TRICOM vaccine, recombinant modified vaccinia Ankara-5T4 vaccine, recombinant fowlpox- TRICOM vaccine, oncolytic herpesvirus NV1020, HPV LI VLP vaccine V504, human papillomavirus bivalent (types 16 and 18) vaccine (CERVARIX®), herpes simplex virus HF10, Ad5CMV-p53 gene, recombinant vaccinia DF3 / MUC1 vaccine, recombinant vaccinia-MUC-1 vaccine, recombinant vaccinia-TRICOM ...

Claims

CLAIMS1. A molecule comprising an antigen binding domain that binds to human FGFR4 and to mouse FGFR4, wherein the molecule binds to human FGFR4 domain 1 (DI) comprising the amino acid sequence set forth in SEQ ID NO: 78, wherein the antigen binding domain binds to an epitope of human FGFR4 DI, wherein the epitope is defined by one or more of the following:(a) the epitope comprises His44, Tyr46, and Arg83 of SEQ ID NO: 78;(b) the epitope comprises at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least thirty, at least forty, or more consecutive amino acids of the sequence SEQ ID NO: 78;(c) the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 44-86 of SEQ ID NO: 78, preferably to amino acid residues 46-86 of SEQ ID NO: 78;(d) the epitope comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to amino acid residues 44-65, preferably to amino acid residues 46-65 of SEQ ID NO: 78;(e) the epitope is within or overlapping amino acid residues 44-86 of SEQ ID NO: 78, preferably amino acid residues 44-65 of SEQ ID NO: 78, more preferably amino acid residues 44-62 of SEQ ID NO: 78; and(f) the epitope comprises one or more amino acid residues ranges selected from: 46- 52, 46-65, 46-67, 46-68, 48-65, 49-65, 54-65, 66-70, 66-71, and 66-78 of SEQ ID NO: 78; preferably from one or more of (a), (c), (d) and (e).

2. The molecule of claim 1, wherein the epitope is a conformational epitope within or overlapping amino acid residues 44-86 of SEQ ID NO: 78, further characterized as defined in (a).

3. The molecule of any one of the preceding claims, wherein the epitope further comprises any one or more, preferably all, of Arg51, Pro54, Trp61 and Met86 of SEQ ID NO: 78, more preferably wherein the epitope still further comprises any one or more, preferably all of, Arg59 and Arg62 of SEQ ID NO: 78.

4. The molecule of any one of the preceding claims, wherein the molecule binds to a FGFR4 domain 1 (DI) comprising the amino acid sequence set forth in SEQ ID NO: 78 with higher affinity than to other FGFR4 domains selected from one or more of: a FGFR4 acid box (AB) comprising the amino acid sequence set forth in SEQ ID NO: 82, a FGFR4 domain 2 (D2) comprising the amino acid sequence set forth in SEQ ID NO: 79, and a FGFR4 domain 3 (D3) comprising the amino acid sequence set forth in SEQ ID NO: 80.

5. The molecule of any one of the preceding claims, wherein the antigen binding domain binds to the FGFR4 domain 1 comprising the amino acid sequence set forth in SEQ ID NO: 78 with a dissociation constant (KD) of 10 nM or less, 8 nM or less, or 5 nM or less.

6. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDDYWFFDL (SEQ ID NO: 3);(b) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDDHWFFDL (SEQ ID NO: 83);(c) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDDNWFFDL (SEQ ID NO: 86);(d) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDSSGSTNYNPSLKS (SEQ ID NO: 89), and a HCDR3 ammo acid sequence of NYDDDYWFFDL (SEQ ID NO: 3);(e) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDDSGSTNYNPSLKS (SEQ ID NO: 93), and a HCDR3 ammo acid sequence of NYDDDYWFFDL (SEQ ID NO: 3);(f) (i) a VL comprising a LCDR1 amino acid sequence of RASQDINNWLA (SEQ ID NO: 97), a LCDR2 ammo acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDDYWFFDL (SEQ ID NO: 3);(g) (i) a VL comprising a LCDR1 amino acid sequence of RASQNINNWLA (SEQ ID NO: 100), a LCDR2 ammo acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDDYWFFDL (SEQ ID NO: 3);(h) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 ammo acid sequence of NASSLQS (SEQ ID NO: 103), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDDYWFFDL (SEQ ID NO: 3);(i) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 ammo acid sequence of DASSLQS (SEQ ID NO: 106), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDD YWFFDL (SEQ ID NO: 3);(j) (i) a VL comprising a LCDR1 amino acid sequence of RASQDINNWLA (SEQ ID NO: 97), a LCDR2 ammo acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDDHWFFDL (SEQ ID NO: 83);(k) (i) a VL comprising a LCDR1 amino acid sequence of RASQNINNWLA (SEQ ID NO: 100), a LCDR2 ammo acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 ammo acid sequence of NYDDDNWFFDL (SEQ ID NO: 86);(l) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 ammo acid sequence of NASSLQS (SEQ ID NO: 103), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDSSGSTNYNPSLKS (SEQ ID NO: 89), and a HCDR3 ammo acid sequence of NYDDD YWFFDL (SEQ ID NO: 3);(m) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 ammo acid sequence of DASSLQS (SEQ ID NO: 106), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDDSGSTNYNPSLKS (SEQ ID NO: 93), and a HCDR3 ammo acid sequence of NYDDD YWFFDL (SEQ ID NO: 3);(n) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and (ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), aHCDR2 amino acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 amino acid sequence of NYDHDYWFFDL (SEQ ID NO: 265);(o) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and (ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 amino acid sequence of NYDDDYWFHDL (SEQ ID NO: 268);(p) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 amino acid sequence of HASSLQS (SEQ ID NO: 271), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and (ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 amino acid sequence of NYDDDYWFFDL (SEQ ID NO: 3); or(q) (i) a VL comprising a LCDR1 amino acid sequence of RASQGINNWLA (SEQ ID NO: 7), a LCDR2 ammo acid sequence of AASSLQS (SEQ ID NO: 8), and a LCDR3 amino acid sequence of QQANSFPLT (SEQ ID NO: 9); and(ii) a VH comprising a HCDR1 amino acid sequence of GYYWS (SEQ ID NO: 4), a HCDR2 ammo acid sequence of EIDHSGSTNYNPSLKS (SEQ ID NO: 2), and a HCDR3 amino acid sequence of NYDEDYWFFDL (SEQ ID NO: 260).

7. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) (i) a VL comprising a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(b) (i) a VL comprising a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), aLCDR2 ammo acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of NYAMH (SEQ ID NO: 110), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(c) (i) a VL comprising a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 108), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(d) (i) a VL comprising aLCDRl amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISRDGNDKYYADSVKG (SEQ ID NO: 112), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(e) (i) a VL comprising a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISADGNDKYYADSVKG (SEQ ID NO: 116), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(f) (i) a VL comprising a LCDR1 amino acid sequence of RASQSIDIWLA (SEQ ID NO: 120), a LCDR2 ammo acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(g) (i) a VL comprising a LCDR1 amino acid sequence of RASQSISIWLA (SEQ ID NO: 123), a LCDR2 ammo acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(h) (i) a VL comprising aLCDRl amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYASYSYT (SEQ ID NO: 126); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(i) (i) a VL comprising a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYHSYSYT (SEQ ID NO: 129); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(j) (i) a VL comprising a LCDR1 amino acid sequence of RASQSIDIWLA (SEQ ID NO: 120), a LCDR2 ammo acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of NYAMH (SEQ ID NO: 110), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(k) (i) a VL comprising a LCDR1 amino acid sequence of RASQSISIWLA (SEQ ID NO: 123), a LCDR2 ammo acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYNSYSYT (SEQ ID NO: 24); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 108), a HCDR2 ammo acid sequence of VISNDGNDKYYADSVKG (SEQ ID NO: 13), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14);(l) (i) a VL comprising a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYASYSYT (SEQ ID NO: 126); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISRDGNDKYYADSVKG (SEQ ID NO: 112), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14); or(m)(i) a VL comprising a LCDR1 amino acid sequence of RASQSINIWLA (SEQ ID NO: 22), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYHSYSYT (SEQ ID NO: 129); and(ii) a VH comprising a HCDR1 amino acid sequence of SYAMH (SEQ ID NO: 15), a HCDR2 ammo acid sequence of VISADGNDKYYADSVKG (SEQ ID NO: 116), and a HCDR3 ammo acid sequence of EGNWNYEDWDYGMDV (SEQ ID NO: 14).

8. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) (i) a VL comprising a LCDR1 amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28);(b) (i) a VL comprising aLCDRl amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNANSDGFDI (SEQ ID NO: 132);(c) (i) a VL comprising aLCDRl amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNENSDGFDI (SEQ ID NO: 135);(d) (i) a VL comprising a LCDR1 amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), aLCDR2 ammo acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGSTFYVDSVKG (SEQ ID NO: 138), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28);(e) (i) a VL comprising aLCDRl amino acid sequence of RASQSISSWLA(SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGTTFYVDSVKG (SEQ ID NO: 141), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28);(f) (i) a VL comprising a LCDR1 amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of MQYRSYSPYT (SEQ ID NO: 145); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28);(g) (i) a VL comprising aLCDRl amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of AQYRSYSPYT (SEQ ID NO: 148); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28);(h) (i) a VL comprising aLCDRl amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of DASSLES (SEQ ID NO: 151), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28);(i) (i) a VL comprising a LCDR1 amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of YASSLES (SEQ ID NO: 154), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28);(j) (i) a VL comprising aLCDRl amino acid sequence of RASQSISSWLA(SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of MQYRSYSPYT (SEQ ID NO: 145); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNANSDGFDI (SEQ ID NO: 132);(k) (i) a VL comprising aLCDRl amino acid sequence of RASQSISSWLA(SEQ ID NO: 33), a LCDR2 amino acid sequence of KASSLES (SEQ ID NO: 23), and a LCDR3 ammo acid sequence of AQYRSYSPYT (SEQ ID NO: 148); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGNTFYVDSVKG (SEQ ID NO: 27), and a HCDR3 ammo acid sequence of LNENSDGFDI (SEQ ID NO: 135);(l) (i) a VL comprising a LCDR1 amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 amino acid sequence of DASSLES (SEQ ID NO: 151), and a LCDR3 ammo acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGSTFYVDSVKG (SEQ ID NO: 138), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28); or(m) (i) a VL comprising a LCDR1 amino acid sequence of RASQSISSWLA (SEQ ID NO: 33), a LCDR2 ammo acid sequence of YASSLES (SEQ ID NO: 154), and a LCDR3 amino acid sequence of QQYRSYSPYT (SEQ ID NO: 35); and(ii) a VH comprising a HCDR1 amino acid sequence of DYAMH (SEQ ID NO: 29), a HCDR2 ammo acid sequence of LISGDGGTTFYVDSVKG (SEQ ID NO: 141), and a HCDR3 ammo acid sequence of LNWNSDGFDI (SEQ ID NO: 28).

9. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and390(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(b) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNYKYDADSVKG (SEQ ID NO: 157), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(c) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNTKYDADSVKG (SEQ ID NO: 161), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(d) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTSTTNYYYGMDV (SEQ ID NO: 165);(e) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTATTNYYYGMDV (SEQ ID NO: 168);(f) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINTYLN (SEQ ID NO: 171), a LCDR2 ammo acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and391(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(g) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINSYLN (SEQ ID NO: 174), a LCDR2 ammo acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(h) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYHNLPYT (SEQ ID NO: 177); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(i) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYANLPYT (SEQ ID NO: 180); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(j) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINTYLN (SEQ ID NO: 171), a LCDR2 ammo acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNYKYDADSVKG (SEQ ID NO: 157), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(k) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINSYLN (SEQ ID NO: 174), a LCDR2 ammo acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and392(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNTKYDADSVKG (SEQ ID NO: 161), and a HCDR3 ammo acid sequence of GGTVTTNYYYGMDV (SEQ ID NO: 39);(l) (i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYHNLPYT (SEQ ID NO: 177); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTSTTNYYYGMDV (SEQ ID NO: 165); or(m)(i) a VL comprising a LCDR1 amino acid sequence of QASQDINNYLN (SEQ ID NO: 44), a LCDR2 amino acid sequence of DASNVET (SEQ ID NO: 45), and a LCDR3 amino acid sequence of QQYANLPYT (SEQ ID NO: 180); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMH (SEQ ID NO: 40), a HCDR2 ammo acid sequence of VISYTGNNKYDADSVKG (SEQ ID NO: 38), and a HCDR3 ammo acid sequence of GGTATTNYYYGMDV (SEQ ID NO: 168).

10. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(b) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of DYVMN (SEQ ID NO: 183), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(c) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence393 of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of NYVMN (SEQ ID NO: 187), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(d) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNEKYYADSVKG (SEQ ID NO: 191), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(e) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNYKYYADSVKG (SEQ ID NO: 196), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(f) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDIDNYLN (SEQ ID NO: 200), a LCDR2 ammo acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(g) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDISNYLN (SEQ ID NO: 203), a LCDR2 ammo acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and394(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(h) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYYNLPYT (SEQ ID NO: 206); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(i) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYANLPYT (SEQ ID NO: 209); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(j) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDIDNYLN (SEQ ID NO: 200), a LCDR2 ammo acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of DYVMN (SEQ ID NO: 183), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);(k) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDISNYLN (SEQ ID NO: 203), a LCDR2 ammo acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYDNLPYT (SEQ ID NO: 46); and(ii) a VH comprising a HCDR1 amino acid sequence of NYVMN (SEQ ID NO: 187), a HCDR2 ammo acid sequence of VISYTGNNKYYADSVKG (SEQ ID NO: 49), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50);395(l) (i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYYNLPYT (SEQ ID NO: 206); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNEKYYADSVKG (SEQ ID NO: 191), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50); or(m)(i) a VL comprising a LCDR1 amino acid sequence of LCDR1 amino acid sequence of QAGQDITNYLN (SEQ ID NO: 54), a LCDR2 amino acid sequence of DAYNLES (SEQ ID NO: 55), and a LCDR3 amino acid sequence of QQYANLPYT (SEQ ID NO: 209); and(ii) a VH comprising a HCDR1 amino acid sequence of SYVMN (SEQ ID NO: 34), a HCDR2 ammo acid sequence of VISYTGNYKYYADSVKG (SEQ ID NO: 196), and a HCDR3 ammo acid sequence of GGQQLVNYYYGMDV (SEQ ID NO: 50).

11. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) (i) a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 61, a LCDR2 amino acid sequence of Sequence NO: B62, and a LCDR3 amino acid sequence of Sequence NO: A63; and(ii) a VH comprising a HCDR1 amino acid sequence of Sequence NO: A58, a HCDR2 amino acid sequence of Sequence NO: A59, and a HCDR3 amino acid sequence of Sequence NO: B60;(b) (i) a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 282, a LCDR2 amino acid sequence of Sequence NO: A68, and a LCDR3 amino acid sequence of Sequence NO: A69; and(ii) a VH comprising a HCDR1 amino acid sequence of Sequence NO: A64, a HCDR2 amino acid sequence of Sequence NO: A65, and a HCDR3 amino acid sequence of Sequence NO: A66;(c) (i) a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 276, a LCDR2 amino acid sequence of SEQ ID NO: 277, and a LCDR3 amino acid sequence of SEQ ID NO: 278; and396(ii) a VH comprising a HCDR1 amino acid sequence of Sequence NO: A70, a HCDR2 amino acid sequence of SEQ ID NO: 283, and a HCDR3 amino acid sequence of Sequence NO: A72;(d) (i) a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 279, a LCDR2 amino acid sequence of SEQ ID NO: 280, and a LCDR3 amino acid sequence of SEQ ID NO: 281; and(ii) a VH comprising a HCDR1 amino acid sequence of SEQ ID NO: 279, a HCDR2 amino acid sequence of SEQ ID NO: 280, and a HCDR3 amino acid sequence of Sequence NO: A75;(e) (i) a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 214, a LCDR2 amino acid sequence of SEQ ID NO: 215, and a LCDR3 amino acid sequence of SEQ ID NO: 9; and(ii) a VH comprising a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 212, and a HCDR3 amino acid sequence of Sequence NO: 213; or(f) (i) a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 214, a LCDR2 amino acid sequence of SEQ ID NO: 275, and a LCDR3 amino acid sequence of SEQ ID NO: 9; and(ii) a VH comprising a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 212, and a HCDR3 amino acid sequence of Sequence NO: 274.

12. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 10;(b) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84;397(c) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 87;(d) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 91 ;(e) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 95;(f) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 98 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 10;(g) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 10;(h) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 10;(i) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 107 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 10;Q) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 98 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 84;398(k) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 101 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 87;(l) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 104 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 91 ;(m) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 107 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 95;(n) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 263;(o) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 266;(p) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 269;(q) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 272 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 10; or(r) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 11 and a399VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 261.

13. The molecule of claim 12, wherein the antigen binding domain comprises:(a) a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 10;(b) a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 84;(c) a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 87;(d) a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 91;(e) a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 95;(f) a VL comprising the sequence of SEQ ID NO: 98 and a VH comprising the sequence of SEQ ID NO: 10;(g) a VL comprising the sequence of SEQ ID NO: 101 and a VH comprising the sequence of SEQ ID NO: 10;(h) a VL comprising the sequence of SEQ ID NO: 104 and a VH comprising the sequence of SEQ ID NO: 10;(i) a VL comprising the sequence of SEQ ID NO: 107 and a VH comprising the sequence of SEQ ID NO: 10;(j) a VL comprising the sequence of SEQ ID NO: 98 and a VH comprising the sequence of SEQ ID NO: 84;(k) a VL comprising the sequence of SEQ ID NO: 101 and a VH comprising the sequence of SEQ ID NO: 87;(l) a VL comprising the sequence of SEQ ID NO: 104 and a VH comprising the sequence of SEQ ID NO: 91 ;(m) a VL comprising the sequence of SEQ ID NO: 107 and a VH comprising the sequence of SEQ ID NO: 95;(n) a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 263;400(o) a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 266;(p) a VL comprising the sequence of SEQ ID NO: 11 and a VH the sequence of SEQ ID NO: 269;(q) a VL comprising the sequence of SEQ ID NO: 272 and a VH comprising the sequence of SEQ ID NO: 10; or(r) a VL comprising the sequence of SEQ ID NO: 11 and a VH comprising the sequence of SEQ ID NO: 261.

14. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 25 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 21;(b) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 25 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 105;(c) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 25 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 238;(d) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 25 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114;(e) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 25 and a VH comprising a sequence having at least 75%, at least 80%, at401 least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 118;(f) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 21;(g) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 124 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 21;(h) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 127 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 21;(i) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 130 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 21;(j) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 121 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 105;(k) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 124 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 238;402(l) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 127 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 114; or(m)a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 130 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 118.

15. The molecule of claim 14, wherein the antigen binding domain comprises:(a) a VL comprising the sequence of SEQ ID NO: 25 and a VH comprising the sequence of SEQ ID NO: 21;(b) a VL comprising the sequence of SEQ ID NO: 25 and a VH comprising the sequence of SEQ ID NO: 105;(c) a VL comprising the sequence of SEQ ID NO: 25 and a VH comprising the sequence of SEQ ID NO: 238;(d) a VL comprising the sequence of SEQ ID NO: 25 and a VH comprising the sequence of SEQ ID NO: 114;(e) a VL comprising the sequence of SEQ ID NO: 25 and a VH comprising the sequence of SEQ ID NO: 118;(f) a VL comprising the sequence of SEQ ID NO: 121 and a VH comprising the sequence of SEQ ID NO: 21;(g) a VL comprising the sequence of SEQ ID NO: 124 and a VH comprising the sequence of SEQ ID NO: 21;(h) a VL comprising the sequence of SEQ ID NO: 127 and a VH comprising the sequence of SEQ ID NO: 21;(i) a VL comprising the sequence of SEQ ID NO: 130 and a VH comprising the sequence of SEQ ID NO: 21;(j) a VL comprising the sequence of SEQ ID NO: 121 and a VH comprising the sequence of SEQ ID NO: 105;403(k) a VL comprising the sequence of SEQ ID NO: 124 and a VH comprising the sequence of SEQ ID NO: 238;(l) a VL comprising the sequence of SEQ ID NO: 127 and a VH comprising the sequence of SEQ ID NO: 114; or(m) a VL comprising the sequence of SEQ ID NO: 130 and a VH comprising the sequence of SEQ ID NO: 118.

16. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 36 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 32;(b) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 36 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 133;(c) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 36 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 136;(d) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 36 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 139;(e) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 36 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 143;404(f) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 146 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 32;(g) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 149 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 32;(h) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 152 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 32;(i) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 32;(j) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 146 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 133;(k) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 149 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 136;(l) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ405ID NO: 152 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 139; or(m)a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 155 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 143.

17. The molecule of claim 16, wherein the antigen binding domain comprises:(a) a VL comprising the sequence of SEQ ID NO: 36 and a VH comprising the sequence of SEQ ID NO: 32;(b) a VL comprising the sequence of SEQ ID NO: 36 and a VH comprising the sequence of SEQ ID NO: 133;(c) a VL comprising the sequence of SEQ ID NO: 36 and a VH comprising the sequence of SEQ ID NO: 136;(d) a VL comprising the sequence of SEQ ID NO: 36 and a VH comprising the sequence of SEQ ID NO: 139;(e) a VL comprising the sequence of SEQ ID NO: 36 and a VH comprising the sequence of SEQ ID NO: 143;(f) a VL comprising the sequence of SEQ ID NO: 146 and a VH comprising the sequence of SEQ ID NO: 32;(g) a VL comprising the sequence of SEQ ID NO: 149 and a VH comprising the sequence of SEQ ID NO: 32;(h) a VL comprising the sequence of SEQ ID NO: 152 and a VH comprising the sequence of SEQ ID NO: 32;(i) a VL comprising the sequence of SEQ ID NO: 155 and a VH comprising the sequence of SEQ ID NO: 32;(j) a VL comprising the sequence of SEQ ID NO: 146 and a VH comprising the sequence of SEQ ID NO: 133;(k) a VL comprising the sequence of SEQ ID NO: 149 and a VH comprising the sequence of SEQ ID NO: 136;406(l) a VL comprising the sequence of SEQ ID NO: 152 and a VH comprising the sequence of SEQ ID NO: 139; or(m)a VL comprising the sequence of SEQ ID NO: 155 and a VH comprising the sequence of SEQ ID NO: 143.

18. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 47 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 43;(b) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 47 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 159;(c) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 47 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 163;(d) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 47 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 166;(e) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 47 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 169;(f) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ407ID NO: 172 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 43;(g) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 175 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 43;(h) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 178 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 43;(i) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 181 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 43;(j) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 172 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 159;(k) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 175 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 163;(l) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 178 and a VH comprising a sequence having at least 75%, at least 80%,408 at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 166; or(m) a VL comprising a sequence having a at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 181 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 169.

19. The molecule of claim 18, wherein the antigen binding domain comprises:(a) a VL comprising the sequence of SEQ ID NO: 47 and a VH comprising the sequence of SEQ ID NO: 43;(b) a VL comprising the sequence of SEQ ID NO: 47 and a VH comprising the sequence of SEQ ID NO: 159;(c) a VL comprising the sequence of SEQ ID NO: 47 and a VH comprising the sequence of SEQ ID NO: 163;(d) a VL comprising the sequence of SEQ ID NO: 47 and a VH comprising the sequence of SEQ ID NO: 166;(e) a VL comprising the sequence of SEQ ID NO: 47 and a VH comprising the sequence of SEQ ID NO: 169;(f) a VL comprising the sequence of SEQ ID NO: 172 and a VH comprising the sequence of SEQ ID NO: 43;(g) a VL comprising the sequence of SEQ ID NO: 175 and a VH comprising the sequence of SEQ ID NO: 43;(h) a VL comprising the sequence of SEQ ID NO: 178 and a VH comprising the sequence of SEQ ID NO: 43;(i) a VL comprising the sequence of SEQ ID NO: 181 and a VH comprising the sequence of SEQ ID NO: 43;(j) a VL comprising the sequence of SEQ ID NO: 172 and a VH comprising the sequence of SEQ ID NO: 159;(k) a VL comprising the sequence of SEQ ID NO: 175 and a VH comprising the sequence of SEQ ID NO: 163;(l) a VL comprising the sequence of SEQ ID NO: 178 and a VH comprising the sequence of SEQ ID NO: 166; or409(m) a VL comprising the sequence of SEQ ID NO: 181 and a VH comprising the sequence of SEQ ID NO: 169.

20. The molecule of any one of claims 1-5, wherein the antigen binding domain comprises:(a) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 53;(b) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 184;(c) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 189;(d) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 193;(e) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 57 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 198;(f) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 201 and a VH comprising a sequence having at least 75%, at least 80%,410 at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 53;(g) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 204 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 53;(h) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 207 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 53;(i) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 210 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 53;(j) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 201 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 184;(k) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 204 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 189;(l) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 207 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 193; or411(m) a VL comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 210 and a VH comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 198.

21. The molecule of claim 20, wherein the antigen binding domain comprises:(a) a VL comprising the sequence of SEQ ID NO: 57 and a VH comprising the sequence of SEQ ID NO: 53;(b) a VL comprising the sequence of SEQ ID NO: 57 and a VH comprising the sequence of SEQ ID NO: 184;(c) a VL comprising the sequence of SEQ ID NO: 57 and a VH comprising the sequence of SEQ ID NO: 189;(d) a VL comprising the sequence of SEQ ID NO: 57 and a VH comprising the sequence of SEQ ID NO: 193;(e) a VL comprising the sequence of SEQ ID NO: 57 and a VH comprising the sequence of SEQ ID NO: 198;(f) a VL comprising the sequence of SEQ ID NO: 201 and a VH comprising the sequence of SEQ ID NO: 53;(g) a VL comprising the sequence of SEQ ID NO: 204 and a VH comprising the sequence of SEQ ID NO: 53;(h) a VL comprising the sequence of SEQ ID NO: 207 and a VH comprising the sequence of SEQ ID NO: 53;(i) a VL comprising the sequence of SEQ ID NO: 210 and a VH comprising the sequence of SEQ ID NO: 53;(j) a VL comprising the sequence of SEQ ID NO: 201 and a VH comprising the sequence of SEQ ID NO: 184;(k) a VL comprising the sequence of SEQ ID NO: 204 and a VH comprising the sequence of SEQ ID NO: 189;(l) a VL comprising the sequence of SEQ ID NO: 207 and a VH comprising the sequence of SEQ ID NO: 193; or(m) a VL comprising the sequence of SEQ ID NO: 210 and a VH comprising the sequence of SEQ ID NO: 198.41222. The molecule of any one of claims 1-21, wherein the antigen binding domain is a full antibody or antigen-binding fragment thereof, a bivalent antibody, bispecific antibody, or a biparatopic antibody.

23. The molecule of any one of claims 1-21, wherein the antigen binding domain is a Fab, F(ab’)2, Fv, a single chain Fv (scFv), a diabody, a single domain antibody, or a camelid antibody.

24. The molecule of any one of claims 1-23, wherein the antigen binding domain comprises one or more heavy chain constant regions selected from the group consisting of IgGl heavy chain constant region or functional fragment thereof, IgG2 heavy chain constant region or functional fragment thereof, IgG3 heavy chain constant region or functional fragment thereof, IgGAl heavy chain constant region or functional fragment thereof, IgGA2 heavy chain constant region or functional fragment thereof, IgG4 heavy chain constant region or functional fragment thereof, IgM heavy chain constant region or functional fragment thereof, IgD heavy chain constant region or functional fragment thereof, and IgE heavy chain constant region or functional fragment thereof.

25. The molecule of claim 24, wherein the one or more heavy chain constant regions comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 65.

26. The molecule of any one of claims 1-25, wherein the antigen binding domain comprises a kappa light chain constant region or functional fragment thereof, a lambda light chain constant region or functional fragment thereof, or a combination thereof.

27. The molecule of claim 26, wherein the kappa / lambda light chain constant regions comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 68.

28. The molecule of any one of claims 1-27, wherein the molecule comprises a first heavy chain, a second heavy chain, and a first light chain, wherein the first heavy chain and the second heavy chain are non-contiguous, wherein:(a) the first heavy chain comprises a first portion of a dimerization domain linked to the VH, wherein the first portion of the dimerization module comprises a first immunoglobulin constant region (Fc region);(b) the first light chain comprises the VL; and413(c) the second heavy chain comprises a second portion of the dimerization domain, wherein the second portion of the dimerization module comprises a second Fc region.

29. The molecule of claim 28, wherein the first Fc region, the second Fc region, or a combination thereof comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 65 or SEQ ID NO: 66.

30. The molecule of claims 28 or 29, wherein the first heavy chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 64, 85, 88, 92, 96, 262, 264, 267 and 270.

31. The molecule of claim 30 wherein the first heavy chain comprises a sequence of any one of SEQ ID NOs: 64, 85, 88, 92, 96, 262, 264, 267 and 270.

32. The molecule of any one of claims 28-31, herein the second heavy chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 64, 85, 88, 92, 96, 262, 264, 267 and 270.

33. The molecule of claim 32, wherein the second heavy chain comprises a sequence of any one of SEQ ID NOs: 64, 85, 88, 92, 96, 262, 264, 267 and 270.

34. The molecule of any one of claims 28-33, wherein the first light chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 67, 99, 102, 233, 236 and 273.

35. The molecule of claim 34, wherein the first light chain comprises a sequence of any one of SEQ ID NOs: 67, 99, 102, 233, 236 and 273.

36. The molecule of any one of claims 28-35, wherein the molecule further comprises a second light chain.

37. The molecule of claim 36, wherein the second light chain comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of any one of SEQ ID NOs: 67, 99, 102, 233, 236 and 273.

38. The molecule of claim 37, wherein the second light chain comprises a sequence of any one of SEQ ID NOs: 67, 99, 102, 233, 236 and 273.

39. The molecule of any one of claims 28-38, wherein the molecule comprises:414(a) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67;(b) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 85; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67;(c) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 88; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67;(d) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 92; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67;(e) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67;(f) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 99;(g) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID415NO: 64; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 102;(h) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 233;(i) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 236;(j) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 85; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 99;(k) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 88; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 102;(l) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 92; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 233;(m)a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 96; and a first light chain comprising a sequence having at least 75%, at least 80%,416 at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 236;(n) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 264; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67;(o) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 267; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67;(p) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 270; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67;(q) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 64; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 273; or(r) a first heavy chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 262; and a first light chain comprising a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO: 67.

40. The molecule of claim 39, wherein the molecule comprises:(a) a first heavy chain comprising a sequence of SEQ ID NO: 64 and a first light chain comprising a sequence of SEQ ID NO: 67;(b) a first heavy chain comprising the sequence of SEQ ID NO: 85; and a first light chain comprising the sequence of SEQ ID NO: 67;417(c) a first heavy chain comprising the sequence of SEQ ID NO: 88; and a first light chain comprising the sequence of SEQ ID NO: 67;(d) a first heavy chain comprising the sequence of SEQ ID NO: 92; and a first light chain comprising the sequence of SEQ ID NO: 67;(e) a first heavy chain comprising the sequence of SEQ ID NO: 96; and a first light chain comprising the sequence of SEQ ID NO: 67;(f) a first heavy chain comprising the sequence of SEQ ID NO: 64; and a first light chain comprising the sequence of SEQ ID NO: 99;(g) a first heavy chain comprising the sequence of SEQ ID NO: 64; and a first light chain comprising the sequence of SEQ ID NO: 102;(h) a first heavy chain comprising the sequence of SEQ ID NO: 64; and a first light chain comprising the sequence of SEQ ID NO: 233;(i) a first heavy chain comprising the sequence of SEQ ID NO: 64; and a first light chain comprising the sequence of SEQ ID NO: 236;(j) a first heavy chain comprising the sequence of SEQ ID NO: 85; and a first light chain comprising the sequence of SEQ ID NO: 99;(k) a first heavy chain comprising the sequence of SEQ ID NO: 88; and a first light chain comprising the sequence of SEQ ID NO: 102;(l) a first heavy chain comprising the sequence of SEQ ID NO: 92; and a first light chain comprising the sequence of SEQ ID NO: 233;(m)a first heavy chain comprising the sequence of SEQ ID NO: 96; and a first light chain comprising the sequence of SEQ ID NO: 236;(n) a first heavy chain comprising the sequence of SEQ ID NO: 264; and a first light chain comprising the sequence of SEQ ID NO: 67;(o) a first heavy chain comprising the sequence of SEQ ID NO: 267; and a first light chain comprising the sequence of SEQ ID NO: 67;(p) a first heavy chain comprising the sequence of SEQ ID NO: 270; and a first light chain comprising the sequence of SEQ ID NO: 67;(q) a first heavy chain comprising the sequence of SEQ ID NO: 64; and a first light chain comprising the sequence of SEQ ID NO: 273; or(r) a first heavy chain the sequence of SEQ ID NO: 262; and a first light chain comprising the sequence of SEQ ID NO: 67.41841. The molecule of any one of claims 28-40, wherein the molecule comprises:(a) a first heavy chain comprising a sequence of SEQ ID NO: 64; a first light chain comprising a sequence of SEQ ID NO: 67; a second heavy chain comprising a sequence of SEQ ID NO: 64; and a second light chain comprising a sequence of SEQ ID NO: 67;(b) a first heavy chain comprising the sequence of SEQ ID NO: 85; a first light chain comprising the sequence of SEQ ID NO: 67; a second heavy chain comprising the sequence of SEQ ID NO: 85; and a second light chain comprising the sequence of SEQ ID NO: 67;(c) a first heavy chain comprising the sequence of SEQ ID NO: 88; a first light chain comprising the sequence of SEQ ID NO: 67; a second heavy chain comprising the sequence of SEQ ID NO: 88; and a second light chain comprising the sequence of SEQ ID NO: 67;(d) a first heavy chain comprising the sequence of SEQ ID NO: 92; a first light chain comprising the sequence of SEQ ID NO: 67; a second heavy chain comprising the sequence of SEQ ID NO: 92; and a second light chain comprising the sequence of SEQ ID NO: 67;(e) a first heavy chain comprising the sequence of SEQ ID NO: 96; a first light chain comprising the sequence of SEQ ID NO: 67; a second heavy chain comprising the sequence of SEQ ID NO: 96; and a second light chain comprising the sequence of SEQ ID NO: 67;(f) a first heavy chain comprising the sequence of SEQ ID NO: 64; a first light chain comprising the sequence of SEQ ID NO: 99; a second heavy chain comprising the sequence of SEQ ID NO: 64; and a second light chain comprising the sequence of SEQ ID NO: 99;(g) a first heavy chain comprising the sequence of SEQ ID NO: 64; a first light chain comprising the sequence of SEQ ID NO: 102; a second heavy chain comprising the sequence of SEQ ID NO: 64; and a second light chain comprising the sequence of SEQ ID NO: 102;(h) a first heavy chain comprising the sequence of SEQ ID NO: 64; a first light chain comprising the sequence of SEQ ID NO: 233; a second heavy chain comprising the sequence of SEQ ID NO: 64; and a second light chain comprising the sequence of SEQ ID NO: 233;419(i) a first heavy chain comprising the sequence of SEQ ID NO: 64; a first light chain comprising the sequence of SEQ ID NO: 236; a second heavy chain comprising the sequence of SEQ ID NO: 64; and a second light chain comprising the sequence of SEQ ID NO: 236;(j) a first heavy chain comprising the sequence of SEQ ID NO: 85; a first light chain comprising the sequence of SEQ ID NO: 99; a second heavy chain comprising the sequence of SEQ ID NO: 85; and a second light chain comprising the sequence of SEQ ID NO: 99;(k) a first heavy chain comprising the sequence of SEQ ID NO: 88; a first light chain comprising the sequence of SEQ ID NO: 102; a second heavy chain comprising the sequence of SEQ ID NO: 88; and a second light chain comprising the sequence of SEQ ID NO: 102;(l) a first heavy chain comprising the sequence of SEQ ID NO: 92; a first light chain comprising the sequence of SEQ ID NO: 233; a second heavy chain comprising the sequence of SEQ ID NO: 92; and a second light chain comprising the sequence of SEQ ID NO: 233;(m) a first heavy chain comprising the sequence of SEQ ID NO: 96; a first light chain comprising the sequence of SEQ ID NO: 236; a second heavy chain comprising the sequence of SEQ ID NO: 96; and a second light chain comprising the sequence of SEQ ID NO: 236;(n) a first heavy chain comprising the sequence of SEQ ID NO: 264; a first light chain comprising the sequence of SEQ ID NO: 67; a second heavy chain comprising the sequence of SEQ ID NO: 264; and a second light chain comprising the sequence of SEQ ID NO: 67;(o) a first heavy chain comprising the sequence of SEQ ID NO: 267; and a first light chain comprising the sequence of SEQ ID NO: 67; a second heavy chain comprising the sequence of SEQ ID NO: 267; and a second light chain comprising the sequence of SEQ ID NO: 67;(p) a first heavy chain comprising the sequence of SEQ ID NO: 270; and a first light chain comprising the sequence of SEQ ID NO: 67; a second heavy chain comprising the sequence of SEQ ID NO: 270; and a second light chain comprising the sequence of SEQ ID NO: 67;420(q) a first heavy chain comprising the sequence of SEQ ID NO: 64; and a first light chain comprising the sequence of SEQ ID NO: 273; a second heavy chain comprising the sequence of SEQ ID NO: 64; and a second light chain comprising the sequence of SEQ ID NO: 273; or(r) a first heavy chain the sequence of SEQ ID NO: 262; and a first light chain comprising the sequence of SEQ ID NO: 67; a second heavy chain comprising the sequence of SEQ ID NO: 262; and a second light chain comprising the sequence of SEQ ID NO: 67.

42. The molecule of any one of the preceding claims, wherein the antigen binding domain is a nonmurine antibody molecule, such a human or humanized antibody molecule, or an antigenbinding fragment thereof, preferably is a fully human antibody.

43. The molecule of any one of the preceding claims, wherein the molecule is conjugated to an agent, preferably wherein the agent comprises one or more of a cytotoxic agent, a chemotherapeutic drug, a tubulin inhibitor, a DNA damaging agent, an immunomodulating agent, an RNA targeting payload, an imaging agent, a therapeutic protein, a biopolymer, a PROTAC degrader or an oligonucleotide; more preferably, wherein the agent is selected from one or more of a maytansinoid, an eribulin, a tubulysin, a cryptophycin, an auristatin, a topoisomerase inhibitor, a Pyrrolo[2,l-c][l,4] benzodiazepine (PBD), an EG5 inhibitor, an enediyne, a duocarmycin, a thailanstatin, a calicheamicin , an amatoxin, a toll-like receptor agonist, a STING agonist, a glucocorticoid receptor modulator, a Bcl-xL inhibitor, a NAMPT inhibitor, a KRAS inhibitor, a JAK kinase inhibitor, and a carmaphycin, even more preferably, wherein the agent is exatecan, SN-38, MMAE, MMAF, PF-06380101, camptothecin, doxorubicin, paclitaxel, methotrexate, adunorubucin, gemcitabine, calicheamicin, DM1, Dxd, IRDye700DX, SG3199, DM4, vedotin, deruxtecan, IRINOTECAN, PNU-159682, alpha- amantin, clezutoclax, methotrexate, genistein, TLR7 / 8 agonist, IMMU-130, IMMU-140, AZD8205, SKB-264, or a derivative thereof, still more preferably where the agent is MMAE, exatecan or deruxtecan.

44. The molecule of claim 43, wherein the agent is conjugated to the antigen binding domain with an average Drug to Antibody Ratio (DAR) of about 4, preferably wherein the agent is MMAE or a topoisomerase I inhibitor, more preferably a camptothecin derivative, such as exatecan or deruxtecan.

45. The molecule of claim 43, wherein the agent is conjugated to the antigen binding domain with an average DAR of about 8, preferably wherein the agent is a topoisomerase I inhibitor, more preferably a camptothecin derivative, such as exatecan or deruxtecan.

46. The molecule of any of claims 43-45, wherein the molecule is conjugated to the agent via a linker.

47. The molecule of claim 46, wherein the linker comprises a cleavable linker, preferably wherein the cleavable linker comprises: v) a peptidyl linker selected from any one of(a) -GGF-;(b) -DGGF- (SEQ ID NO: 243);(c) -(D-) D-GGF- (SEQ ID NO: 244); wherein (D)-D is a D-aspartic acid;(d) -EGGF- (SEQ ID NO: 245);(e) -GGFG- (SEQ ID NO: 246);(f) -SGGF- (SEQ ID NO: 247);(g) -KGGF- (SEQ ID NO: 248);(h) -DGGFG- (SEQ ID NO: 249);(i) -GGFGG- (SEQ ID NO: 250);(j) -DDGGFG- (SEQ ID NO: 251);(k) -KDGGFG- (SEQ ID NO: 252); and(l) -GGFGGGF- (SEQ ID NO: 253); vi) a peptidyl linker cleavable by an intracellular protease, preferably a Val-Cit linker, a Val- Ala or a Phe-Lys linker; vii) a linker cleavable by a glycosidase, preferably by a glucuronidase, more preferably the linker comprises D-glucuronic acid or glucuronide; or viii) any combination thereof.

48. The molecule of any one of claims 46-47, wherein the linker comprises:- a PABC spacer, an ethylenediamine-carbamate spacer or a hemiaminal spacer; preferably a PABC spacer;- a Gly;- a chitosan;- a polyethylene glycol (PEG);- Maleimidoacetyl, Maleimidocaproyl or Maleimidopropyl; or- any combination thereof.

49. The molecule of any one of claims 46-48, wherein the linker comprises Maleimidocaproyl- Val-Cit-PABC and the payload comprises or consists of MMAE, preferably, wherein the payload is conjugated to the antigen binding domain with an average Drug to Antibody Ratio (DAR) of about 4.

50. The molecule of any one of claims 46-48, wherein the linker comprises: a) Maleimidopropyl-PEG-Val-Ala-PABC and the payload comprises or consists of exatecan, preferably wherein the payload is conjugated to the antigen binding domain with an average DAR of about 4 or of about 8; b) Maleimidopropyl-Val-Cit-PABC-Chitosan and the payload comprises or consists of exatecan, preferably wherein the payload is conjugated to the antigen binding domain with an average DAR of about 4 or of about 8; c) Maleimidopropyl-Gly-PABC-D-glucuronic acid and the payload comprises or consists of exatecan, preferably wherein the payload is conjugated to the antigen binding domain with an average DAR of about 4 or of about 8; or d) Maleimidocaproyl-Gly-Gly-Phe-Gly and the payload comprises or consists of deruxtecan, preferably wherein the payload is conjugated to the antigen binding domain with an average DAR of about 4 or of about 8, more preferably of about 8.

51. A recombinant polynucleotide molecule comprising the polynucleotide sequences encoding the molecule of any one of claims 1-42, preferably wherein the recombinant polynucleotide molecule is an isolated recombinant polynucleotide molecule.

52. A vector comprising the recombinant polynucleotide molecule of claim 51.

53. A cell comprising the recombinant polynucleotide molecule of claim 51, or the vector of claim 52.

54. A pharmaceutical composition comprising the molecule of any one of claims 1-42, the recombinant polynucleotide of claim 51, the vector of claim 52, or the cell of claim 53, and a pharmaceutically acceptable carrier, excipient, or diluent.

55. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition comprises the molecule conjugated to an agent of any one of claims 42-50 and at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least 72.5%, at least 73%, at least 73.5%, at least 74%, at least 74.5%, or at least 75% of the molecules have a DAR4, preferably wherein the agent is MMAE.42356. The pharmaceutical composition of claim 42, wherein the pharmaceutical composition comprises the molecule conjugated to an agent of any one of claims 42-50 and at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, or at least 95% of the molecules have a DAR8, preferably wherein the agent is a topoisomerase I inhibitor, more preferably a camptothecin derivative, such as exatecan or deruxtecan.

57. A molecule of any one of claims 1-42, a recombinant polynucleotide of claim 51, a vector of claim 52, a cell of claim 53, or a pharmaceutical composition of any of claims 54 to 56, or a combination thereof, for use as a medicament.

58. A molecule of any one of claims 1-42, a recombinant polynucleotide of claim 51, a vector of claim 52, a cell of claim 53, or a pharmaceutical composition of any one of claims 54 to 56, or a combination thereof, for use in the treatment of cancer.

59. The molecule, the recombinant polynucleotide, the vector, the cell or the pharmaceutical composition for use of claim 58, wherein the cancer is a solid tumor cancer, a hematological cancer, a metastatic cancer, a soft tissue tumor, or a combination thereof.

60. The molecule, the recombinant polynucleotide, the vector, the cell or the pharmaceutical composition for use of claim 58, wherein the cancer is the solid tumor cancer, and wherein the solid tumor cancer is selected from the group consisting of squamous cell carcinoma, , adenocarcinoma, adrenocortical carcinoma, head and neck cancer, esophageal cancer (e.g., gastroesophageal junction cancer), gastric cancer (e.g., gastroesophageal junction cancer), ovarian cancer, cervical cancer, uterine cancer, lung cancer, breast cancer, renal cancer, prostate cancer, sarcoma, skin cancer, melanoma, kidney cancer, duodenum cancer, small intestine cancer, large intestine cancer, colorectal cancer, liver cancer (e.g., hepatocellular carcinoma), pancreatic cancer, bladder cancer, rhabdomyosarcoma, cholangiocarcinoma, neuroendocrine tumor or testicular germ cell tumor, preferably wherein the solid tumor cancer is breast cancer, and more preferably wherein the breast cancer is a HER2- breast cancer, the breast cancer is a HER2+ breast cancer, the breast cancer is a HR+ / HER2- breast cancer, the breast cancer is a HR- / HER2+ breast cancer, the breast cancer is a HR+ / HER2+ breast cancer, the breast cancer is a Triple Negative Breast Cancer (TNBC),424 the breast cancer is a HER2-enriched breast cancer, the breast cancer is resistant or refractory to a CDK4 / 6 inhibitor, such as a CDK4 / 6 inhibitor selected from abemaciclib, palbociclib, and ribociclib, the breast cancer is resistant or refractory to an endocrine therapy, or the breast cancer is resistant or refractory to a CDK4 / 6 inhibitor and an endocrine therapy.

61. The molecule, the recombinant polynucleotide, the vector, the cell or the pharmaceutical composition for use of claim 58, wherein the cancer is the hematological cancer, and wherein the hematological cancer is leukemia or lymphoma.

62. The molecule, the recombinant polynucleotide, the vector, the cell or the pharmaceutical composition for use of any one of claims 58-61, wherein the cancer is characterized by a cancer antigen present on the cancer.

63. The molecule, the recombinant polynucleotide, the vector, the cell or the pharmaceutical composition for use of claim 62, wherein the cancer antigen is a tumor antigen, a stromal antigen, or a hematological antigen.

64. The molecule, the recombinant polynucleotide, the vector, the cell or the pharmaceutical composition for use of claim 62 or 63, wherein the cancer antigen is FGFR4.

65. The molecule, the recombinant polynucleotide, the vector, the cell or the pharmaceutical composition for use of claim 64, wherein the method of treatment comprises determining whether the subject has cancer cells that express a higher level of FGFR4 as compared to a reference value, such as a control sample in a healthy subject or a control sample of a cell line expressing low levels of FGFR4.

66. The molecule, the recombinant polynucleotide, the vector, the cell or the pharmaceutical composition for use of claim 58, wherein the cancer is a metastatic cancer of squamous cell carcinoma, adenocarcinoma, adrenocortical carcinoma, head and neck cancer, esophageal cancer, gastric cancer, ovarian cancer, cervical cancer, uterine cancer, lung cancer, breast cancer, renal cancer, prostate cancer, sarcoma, skin cancer, melanoma, kidney cancer, duodenum cancer, small intestine cancer, large intestine cancer, colorectal cancer, liver cancer (e.g., hepatocellular carcinoma), pancreatic cancer, bladder cancer, rhabdomyosarcoma, cholangiocarcinoma, neuroendocrine tumors, testicular germ cell tumor, leukemia, or lymphoma.